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A B S T R A C T
Background
Chronic kidney disease (CKD) is associated with high morbidity and death, which increases as CKD progresses to end-stage kidney disease
(ESKD). There has been increasing interest in developing innovative, effective and cost-efficient methods to engage with patient popula-
tions and improve health behaviours and outcomes. Worldwide there has been a tremendous increase in the use of technologies, with
increasing interest in using eHealth interventions to improve patient access to relevant health information, enhance the quality of health-
care and encourage the adoption of healthy behaviours.
Objectives
This review aims to evaluate the benefits and harms of using eHealth interventions to change health behaviours in people with CKD.
Search methods
We searched the Cochrane Kidney and Transplant Register of Studies up to 14 January 2019 through contact with the Information Specialist
using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE,
conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs using an eHealth intervention to promote behaviour change in people with CKD were
included. There were no restrictions on outcomes, language or publication type.
Data collection and analysis
Two authors independently assessed trial eligibility, extracted data and assessed the risk of bias. The certainty of the evidence was as-
sessed using GRADE.
eHealth interventions for people with chronic kidney disease (Review)
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Main results
We included 43 studies with 6617 participants that evaluated the impact of an eHealth intervention in people with CKD. Included studies
were heterogeneous in terms of eHealth modalities employed, type of intervention, CKD population studied and outcomes assessed. The
majority of studies (39 studies) were conducted in an adult population, with 16 studies (37%) conducted in those on dialysis, 11 studies
(26%) in the pre-dialysis population, 15 studies (35%) in transplant recipients and 1 studies (2%) in transplant candidates We identified
six different eHealth modalities including: Telehealth; mobile or tablet application; text or email messages; electronic monitors; inter-
net/websites; and video or DVD. Three studies used a combination of eHealth interventions. Interventions were categorised into six types:
educational; reminder systems; self-monitoring; behavioural counselling; clinical decision-aid; and mixed intervention types. We identi-
fied 98 outcomes, which were categorised into nine domains: blood pressure (9 studies); biochemical parameters (6 studies); clinical end-
points (16 studies); dietary intake (3 studies); quality of life (9 studies); medication adherence (10 studies); behaviour (7 studies); physical
activity (1 study); and cost-effectiveness (7 studies).
Only three outcomes could be meta-analysed as there was substantial heterogeneity with respect to study population and eHealth modal-
ities utilised. There was found to be a reduction in interdialytic weight gain of 0.13kg (4 studies, 335 participants: MD -0.13, 95% CI -0.28
to 0.01; I2 = 0%) and a reduction in dietary sodium intake of 197 mg/day (2 studies, 181 participants: MD -197, 95% CI -540.7 to 146.8; I2 =
0%). Both dietary sodium and fluid management outcomes were graded as being of low evidence due to high or unclear risk of bias and
indirectness (interdialytic weight gain) and high or unclear risk of bias and imprecision (dietary sodium intake). Three studies reported
death (2799 participants, 146 events), with 45 deaths/1000 cases compared to standard care of 61 deaths/1000 cases (RR 0.74, CI 0.53 to
1.03; P = 0.08). We are uncertain whether using eHealth interventions, in addition to usual care, impact on the number of deaths as the
certainty of this evidence was graded as low due to high or unclear risk of bias, indirectness and imprecision.
Authors' conclusions
eHealth interventions may improve the management of dietary sodium intake and fluid management. However, overall these data suggest
that current evidence for the use of eHealth interventions in the CKD population is of low quality, with uncertain effects due to method-
ological limitations and heterogeneity of eHealth modalities and intervention types. Our review has highlighted the need for robust, high
quality research that reports a core (minimum) data set to enable meaningful evaluation of the literature.
P L A I N   L A N G U A G E   S U M M A R Y
eHealth interventions for people with chronic kidney disease
What is the issue?
Chronic kidney disease (CKD) is a condition where kidneys have reduced function over a period of time. To remain well people with CKD
need to follow complex diet, lifestyle and medication advice and often need to use several specialist medical services. Some people with
advanced CKD may need dialysis or treatment with a kidney transplant. Enabling patients to manage this condition by themselves im-
proves quality and length of life and reduces healthcare costs. Electronic health (eHealth) interventions may improve patients’ ability to
look after themselves and improve care provided by healthcare services. eHealth interventions refer to "health services and information
delivered or enhanced through the Internet and related technologies". However, there is little research evaluating the impact of eHealth
interventions in CKD.
What did we do?
We focused on randomised controlled trials (RCT), which enrolled people with CKD (including pre-dialysis, dialysis or kidney transplant),
and compared eHealth interventions to usual care.
What did we find?
We found 43 studies involving 6617 people who had CKD that examined if eHealth interventions improve patient care and health out-
comes. eHealth interventions used different modes of technology, such as Telehealth, electronic monitors, mobile or tablet applications,
text message or emails, websites, and DVDs or videos. Interventions were classified by their intention: educational, reminder systems,
self-monitoring, behavioural counselling, clinical decision-aids and mixed interventions. We categorised outcomes into nine domains: di-
etary intake, quality of life, blood pressure control, medication adherence, results of blood tests, cost-analysis, behaviour, physical activity
and clinical end-points such as death. We found that it was uncertain whether using an eHealth interventions improved clinical and pa-
tient-centred outcomes compared with usual care. The quality of the included studies was low, meaning we could not be sure that future
studies would find similar results.
Conclusions
We are uncertain whether using eHealth interventions improves outcomes for people with CKD. We need large and good quality research
studies to help understand the impact of eHealth on the health of people with CKD.
eHealth interventions for people with chronic kidney disease (Review)
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Summary of findings for the main comparison.   EHealth interventions compared to standard care in chronic kidney disease populations
EHealth interventions compared to standard care in chronic kidney disease populations
Patient or population: chronic kidney disease populations
Setting: 
Intervention: eHealth interventions
Comparison: standard care
Anticipated absolute effects* (95% CI)Outcomes
Risk with
standard
care
Risk with eHealth in-
terventions
Relative effect
(95% CI)
№ of participants
(studies)
Certainty of the evidence
(GRADE)
Study populationMortality
follow up: mean 12 months
61 per 1,000 45 per 1,000
(32 to 62)
RR 0.74
(0.53 to 1.03)
2906
(3 RCTs) 4
⊕⊝⊝⊝
VERY LOW 1 2 3
Interdialytic weight gain
follow up: range 6 weeks to 16
weeks
  MD 0.13 lower
(0.27 lower to 0.01
higher)
- 335
(4 RCTs) 5
⊕⊕⊝⊝
LOW 1 2
Dietary sodium intake
follow up: mean 4 months
  MD 197 mg lower
(540.7 lower to 146.8
higher)
- 181
(2 RCTs) 6
⊕⊕⊝⊝
LOW 1 3
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level for uncertain or high risk of bias (allocation, blinding, outcome reporting, other biases)
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2 Downgraded one level for inconsistency (different eHealth interventions used, different study lengths)
3 Downgraded one level for imprecision (small sample size or small number of events, confidence intervals overlap)
4 Behavioural counselling intervention (Ishani 2016), Clinical Decision Aid (Cooney 2015), Self-monitoring and Education (Navaneethan 2017)
5 Behavioural counselling intervention (BalanceWise-HD 2013), Self-monitoring intervention (Schulz 2007, Welch 2013, Williams 2017)
6 Behavioural counselling intervention (BalanceWise-HD 2013), Self-monitoring intervention (Koprucki 2010)
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B A C K G R O U N D
Description of the condition
Chronic Kidney Disease (CKD) is associated with high morbidity and
death, which increases as CKD progresses to end-stage kidney dis-
ease (ESKD). Complications of CKD include cardiovascular disease,
premature death, cancer, cognitive decline, anaemia, bone and
mineral disorders and bone fractures, and hospitalisation, all as-
sociated with high health care usage (Stevens 2013; Jha 2013). En-
hancing patient engagement and self-management are the corner-
stones of optimal chronic disease management (Tong 2007). Self-
management programs can improve patient knowledge, health-re-
lated quality of life, delay the need for dialysis, improve clinical out-
comes (e.g. blood pressure), improve treatment adherence and im-
prove survival (Bonner 2014; Chen 2011; Devins 2005). The preven-
tion of CKD, and delaying its progression to ESKD, requires complex
care because it involves both specific CKD management, as well
as management of other prevalent co-morbidities (Lopez-Vargas
2014). Interventions should focus on effective, cost-efficient meth-
ods to improve modifiable risk factors such as weight, blood glu-
cose control, blood pressure (BP) control and poor dietary intake
that can improve morbidity and death (Couser 2011).
Description of the intervention
With rates of CKD and renal replacement therapy rising, there is
a need to find innovative and efficient ways to engage with peo-
ple with CKD and improve health behaviours and outcomes. World-
wide there is a tremendous increase in the use of technologies with
up to 94% of people in developed countries accessing the internet
or owning a smartphone (Pew Research Center 2016). In healthcare
there is increasing interest in utilising technology-based interven-
tions, commonly referred to as eHealth, to improve patient engage-
ment and enhance care. eHealth refers to"health services and in-
formation delivered or enhanced through the Internet and relat-
ed technologies" (Eysenbach 2001), with these interventions being
used to replace standard care or used as an adjunct to standard
care. There is a variety of different eHealth modalities reported in
the literature, including: Telehealth, mobile phone (including text
messaging and the use of applications on mobile phones), internet
and computer, electronic monitors and wireless and Bluetooth en-
abled devices. Within these eHealth interventions there is wide use
of these tools, which are categorised as patient self-management
interventions or clinician decision support tools.
With more people using technology, the development, adoption
and implementation of eHealth holds tremendous promise to im-
prove consumer access to relevant health information, enhance
the quality of care and encourage the adoption of healthy be-
haviours. However, there is currently no published systematic re-
view of data regarding the optimal type, intensity and duration of
eHealth strategies to most effectively elicit knowledge and behav-
iour change. Additionally, there is currently no systematic review of
data regarding the impact of eHealth interventions to improve pa-
tient-centred and clinical outcomes in the CKD population.
How the intervention might work
There are promising outcomes of using eHealth interventions,
when used in addition to traditional counselling techniques, for im-
proving disease management in chronic disease populations. Sys-
tematic reviews evaluating the impact of various eHealth interven-
tions compared to standard care report similar or improved results
regarding glycaemic control (Kitsiou 2017), CVD clinical outcomes
(e.g. hospitalisations, myocardial infarction, stroke) and CVD risk
factors (e.g. body mass index, blood pressure, cholesterol) (Wid-
mer 2015), weight loss maintenance (Sorgente 2017), dietary intake
(Cotter 2014; Kelly 2016) and exercise behaviours (Cotter 2014).
However, to date poor study methodologies and insufficient re-
porting limit the determination of mechanisms that have prompt-
ed behaviour change and resulted in the success or failure of inter-
ventions. (Kitsiou 2017; Widmer 2015). Further research is needed
to ascertain the most effective eHealth intervention/s to promote
behaviour change in different contexts and diseases. In addition,
evaluation of the level of consumer personalisation, frequency of
interaction and duration (e.g. number of weeks, months or years)
of interventions is needed. Similar to traditional interventions (e.g.
in-person counselling, paper-based education), eHealth interven-
tions that are designed with a theoretical basis incorporating con-
tent that is adaptive to individuals’ needs and utilises interactive
components such as self-monitoring, personalised feedback, bidi-
rectional communication and group or peer support may result in
better clinical and patient-centred outcomes (Cotter 2014; Kitsiou
2017; Widmer 2015). To date economic evaluations of eHealth in-
terventions has been sparse and highlights an important area for
further research (Kitsiou 2017; Sanyal 2018).
The use of eHealth interventions in chronic diseases, such as dia-
betes and CVD, have shown eHealth interventions can improve or
provide similar outcomes to traditional interventions (Kitsiou 2017;
Widmer 2015). Given the current literature showing positive trends
for the use of eHealth in chronic disease management and health
behaviour change, it is foreseeable that the CKD population will
benefit from the use of eHealth interventions and further review of
the literature in CKD is warranted.
Why it is important to do this review
It is important to conduct this review, as strategies for improving
patient engagement and enhancing outcomes are vital to reduce
morbidity and death associated with all stages of CKD. Additionally,
eHealth holds much promise for enhancing the delivery of health-
care in CKD and it is vital to determine which strategies are effective
at promoting behaviour change and improve outcomes in CKD.
O B J E C T I V E S
This review aimed to evaluate the benefits and harms of using
eHealth interventions to change health behaviours in people with
CKD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment was
obtained by alteration, use of alternate medical records, date of
birth or other predictable methods) will be included.
Types of participants
Adults and children who have been diagnosed with CKD (i.e. pre-
dialysis, dialysis and kidney transplant recipients) were included.
eHealth interventions for people with chronic kidney disease (Review)
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Diagnosis of CKD is defined by estimated GFR (eGFR) < 60 mL/min
or, eGFR < 90 mL/min with albuminuria or haematuria, for at least
three months or as defined using other clinically indicated criteria.
Types of interventions
Any interventions that the authors report to be using eHealth tech-
nologies to promote behaviour change in CKD. eHealth technolo-
gies include:
• Telephone and Telehealth• Mobile phone (including applications available on these de-
vices)• Computers and tablets (including applications available on
these devices)• Personal Digital Assistants• Internet (including e-mail)• Electronic transmission (e.g. using technologies such as Blue-
tooth)• Social Media• Electronic decision support tools.
The comparisons were as follows.
1. eHealth intervention versus non-eHealth intervention
2. eHealth intervention versus alternate eHealth intervention
3. eHealth intervention versus no intervention or usual care
Meta-analyses were conducted by analysing similar interventions
of the same classifications (e.g. educational versus reminder sys-
tems) together for analysis.
Types of outcome measures
Time intervals at which outcome assessment takes place may af-
fect the effect of the intervention programs. We considered all time
frames used by authors.
1. Clinical parameters
• Electrolyte management (measured using biochemical mea-
surements)• Kidney function (measured using eGFR and/or serum creatinine)• Fluid management (measured using interdialytic weight gain
(IDWG))• Co-morbidity management (measured using BP control, dyslipi-
daemia, HbA1c, fasting and random blood glucose readings, an-
thropometry)• Hospitalisation rates• Death (all causes)
2. Patient-centred parameters
• Dietary intake and behaviours (measured using self-reported
data and qualitative and quantitative surveys)• Physical activity behaviours (using validated tools, quantitative
and qualitative surveys, self-reported data)• Adherence to medications (using validated or self-reported da-
ta)• Adherence to appointments (using validated or self-reported
data)
• Quality of life (measured using global or disease-specific validat-
ed tools)• Nutritional status (measured using validated tools)• Self-management and self-efficacy• Satisfaction with interventions.
3. Cost effectiveness
• Incremental cost-effectiveness ratios (defined as the cost per
quality-adjusted life year gained)• Cost per Disability Adjusted Life Years (DALY)• Costs associated with eHealth intervention.
4. Potential harms
• Additional patient or health professional time associated with
the use of eHealth intervention• Anxiety due to frequent monitoring• Accidents or accidental deaths associated with using the
eHealth intervention (e.g. reading text message while driving).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Register of Stud-
ies up to 14 January 2019 through contact with the Information
Specialist using search terms relevant to this review. The Register
contains studies identified from the following sources.
1. Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings
of major kidney and transplant conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Register are identified through searches of
CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane
Kidney and Transplant. Details of search strategies, as well as a
list of handsearched journals, conference proceedings and current
awareness alerts, are available in the Specialised Register section of
information about Cochrane Kidney and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and clinical
practice guidelines.
2. Letters seeking information about unpublished or incomplete
trials to investigators known to be involved in previous studies.
Data collection and analysis
Selection of studies
We used the search strategy described to obtain titles and abstracts
of studies relevant to the review. Two authors screened the titles
and abstracts independently, studies that are not applicable were
discarded. However, studies and reviews thought to include rele-
eHealth interventions for people with chronic kidney disease (Review)
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vant data or information on studies were retained initially. Two au-
thors independently assessed retrieved abstracts, and when nec-
essary the full text, of these studies to determine studies that satis-
fied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by the same au-
thors using standard data extraction forms. Studies reported in
non-English language were translated before assessment. Where
more than one publication of a study was found, only the publica-
tion with the most complete data was included, however when rel-
evant outcomes were only published in earlier versions these data
were used. Further information required from the original author
was requested by written correspondence and any relevant infor-
mation obtained in this manner was included in the review. Dis-
agreements were resolved in consultation with a third author.
Assessment of risk of bias in included studies
The following items were assessed independently by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately pre-
vented during the study?* Participants and personnel (performance bias)* Outcome assessors (detection bias)• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e9ect
For dichotomous outcomes (e.g. incidence of ESKD, death) results
were expressed as risk ratio (RR) with 95% confidence intervals (CI).
Where continuous scales of measurement were used to assess the
effects of treatment (e.g. quality of life, body weight), the mean dif-
ference (MD) was used, or the standardised mean difference (SMD)
if different scales have been used, also reporting 95% confidence
intervals (CI).
Unit of analysis issues
For studies with multiple treatment groups we combined all rel-
evant experimental intervention groups of the study into a single
group and combined all relevant control intervention groups into a
single group to enable single pairwise comparison.
Dealing with missing data
Any further information required from the original authors was re-
quested by email correspondence and relevant information ob-
tained in this manner was included in the review. Evaluation of im-
portant numerical data such as screened, randomised patients as
well as intention-to-treat, as-treated and per-protocol population
was carefully performed. Attrition rates, losses to follow-up and
withdrawals were investigated. Issues of missing data and imputa-
tion methods (for example, last-observation-carried-forward) was
critically appraised (Higgins 2011).
Assessment of heterogeneity
We first assessed the heterogeneity by visual inspection of the for-
est plot. Heterogeneity was then analysed using a Chi2 test on N-1
degrees of freedom, with an alpha of 0.05 used for statistical signif-
icance and with the I2 test (Higgins 2003). A guide to the interpreta-
tion of I2 values was as follows.
• 0% to 40%: might not be important• 30% to 60%: may represent moderate heterogeneity• 50% to 90%: may represent substantial heterogeneity• 75% to 100%: considerable heterogeneity.
The importance of the observed value of I2 depends on the mag-
nitude and direction of treatment effects and the strength of evi-
dence for heterogeneity (e.g. P-value from the Chi2 test, or a confi-
dence interval for I2) (Higgins 2011).
Assessment of reporting biases
Due to the small number of studies we were unable to assess for the
existence of small study bias using funnel plots.
Data synthesis
We classified our studies by target of intervention (educational,
reminder system, educational plus reminders, behavioural coun-
selling, self-monitoring and clinical decision aid). Treatment esti-
mates for specified outcomes (those that were reported by two
or more studies) were summarised within groups of intervention
types and treatment effects were summarised using random-ef-
fects meta-analysis. The eHealth interventions and associated im-
plementation strategies were described using the "Better reporting
of interventions: Template for Intervention Description and Repli-
cation (TIDieR) checklist and guide" (Hoffmann 2014) and tabulat-
ed in the review.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was used to explore possible sources of hetero-
geneity. In our protocol we stated we would conduct subgroup
analysis based on technology (e.g. mobile phone, internet). How-
ever, classifying interventions using technology type did not ex-
plain heterogeneity between interventions. Additionally, classifica-
tion of studies by the World Health Organization's framework of in-
terventions for clients (Appendix 3) did not provide sufficient sub-
group differentiation as the majority of studies could be classified
into two types of interventions: targeted communication to clients
and personal health tracking. We determined that heterogeneity
between eHealth interventions was better explained by the target
of the intervention (e.g. educational versus self-monitoring) and
therefore we used these classifications when conducting subgroup
analyses. There were insufficient extractable data to conduct sub-
group and univariate meta-regression analysis to explore the fol-
lowing variables as possible sources of heterogeneity: mean study
age, mean proportion of men, adequacy of allocation concealment,
sample size, and duration of follow up (< 12 months versus ≥ 12
months).
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Sensitivity analysis
There were insufficient extractable data to perform the following
sensitivity analyses in order to explore the influence of the follow-
ing factors on effect size:
• Repeating the analysis excluding unpublished studies• Repeating the analysis taking account of risk of bias, as specified• Repeating the analysis excluding any very long or large studies
to establish how much they dominate the results• Repeating the analysis excluding studies using the following fil-
ters: diagnostic criteria, language of publication, source of fund-
ing (industry versus other), and country.
'Summary of findings' tables
We presented the main results of the review in 'Summary of find-
ings' tables. These tables present key information concerning the
quality of the evidence, the magnitude of the effects of the inter-
ventions examined, and the sum of the available data for the main
outcomes (Schünemann 2011a). The 'Summary of findings' table
includes an overall grading of the evidence related to each of the
main outcomes using the GRADE (Grades of Recommendation, As-
sessment, Development and Evaluation) approach (GRADE 2008;
GRADE 2011). The GRADE approach defines the quality of a body of
evidence as the extent to which one can be confident that an esti-
mate of effect or association is close to the true quantity of specific
interest. The quality of a body of evidence involves consideration of
within-trial risk of bias (methodological quality), directness of evi-
dence, heterogeneity, precision of effect estimates and risk of pub-
lication bias (Schünemann 2011b).
The key outcomes presented in the Summary of findings table 1 in-
clude:
• Death• Fluid management• Dietary intake (sodium).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
We searched the Specialised Register and identified 132 records.
After screening titles and abstracts and full-text review, 43 stud-
ies (93 records) were included and nine studies (27 records) were
excluded. Twelve ongoing studies were identified (CONNECT 2017;
eNEPHRO 2017; Jung 2017; KARE 2015; Kosaka 2017; MAGIC 2016;
NCT00394576; NCT02097550; NCT02610946; TELEGRAFT 2015; Wa-
terman 2015; WISHED 2016), These 12 studies and will be assessed
in a future update of this review (Figure 1).
 
Figure 1.   Study flow diagram.
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Included studies
We included 43 studies (93 reports; 6617 participants) in this re-
view. The included studies were conducted between 1999 and
2017, with the majority published since 2010 (38 of 43 studies,
88%). Nine studies (Durand 2000; Halleck 2017; Han 2016; Hard-
staff 2002; Jammalamadaka 2015; Ong 2017; Potter 2016; SUBLIME
2016; White 2010) (23%) had only abstracts from conference pro-
ceedings or short reports available. All studies were published in
English. The majority of studies were conducted in an adult pop-
ulation (39 studies), and the majority of studies were conducted
in North America (26 studies). Eleven studies enrolled 4315 partici-
pants with pre-dialysis CKD, 10 studies enrolled 681 participants on
haemodialysis (HD), six studies enrolled 281 participants on peri-
toneal dialysis, 15 studies enrolled 1281 kidney transplant recipi-
ents, and one study enrolled 288 transplant candidates. Participant
numbers ranged from 6 to 2199 (mean study population, 153; me-
dian study population, 75), with study durations varying from one
clinic appointment to 24 months (median follow-up period was 16
weeks). Most (20 studies) compared an eHealth intervention to usu-
al care involving traditional methods (e.g. face-to-face counselling),
11 studies did not adequately describe the control group and 12
studies compared an active eHealth intervention to a passive, con-
trol eHealth intervention. Studies used various eHealth technolo-
gies including: Telehealth (e.g. phone calls, video monitoring, tele-
conferencing) (10 studies), mobile phone or tablet applications (11
studies), mobile phone text messaging or emails (2 studies), elec-
tronic monitors (11 studies), internet or website (4 studies), video
or DVD (2 studies), or mixed methods, where more than one eHealth
technology was used (3 studies). Table 1 provides an overview of
the characteristics of included studies.
Our study classifications were as follows:
• Educational (four studies: Baraz 2014; Diamantidis 2015; Giaco-
ma 1999; InformMe 2017)• Reminders (6 studies: Halleck 2017; Han 2016; Henriksson 2016;
Jammalamadaka 2015; McGillicuddy 2013; Potter 2016)• Self-monitoring (9 studies: BALANCEWise-HD 2011; BALANCE-
Wise-PD 2011; Koprucki 2010; Kullgren 2015; Ong 2017; Rifkin
2013; Schulz 2007; Welch 2013; Williams 2017)• Behavioural counselling (16 studies: BalanceWise-HD 2013;
BRIGHT 2013; Cargill 2003; iDiD 2016; Ishani 2016; Kargar Jahro-
mi 2016; Li 2014b; MESMI 2010; Poorgholami 2016a; Reil-
ly-Spong 2015; Russell 2011; Schmid 2016; Swallow 2016; TAKE-
IT 2014; White 2010)• Clinical decision-aids (4 studies: Cooney 2015; Durand 2000;
Hardstaff 2002; iChoose 2016)• Mixed interventions (4 studies: Navaneethan 2017; Reese 2017;
Robinson 2014a; Robinson 2015)
Of the 43 studies, seven studies reported outcome data used in
quantitative analyses, while data from 24 studies could only be
presented descriptively. Eleven studies could not be included in
qualitative analyses due to insufficient reporting of outcome data
(Cargill 2003; Diamantidis 2015; Giacoma 1999; Halleck 2017; Han
2016; Ong 2017; SUBLIME 2016; White 2010) or data was only be-
ing available for the intervention group (BALANCEWise-HD 2011,
BALANCEWise-PD 2011; Swallow 2016). Reported outcomes were
broadly categorised as:
Clinical parameters
• Blood pressure control (9 studies)• Biochemical parameters (6 studies)• Clinical end-points (16 studies)
Patient-centred parameters
• Dietary intake (3 studies)• Quality of life (9 studies)• Medication adherence (10 studies)• Behaviour (7 studies)• Physical activity (1 study)
Cost-effectiveness
• Cost-analysis (7 studies)
We identified 98 outcomes within these domains. However, 65 out-
comes (66%) were only reported by single studies. Additionally,
due to the heterogeneity of interventions only three outcomes (di-
etary sodium intake, IDWG and death) were able to be quantitative-
ly analysed. Tables 2 to 7 (Table 2; Table 3; Table 4; Table 5; Table
6; Table 7) contain descriptive analyses for reported outcomes. Fig-
ure 2 depicts a bubble plot of reported outcomes.
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Figure 2.   Bubble plot of reported outcomes by intervention type
 
Excluded studies
Nine studies (27 reports) were excluded during title and full text
screening. The reasons for exclusion were study population did not
have CKD (Abdel-Kader 2011; Korus 2017; RaDIANT 2014; Rober-
to 2009; Wilson 2014), interventions did not include eHealth (Chen
2011e; SMILE 2010) and the wrong study design (Morales-Barria
2016; Warren 2009).
Risk of bias in included studies
Figure 3 provides a summary of the risk of bias for the included
studies with the study-level data provided in Figure 4. Methodolog-
ical quality varied considerably, with many studies providing insuf-
ficient information to accurately assess the risk of bias.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 4.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 4.   (Continued)
 
 
eHealth interventions for people with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 4.   (Continued)
 
eHealth interventions for people with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Allocation
Random sequence generation
Random sequence generation was assessed as low risk of bias in 24
studies (BalanceWise-HD 2013; Baraz 2014; BRIGHT 2013; Cooney
2015; Giacoma 1999; Henriksson 2016; iChoose 2016; iDiD 2016; In-
formMe 2017; Ishani 2016; Kullgren 2015; Li 2014b; MESMI 2010;
Navaneethan 2017; Poorgholami 2016a; Reilly-Spong 2015; Rifkin
2013; Robinson 2014a; Robinson 2015; Russell 2011; Schmid 2016;
Swallow 2016; TAKE-IT 2014; Welch 2013), and unclear in the re-
maining 19 studies.
Allocation concealment
Allocation concealment was assessed at low risk of bias in 13 stud-
ies (BRIGHT 2013; Cooney 2015; Giacoma 1999; Henriksson 2016;
iDiD 2016; InformMe 2017; Ishani 2016; MESMI 2010; Reilly-Spong
2015; Rifkin 2013; Robinson 2014a; Russell 2011; TAKE-IT 2014), and
unclear in the remaining 30 studies with insufficient information to
permit judgment.
Blinding
Performance bias
Performance bias (participants) was assessed as being at high or
unclear risk of bias in all studies.
In four studies (Jammalamadaka 2015; MESMI 2010; Navaneethan
2017; Robinson 2014a) performance bias (personnel) was assessed
to be at low risk of bias. Twenty-seven studies were assessed to be
at high risk of bias (BALANCEWise-HD 2011; BalanceWise-HD 2013;
BALANCEWise-PD 2011; Baraz 2014; BRIGHT 2013; Cargill 2003;
Cooney 2015; Giacoma 1999; iChoose 2016; iDiD 2016; InformMe
2017; Ishani 2016; Kargar Jahromi 2016; McGillicuddy 2013; Ong
2017; Poorgholami 2016a; Potter 2016; Reese 2017; Reilly-Spong
2015; Rifkin 2013; Russell 2011; Schmid 2016; Schulz 2007; Swallow
2016; TAKE-IT 2014; Welch 2013; White 2010) and unclear in the re-
maining 12 studies.
Detection bias
Detection bias (objective outcomes) was assessed to be at low risk
of bias in 42 studies, and unclear in one study (Halleck 2017).
Detection bias (subjective outcomes) was assessed as being at low
risk of bias in 17 studies (BALANCEWise-HD 2011; BALANCEWise-PD
2011; Cargill 2003; Durand 2000; Hardstaff 2002; Henriksson 2016;
iChoose 2016; Ishani 2016; Jammalamadaka 2015; Navaneethan
2017; Ong 2017; Potter 2016; Reese 2017; Robinson 2014a; Robin-
son 2015; TAKE-IT 2014; Williams 2017), high risk of bias in 14 stud-
ies (BalanceWise-HD 2013; BRIGHT 2013; Cooney 2015; Diamantidis
2015; Halleck 2017; Han 2016; Kullgren 2015; McGillicuddy 2013;
MESMI 2010; Reilly-Spong 2015; Rifkin 2013; Russell 2011; Welch
2013; White 2010), and unclear in the remaining 12 studies.
Incomplete outcome data
Twenty-four studies were considered to be low risk of attrition
bias (Baraz 2014; BRIGHT 2013; Cargill 2003; Cooney 2015; Diaman-
tidis 2015; Henriksson 2016; iChoose 2016; iDiD 2016; InformMe
2017; Ishani 2016; Jammalamadaka 2015; Kargar Jahromi 2016;
McGillicuddy 2013; MESMI 2010; Navaneethan 2017; Poorgholami
2016a; Reese 2017; Reilly-Spong 2015; Rifkin 2013; Robinson 2014a;
Robinson 2015; Schmid 2016; TAKE-IT 2014; Williams 2017). Five
studies (Hardstaff 2002; Russell 2011; SUBLIME 2016; Swallow 2016;
Welch 2013) were assessed to be at high risk of bias as more than
20% of participants were lost to follow-up; the remaining 14 studies
were unclear due to insufficient information.
Selective reporting
Studies were considered to be at high risk of bias if data were
provided in a format which could not be entered into the meta-
analyses or if stated outcomes were not reported. We assessed
three studies (BRIGHT 2013; Navaneethan 2017; TAKE-IT 2014) to
be at low risk of reporting bias. Fourteen studies were assessed
at high risk of reporting bias (BALANCEWise-HD 2011; BALANCE-
Wise-PD 2011; Diamantidis 2015; Giacoma 1999; Han 2016; iDiD
2016; Li 2014b; MESMI 2010; Ong 2017; Reilly-Spong 2015; Russell
2011; Schulz 2007; SUBLIME 2016; Swallow 2016), and the remain-
ing 26 studies were unclear due to insufficient information. Ten
studies only had abstracts or short reports available, limiting our
ability to accurately assess reporting bias.
Other potential sources of bias
One study was assessed to be at low risk of other potential bias
due to transparent reporting and following protocol (BRIGHT 2013).
Thirteen studies were assessed to be at high risk of bias (Cargill
2003; Cooney 2015; Giacoma 1999; Hardstaff 2002; iDiD 2016; Jam-
malamadaka 2015; Kullgren 2015; Li 2014b; McGillicuddy 2013; Na-
vaneethan 2017; Robinson 2014a; Robinson 2015; Welch 2013), and
the remaining 29 studies were assessed to have unclear risk due to
insufficient information.
E9ects of interventions
See: Summary of findings for the main comparison EHealth in-
terventions compared to standard care in chronic kidney disease
populations
Because of considerable heterogeneity in the population, interven-
tions, and outcomes, we were unable to generate meaningful sum-
mary estimates with the exception of death, self-management for
IDWG and dietary sodium intake. The remainder of the studies are
grouped by six categories of interventions and the results summa-
rized descriptively.
Death (all causes)
Three studies conducted in pre-dialysis CKD populations using
behavioural counselling (Ishani 2016), education (Navaneethan
2017), and clinical decision-aid (Cooney 2015) interventions report-
ed death (Figure 5). The certainty of evidence was considered to be
very low due to high or uncertain risk of bias, imprecision and indi-
rectness. We are uncertain whether employing various eHealth in-
terventions reduces the number of deaths (Analysis 1.1 (3 studies,
2906 participants): RR 0.74, 95% CI 0.53 to 1.03; I2 = 0%).
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Figure 5.   Forest plot of comparison: 1 Death, outcome: 1.1 Death.
 
Interdialytic weight gain
Four studies conducted in HD-dependent populations using self-
management (BalanceWise-HD 2013) and self-monitoring inter-
ventions (Schulz 2007; Welch 2013; Williams 2017) reported IDWG
(Figure 6). The certainty of evidence was considered to be low due
to high or uncertain risk of bias and indirectness. Participants us-
ing electronic self-monitoring devices (e.g. personal digital assis-
tants, Fitbit Flex or wireless body weight scales) reduced their av-
erage IDWG by 0.13 kg. Using an eHealth intervention to enhance
patient self-monitoring may lead to slightly improved IDWG when
compared to a non-eHealth intervention usual care group (Analysis
2.1 (4 studies, 335 participants): MD -0.13 kg, 95% CI -0.27 to 0.01;
I2 = 0%).
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Figure 6.   Forest plot of comparison: Interdialytic weight gain
 
Dietary sodium intake
Two studies using behavioural counselling (BalanceWise-HD 2013;
SUBLIME 2016) and one using self-monitoring interventions (Ko-
prucki 2010) reported dietary sodium intake. Two were able to
be combined due to similarities in target population (dialysis-de-
pendent populations), study length, and eHealth intervention used
(BalanceWise-HD 2013; Koprucki 2010) (Figure 7). The certainty of
evidence was considered to be low due to high or uncertain risk
of bias and imprecision (small sample size). Participants using an
electronic dietary monitoring application consumed 197 mg less
sodium/day. Self-monitoring interventions with additional coun-
selling from a clinician (e.g. use of personal digital assistants to
track dietary intake with dietetic consultation) may lead to slightly
improved dietary sodium intakes in a dialysis-dependent popula-
tion (Analysis 3.1 (2 studies, 181 participants): MD -196.97, 95% CI
-540.76 to 146.83; I2 = 0%). SUBLIME 2016 did not provide sufficient
detail to be included in the meta-analysis, however they reported
a statistically significant improvement in dietary sodium intake fol-
lowing a three-month internet-based self-management interven-
tion in CKD population when compared to a non-eHealth control
group.
 
Figure 7.   Forest plot of comparison: 5 Dietary sodium, outcome: 5.1 Dietary sodium intake.
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Educational interventions
Educational interventions were defined as interventions aimed at
improving knowledge and skills that can be acquired by learning
and instruction.
Four studies (Baraz 2014; Diamantidis 2015; Giacoma 1999; Infor-
mMe 2017) involving 457 participants evaluated educational inter-
ventions. Studies were conducted in various populations, including
CKD (20 participants) (Diamantidis 2015), HD (90) (Baraz 2014), kid-
ney transplant candidates (288) (InformMe 2017), and kidney trans-
plant recipients (59) (Giacoma 1999).
A range of technologies were used, including iPad application (Dia-
mantidis 2015; InformMe 2017), mobile phone text messaging (Dia-
mantidis 2015), and video (Baraz 2014, Giacoma 1999). Three stud-
ies (Giacoma 1999, Baraz 2014, InformMe 2017) compared the
eHealth intervention to usual in-person education, while Diaman-
tidis 2015 compared two eHealth interventions.
Knowledge was measured by Giacoma 1999 and InformMe 2017.
Knowledge improved in the iPad education group compared to
usual care (Analysis 8.1.1: SMD 0.59, 95% CI 0.35, 0.82; P < 0.001) (In-
formMe 2017) and post video-based education (t = 4.9; P < 0.0001)
(Giacoma 1999) (Table 2). InformMe 2017 evaluated participants
willingness to accept a high risk donor kidney (Table 2), however
there was no significant difference between the participants receiv-
ing education modules on an iPad app and those receiving usual
care (Analysis 10.3.1: MD -0.20, 95% CI -0.44 to 0.03; P = 0.09). Baraz
2014 evaluated a number of quality of life domains using the SF-36
(Table 2). There was no significant difference between oral or video
education in any domains of physical or emotional quality of life.
Diamantidis 2015 evaluated usability of text messaging and iPad
applications and reported low rate of errors in both the text mes-
saging and iPad application groups, however did not provide suffi-
cient information for analysis. All outcomes reported in education-
al interventions are outlined in Table 2.
Reminder interventions
Reminder interventions were defined as systems used to prompt
or aid the memory. The systems can be audible or visual alarms,
computerized reminders or phone calls or messaging.
Five studies (Han 2016; Henriksson 2016; Jammalamadaka 2015;
McGillicuddy 2013; Potter 2016) involving 311participants eval-
uated a reminder intervention. Studies were conducted in kid-
ney transplant recipients (271 participants) (Han 2016; Henriksson
2016; McGillicuddy 2013; Potter 2016) and HD (40) (Jammalamada-
ka 2015). Wireless or electronic medication trays with audible and/
or visual alarms (Henriksson 2016; McGillicuddy 2013; Potter 2016),
mobile phone application (Han 2016), and mobile phone text mes-
sage reminders (Jammalamadaka 2015) were evaluated. All five
studies compared the use of an eHealth intervention to usual care.
Adherence was evaluated by three studies (Han 2016; Henriksson
2016; McGillicuddy 2013). McGillicuddy 2013 reported an improve-
ment in medication adherence at three months (Analysis 6.2.3: MD
3.22, 95% CI 1.76 to 4.68). Henriksson 2016 only evaluated adher-
ence in the intervention group and reported 97.9% compliance
with immunosuppressive treatment at three months and 96% at
10 to 12 months. Han 2016 reported no difference in adherence be-
tween the intervention and control groups (74.1% versus 66.1%,
P = 0.36). Both Potter 2016 and Henriksson 2016 reported number
of biopsies performed, with Potter 2016 reporting less biopsies in
the intervention group (4 versus 9). Conversely, Henriksson 2016
reported a higher rate of biopsies performed in the intervention
group, with 32 biopsies needed in 17 participants, compared to 60
biopsies needed in 38 control participants. All outcomes reported
in reminder interventions are detailed in Table 3.
Self-monitoring interventions
Self-monitoring interventions were defined as interventions that
are aimed at measuring one’s target behaviour and comparing to
an external standard or goal that can result in lasting improve-
ments in behaviour.
Nine studies (BALANCEWise-HD 2011; BALANCEWise-PD 2011; Ko-
prucki 2010; Kullgren 2015; Ong 2017; Rifkin 2013l Schulz 2007;
Welch 2013; Williams 2017) involving 498 participants utilised a
self-monitoring intervention. Studies were conducted in HD (215
participants) (BALANCEWise-HD 2011; Schulz 2007; Welch 2013;
Williams 2017), peritoneal dialysis (45) (BALANCEWise-PD 2011; Ko-
prucki 2010), CKD (206) (Ong 2017; Rifkin 2013), and paediatric kid-
ney transplant recipients (32) (Kullgren 2015). Personal digital as-
sistant (BALANCEWise-HD 2011, BALANCEWise-PD 2011; Koprucki
2010; Welch 2013), telemetric bodyweight machine (Schulz 2007),
an interactive water bottle (Kullgren 2015), Fitbit Flex physical ac-
tivity tracker (Williams 2017), and wireless transmission of clinical
data to a healthcare team (Rifkin 2013) were evaluated. One study
compared an interactive dietary monitoring application to a pas-
sive physical activity log (Welch 2013). Williams 2017 compared the
use of a Fitbit Flex tracker with feedback regarding physical ac-
tivity and sleep to no feedback. Koprucki 2010 compared an in-
teractive dietary monitoring application plus computer-based ed-
ucation module versus computer-based education module alone.
The remaining four studies (BALANCEWise-HD 2011; Kullgren 2015;
Rifkin 2013; Schulz 2007) compared an eHealth intervention to usu-
al care.
Systolic and diastolic blood pressure was reported by three studies
(Ong 2017; Rifkin 2013; Schulz 2007). Rifkin 2013 found no signifi-
cant change in systolic or diastolic blood pressure between eHealth
and usual care groups. Schulz 2007 found no significant chance in
systolic blood pressure, however did report a significant improve-
ment in diastolic blood pressure with the use of telemetric body
weight scales compared to usual care. Ong 2017 reported a signif-
icant reduction in systolic and diastolic blood pressure with the
use of a blood pressure self-monitoring application that provided
feedback, compared to a passive self-monitoring application (MD
-5 mmHg and -3.5 mmHg respectively).
Williams 2017 was the only study to report physical activity, and re-
ported no difference in physical activity with the use of a Fitbit Flex
with feedback on progress or no feedback on progress. Kullgren
2015 reported a significantly higher fluid intake in the intervention
group using an interactive water bottle compared to those in the
control group, however there were no differences in serum sodium,
urea, or creatinine.
No data from BALANCEWise-HD 2011 or BALANCEWise-PD 2011
could be reported as only intervention group data was reported.
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All outcomes reported in self-monitoring interventions are outlined
in Table 4.
Behavioural counselling interventions
Behavioural counselling interventions were defined as interven-
tions aimed at enabling patients to assume responsibility for man-
aging their condition through the systematic provision of educa-
tion and supportive interventions to increase skills and confidence
in managing health problems, and included regular assessment
and/or progress, goal setting and problem solving support.
Sixteen studies (BalanceWise-HD 2013; BRIGHT 2013; Cargill 2003;
iDiD 2016; Ishani 2016; Kargar Jahromi 2016; Li 2014b; MESMI
2010; Poorgholami 2016a; Reilly-Spong 2015; Russell 2011; Sch-
mid 2016; SUBLIME 2016; Swallow 2016; TAKE-IT 2014; White 2010)
involving 2069 participants utilised a behavioural counselling in-
tervention. Studies were conducted in CKD (1240 participants)
(BRIGHT 2013; Ishani 2016; MESMI 2010; SUBLIME 2016; Swallow
2016), HD (339) (BalanceWise-HD 2013; iDiD 2016; Kargar Jahromi
2016; Poorgholami 2016a), peritoneal dialysis (206) (Cargill 2003;
Li 2014b; White 2010), kidney transplant recipients (124) (Sch-
mid 2016; Reilly-Spong 2015; Russell 2011), and adolescent kid-
ney transplant recipients (169) (TAKE-IT 2014). Telephone (Kar-
gar Jahromi 2016; Li 2014b; Poorgholami 2016a), telephone plus
website (BRIGHT 2013; iDiD 2016), telephone plus DVD education
(MESMI 2010), videoconferencing support (Cargill 2003; Schmid
2016; Reilly-Spong 2015; White 2010), Telehealth support with wire-
less transmission of clinical data (Ishani 2016), websites (SUBLIME
2016; Swallow 2016), personal digital assistants (BalanceWise-HD
2013), and electronic medication monitors with clinician support
(Russell 2011; TAKE-IT 2014) were evaluated. One study compared
a videoconferencing to telephone support (Reilly-Spong 2015), All
other studies compared eHealth to non-eHealth usual care.
Fatigue was evaluated by three studies (BRIGHT 2013; Li 2014b;
Reilly-Spong 2015), with no differences detected between eHealth
intervention and control groups in any studies. Four studies (Sch-
mid 2016; MESMI 2010; Russell 2011; TAKE-IT 2014) evaluated med-
ication adherence.
Three studies (Russell 2011; Schmid 2016; TAKE-IT 2014) report-
ed significant improvements in medication adherence when using
electronic monitoring plus clinician counselling. Russell 2011 re-
ported a significant improvement in medication adherence using
electronic medication monitoring with nurse education (SMD 1.27,
95% CI 0.01 to 2.53; P = 0.039). Similarly Schmid 2016 reported a
significant improvement in medication adherence utilising video
monitoring support with a multidisciplinary team (RR 1.90, 95% CI
1.15 to 3.14; P = 0.013). TAKE-IT 2014 reported a significant improve-
ment in both medication taking adherence (OR 1.66, CI 1.15 to 2.39)
and timing adherence (OR 1.74, CI 1.21 to 2.50) using personalised
coaching with electronic medication reminders. There was no dif-
ference in medication adherence in eHealth intervention or control
groups reported by MESMI 2010.
Anxiety was evaluated by four studies (BRIGHT 2013; iDiD 2016; Kar-
gar Jahromi 2016; Reilly-Spong 2015). Kargar Jahromi 2016 report-
ed a significant reduction in anxiety following a one month tele-
phone follow-up intervention (MD -5.15, 95% CI -6.29 to -4.01; P
= 0.01), however BRIGHT 2013, iDiD 2016 and Reilly-Spong 2015
found no difference in anxiety levels between eHealth intervention
and control groups.
Depression was evaluated by three studies (iDiD 2016; Kargar
Jahromi 2016; Reilly-Spong 2015). Whilst Kargar Jahromi 2016 re-
ported significantly less depression in the telephone follow-up
group (MD -5.09, 95% CI -6.22 to -3.96; P = 0.05), Reilly-Spong 2015
reported higher levels in the eHealth intervention group receiving
group teleconference support when compared to those a one-on-
one telephone support (MD 0.72, 95% CI 0.15 to 1.28; P = 0.05). iDiD
2016 reported no difference in levels of depression when compar-
ing an online CBT intervention versus online CBT with telephone
support.
Three studies evaluated blood pressure (BRIGHT 2013; Ishani 2016;
MESMI 2010). BRIGHT 2013 reported a significant improvement in
blood pressure control when utilising a multi-modal eHealth inter-
vention (telephone follow-up and website) compared to usual care.
Ishani 2016 and MESMI 2010 reported no difference in blood pres-
sure control.
Two studies (Ishani 2016; Li 2014b) evaluated hospital readmission
rates, however no difference was found between eHealth interven-
tion and control groups.
All outcomes reported by behavioural counselling interventions
are outlined in Table 5.
Clinical decision-aid interventions
Clinical decision-aids provided clinicians or patients with knowl-
edge and person-specific information presented at times to en-
hance decision-making.
Four studies (Cooney 2015; Durand 2000; Hardstaff 2002; iChoose
2016) involving 2543 participants utilised a clinical decision-aid in-
tervention. Studies were conducted in various populations, includ-
ing CKD (2642 participants) (Cooney 2015; iChoose 2016), kidney
transplant recipients (100) (Hardstaff 2002), and peritoneal dialy-
sis (30) (Durand 2000). Telephone follow-up (Cooney 2015), an on-
line risk calculator (iChoose 2016), blue-tooth transmission of clin-
ical data to clinicians (Durand 2000), and Smartcap medication
caps (Hardstaff 2002) were evaluated. All four studies compared an
eHealth intervention to usual care.
Medication adherence was evaluated by two studies (Cooney 2015;
Hardstaff 2002). Hardstaff 2002 reported an improvement in med-
ication adherence in the eHealth group compared to usual care (RR
1.9, 95% CI 1.15 to 3.14). Cooney 2015 reported no significant differ-
ence in medication adherence between those receiving telephone
follow-up and those who did not (MD -0.08, 95% CI -0.17 to 0.00);
however 51.5% of the intervention group did not receive the inter-
vention. Cooney 2015 reported a lower rate of death in the interven-
tion group, however this did not reach statistical significance (RR
0.71, 95% CI 0.5 to 1.01; P = 0.06).
All outcomes reported in clinical decision-aid interventions are out-
lined in Table 6.
Mixed interventions
Four studies (Navaneethan 2017; Reese 2017; Robinson 2014a;
Robinson 2015) involving 602 participants employed interventions
with multiple strategies. Three studies were conducted in kidney
transplant recipients (Reese 2017; Robinson 2014a; Robinson 2015)
and one study in CKD (Navaneethan 2017). Reese compared usu-
al care to a reminder intervention and a reminder plus education
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intervention. Robinson 2014a compared a paper based education
module electronic reminders to usual care; Robinson 2015 com-
pared an iPad education module with electronic reminders top usu-
al care; and Navaneethan 2017 compared usual care (electronic
self-monitoring) to usual care plus education (direction to an edu-
cational website).
Knowledge, self-care behaviours, attitudes towards performing be-
haviour and willingness to perform behaviour were evaluated by
two studies (Robinson 2014a; Robinson 2015). There was a signifi-
cant improvement in knowledge, self-care behaviours, attitudes to-
wards performing behaviour and willingness to perform behaviour
in the eHealth intervention groups of both studies.
Reese 2017 reported a significant improvement in medication ad-
herence from three to six months of the study with 55% adherence
in usual care versus 78% in the reminders group and 88% in the re-
minders plus education group (P < 0.001).
Navaneethan 2017 reported no significant difference in rate of kid-
ney function decline, rate of hospitalisations, dialysis initiation
or transplantation and death during the two year study period
between usual care and the additional educational intervention
group.
All outcomes reported in mixed intervention studies are detailed in
Table 7.
Cost-analysis
Seven of 43 studies described costs associated with delivery of
the eHealth intervention. Five studies (BRIGHT 2013; Durand 2000;
Henriksson 2016; Schmid 2016; SUBLIME 2016) reported cost-sav-
ings associated with the use of eHealth interventions. Positive cost-
analyses were based on cost of unexpected treatments (e.g. rejec-
tions, unplanned hospital admissions, increased specialist consul-
tant visits) being higher in control groups or intervention groups
having lower cost of treatment due to improved disease control (re-
duced blood pressure, reduced sodium intake). Cargill 2003 report-
ed significantly higher costs due to set up of videophones and inter-
net lines and ongoing phone charges, and one study (iDiD 2016) re-
ported increased costs due to the increased rate of inpatient hospi-
tal admissions, that the authors attributed to the unevenly distrib-
uted allocation to the intervention arm.
Acceptability and feasibility
Eighteen studies measured acceptability (e.g. satisfaction, ease of
use) and feasibility (e.g. intervention adherence and uptake). Stud-
ies reported participant satisfaction due to ease of use, low burden
of eHealth intervention, informative and enjoyment of increased in-
teractions with healthcare staF. eHealth interventions were report-
ed as feasible due to high uptake and high levels of participant sat-
isfaction. However, technical issues (e.g. poor internet connection
or device failure) were reported to limit intervention uptake (Cargill
2003; McGillicuddy 2013).
Harms
Only Henriksson 2016 reported that six participants had prema-
turely withdrawn from the electronic medication monitoring trial
due to feeling overly monitored. Other potential harms were not re-
ported by any studies.
D I S C U S S I O N
Summary of main results
We identified 43 studies (93 reports, 6617 participants) that were
conducted using a variety of eHealth technologies to replace or en-
hance standard care in CKD. eHealth interventions were evaluated
for a mean of 12 weeks (ranging from one clinic appointment to 12
months), with the majority of studies (27; 63%) enrolling less than
100 participants. Interventions were classified as either education-
al, reminders, self-monitoring, behavioural counselling clinical de-
cision aids or mixed interventions, and were either compared to tra-
ditional methods (e.g. face-to-face counselling) (20) or to a different
eHealth intervention (12); in 11 studies the control group was not
described. The studies included in this review involved people with
CKD stage 1-5, dialysis-dependent populations, transplant recipi-
ents and transplant candidates; the majority of studies were con-
ducted in an adult population (40 studies).
There was considerable heterogeneity between eHealth interven-
tion designs and eHealth technologies used. The multiplicity of out-
comes reported limited our ability to conduct meaningful meta-
analyses. Only three outcomes could be meta-analysed (dietary
sodium intake, IDWG, death) due to substantial variation between
eHealth intervention, study population and study length. Clinical
end-point outcomes were the most frequently reported, with 16
studies reporting 25 different clinical end-points, 19 of which were
only reported by one study. Additionally, there was a substantial
number of behavioural, biochemical, and quality of life outcomes
reported by only one study, limiting our ability to synthesize the
data and formulate conclusions. Also, high or unclear risk of bias
in many of the included studies, combined with imprecision in ef-
fect measurements, indirectness of interventions and study popu-
lations and poor reporting of study results led to low confidence in
results. No studies in this review reported on outcomes related to
physical activity or nutritional status.
Overall, these data suggest that current evidence for eHealth inter-
ventions in the CKD population is of low quality and is insufficient to
guide clinical practice. However, possible benefits may be reduced
costs relating to patient care. The increasing use of technology in
people’s lifestyles, and the high levels of participant satisfaction
and acceptability reported by studies, suggest that eHealth inter-
ventions may offer an adjunct to usual care in CKD. However, due
to the low and very low quality of evidence it is unclear whether
eHealth interventions alone alter health related behaviours in CKD
population. Additionally, it remains unclear whether eHealth in-
terventions offer a cost-effective alternative to current treatment
models.
Overall completeness and applicability of evidence
The strengths of this review include comprehensive systematic
searching for eligible studies, rigid inclusion criteria for RCTs and
data extraction and analysis by two independent investigators,
which limited the risk of errors in determining study eligibility, data
extraction, risk of bias assessment, and data synthesis. We aimed
to evaluate the effectiveness of eHealth interventions to improve
a range of important outcomes for people with CKD. We could not
robustly assess the effect of eHealth as there were few studies of
sufficient size and duration with adequate reporting of methods
and outcomes to examine clinical or patient outcomes. The vari-
ability in outcome measures and measurement tools used limited
eHealth interventions for people with chronic kidney disease (Review)
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our ability to synthesize the data, and the use of standardised out-
comes would be helpful in the future.
Quality of the evidence
We assessed the quality of evidence using GRADE methodology.
Full-length journals were available for 33 studies, whilst 10 stud-
ies had only abstracts or short reports available. Included studies
were commonly reported incompletely and were of poor method-
ological quality. The majority of studies were assessed to be at high
risk or uncertain risk of bias relating to selection bias, performance
bias, detection bias (subjective outcomes), reporting bias, and oth-
er biases. The high level of uncertain risk of bias assessment was
due to poor methodological and outcome reporting of studies.
The overall certainty of evidence using GRADE was assessed as low
for dietary sodium intake and IDWG. Our ability to conduct meta-
analyses was limited due to small, heterogeneous study popula-
tions, substantial variability of eHealth technologies used and the
multiplicity of reported outcomes.
Potential biases in the review process
Potential biases in this review relate to the data availability in the
individual studies. Firstly, the small number of data observations
limited our ability to conduct robust statistical estimates of hetero-
geneity and meant we could not assess for potential publication
bias due to the small number of studies. Secondly, studies were fre-
quently at high risk of bias but poorer quality studies could not be
excluded from sensitivity analyses due to the limited number of da-
ta observations. Thirdly, adverse event reporting in the available
studies was inconsistent and infrequent. Finally, whilst a compre-
hensive search of the Cochrane Kidney and Transplant Specialised
Register was performed for this review, reducing the possibility that
potential eligible studies were omitted from the review, eligible
studies published after the last search date or published in con-
gress proceedings not routinely searched could have been missed.
Agreements and disagreements with other studies or
reviews
Systematic reviews have evaluated the impact of various eHealth
interventions such as telephone or mobile phone text message re-
minders (Beratarrechea 2014; Hamine 2015), electronic reminders
(Tao 2015; Vervloet 2012) and electronic medication packaging
(Checchi 2014) on treatment and medication adherence in non-
CKD, chronic disease populations. These reviews have reported
positive improvements in medication adherence and appointment
adherence, however similar to our review, authors highlighted poor
methodological quality limiting the results of these interventions.
Tao 2015 evaluated 22 RCTs (3152 participants) reported a 29% im-
provement in medication adherence with the use of electronic re-
minders (95% CI 0.18 to 0.41; P = 0.00). Similar to our findings, the
authors highlight that the small number of studies and high hetero-
geneity of interventions limited results and any robust conclusions.
We were unable to conduct sensitivity analyses due to the small
number of studies included in our meta-analyses; we could not
form any conclusions about the impact of type of technology used,
behaviour change techniques and intensity of intervention. How-
ever in previous literature, it has been reported that eHealth inter-
ventions that were individualised and incorporated strategies such
as self-monitoring, personalised feedback and group or peer sup-
port resulted in significantly better outcomes, such as weight loss
and diet and physical activity behaviours (Cotter 2014; Raajimak-
ers 2015). It has also been reported that web, mobile phone text
messaging and telemedicine technologies were more effective at
improving CVD outcomes, than email, mobile phone, applications
and monitoring sensors (Widmer 2015). Similar to our review, oth-
er systematic reviews evaluating eHealth interventions have been
limited by small number of studies of low methodological quality.
A previous systematic review of mobile technology interventions
reported that overall usability, feasibility and acceptability were
high among end-users, and resulted in increased self-management
and knowledge (Hamine 2015). Our review also indicates that par-
ticipant satisfaction was high for eHealth interventions (including
video monitoring, Telehealth, dietary monitoring applications and
websites). Similar to previous reviews (Kitsiou 2017; Sanyal 2018),
economic evaluation of interventions in our review was lacking
and insufficient to evaluate the cost-effectiveness of these inter-
ventions.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, these data suggest that current evidence for the use of
eHealth interventions in the CKD population is of low quality and
insufficient to make a recommendation regarding their use to im-
prove clinical care. Further cost-analysis data is needed to ascer-
tain whether eHealth interventions offer a cost-effective alterna-
tive to standard practice. However, eHealth interventions appear to
be acceptable to patients and feasible if technical issues are man-
aged. Our findings indicate that eHealth interventions utilising be-
havioural counselling or self-monitoring may help to improve fluid
management and dietary sodium intake in dialysis patients, how-
ever further evaluation is needed. This has been supported by stud-
ies conducted in other chronic diseases (Cotter 2014; Raajimakers
2015) that found interventions using self-monitoring, personalized
feedback and peer group support improved outcomes. Current ev-
idence from our review was insufficient to make recommendations
for incorporation of specific eHealth strategies to enhance current
care. Utilizing self-monitoring techniques, providing personalized
feedback and facilitating peer group support may enhance future
practice and should be further evaluated in the CKD population.
Implications for research
Questions remain about the impact of eHealth interventions on
clinical end-points and patient-centred outcomes in the CKD pop-
ulation, with additional studies in CKD required to evaluate the
impact of eHealth interventions to patient care. Future research
should focus on larger scale trials to allow for meaningful inter-
pretation of results. Additionally, evaluation and reporting of trials
should be based on established frameworks that maintain method-
ological quality.
Our review has highlighted the need for robust, high quality re-
search that reports core (minimum) data set as outlined by the
SONG collaboration (SONG 2017), including both clinical and pa-
tient-centred outcomes, to enable meaningful evaluation of liter-
ature. Further, cost-effectiveness, process and qualitative evalua-
tions of interventions are needed to ensure robust assessment of
the impact of these interventions.
Evidence of the use of established frameworks to design and eval-
uate the interventions included in this review, such as the Behav-
iour Change Wheel, CONSORT-EHEALTH, RE-AIM, was lacking. Fu-
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ture studies would benefit from drawing on frameworks that re-
quire theoretical modelling between processes and outcomes and
a process evaluation of the study (Craig 2008; Michie 2013). All stud-
ies should provide greater description of intervention and standard
models of care being assessed (Hoffmann 2014; Warner 2017) and
include process evaluations of how they are being implemented
(Moore 2013), using reporting guidelines for complex interventions.
In diabetic populations the use of these alert systems has improved
medication adherence (Tao 2015) and highlights an important area
in CKD that warrants further evaluation. Our systematic review re-
ported on five studies using electronic alerts however due to small
sample sizes and poor methodological quality we have been un-
able to provide recommendations for the use of these alerts. Based
on our findings and previous literature (Cotter 2014; Raajimak-
ers 2015) interventions incorporating self-monitoring and person-
alised counselling should be further pursued.
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Methods • Study design: parallel RCT; 98 HD patients assessed for eligibility; 22 randomised• Study duration: 16 weeks• Study follow-up: 16 weeks
Participants • Country: USA• Setting: multicentre (3 sites)• Dialysis-dependent CKD• Number (randomised/completed): intervention group (11/9); control group (11/10)• Mean age ± SD (years): intervention group (56 ± 15.9); control group (not reported)• Sex (M/F): intervention group (6/4); control group (not reported)• Race: intervention group (9/10 minority race); control group (not reported)• Exclusion criteria: could not read or write; planned to move out of area or change dialysis centres
during the study period
Interventions • Intervention type classification: self-monitoring• eHealth intervention: PDA application
Intervention group
• PDA-based diet self-monitoring* PDA-based dietary self-monitoring using a nutrient database with individual nutrient and calorie
goals as per renal dietitian. Electronic food diary logs uploaded when meeting face to face* 16 weeks of dietary counselling based on Social Cognitive Theory. Primarily focused on moderating
dietary sodium intake, additional counselling if electronic record suggested inadequate protein or
caloric intake or laboratory markers showing hyperphosphataemia or hyperkalaemia. Counselling
conducted face-to-face occurring twice a week during weeks 1 to 6, weekly during weeks 7 to 12,
and every other week for weeks 13 to 16
Control group
• Not reported
Outcomes Adherence to diet self-monitoring (intervention group only)
• Number of meals entered
Notes • No other publications for this study identified• Funding source: work was supported by the following grants: Paul Teschan Research Foundation, NIH/
NIDDK/DK-R21DK067181, NIH/NCRR/CTSA-UL1-RR024153,and NIH/NCRR/GCRC-M01- RR000056
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
High risk The intervention and attention control activities were conducted by study staF
as an addition to, but not as a replacement for, standard care
BALANCEWise-HD 2011 
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Blinding of personnel
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Number of meals entered was an objective measure
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk Primary outcomes were not reported
Other bias Unclear risk Inadequate sample size to meet power calculation
BALANCEWise-HD 2011  (Continued)
 
 
Methods • Study design: parallel RCT; 257 HD patients assessed for eligibility; 179 randomised• Study duration: September 2009 to September 2012• Study follow-up: 16 weeks
Participants • Country: USA• Setting: multicentre (3 sites)• Dialysis-dependent CKD for at least 3 months• Number (randomised/completed): intervention group (93/81) control group (86/79)• Median age, IQR (years): intervention group (62, 53-71); control group (60, 50-69)• Sex (M/F): intervention group (57/36); control group (44/41)• Exclusion: could not read, write, or speak English; could not see the PDA or use a stylus to make se-
lections from the PDA screen; had overt dementia; planned to move out of the area or change dialy-
sis centres or receive living donor transplant within the study period; life expectancy of less than 12
months; institutionalised; those who were unwilling to speak 1 to 2 times/week with a study dietitian
or record their food consumption during the 16-week study period
Interventions • Intervention type classification: behavioural counselling• eHealth intervention: PDA application
Intervention group
• PDA-based diet self-monitoring* 6 education sessions with dietitian before PDA self-monitoring PDA dietary self-monitoring + twice
weekly behavioural counselling for 8 weeks and once weekly weeks 9-12 and every second week
weeks 13-16
Control group
• Attention control* 6 education sessions with dietitian; received PDA programmed with nutritional requirements at
end of study
Outcomes • IDWG (measured at baseline, 8 and 16 weeks)• Dietary sodium intake (measured at baseline, 8 and 16 weeks): measured using 24 hour dietary recalls
BalanceWise-HD 2013 
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• Adherence to intervention (number of meals entered and appointments attended): measured in the
intervention group only at 16 weeks• Perceived difficulties and determinants of dietary intake (measured at 16 weeks): 34-item question-
naire using Likert scale, pertaining to problems they encountered in following HD diet in previous 2
months
Notes • Dialysis adequacy statistically significant in attention control group at baseline (P < 0.001)• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomised using a permuted block algorithm developed by
the study statistician
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk The intervention and attention control activities were conducted by study staF
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Use of objective measures (IDWG, adherence)
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Self-reported dietary sodium intake and perceived difficulties questionnaire
are subjective
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Overall 89.4% completion rate - reasons for drop out reported but no mention
if significantly different
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
BalanceWise-HD 2013  (Continued)
 
 
Methods • Study design: parallel RCT; 30 peritoneal dialysis patients assessed for eligibility; 26 randomised• Study duration: 16 weeks• Study follow-up: 16 weeks
Participants • Country: USA• Setting: multicentre (3 sites)• Dialysis-dependent CKD
BALANCEWise-PD 2011 
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• Number (randomised/completed): intervention group (13/11); control group (13/10)• Mean age ± SD (years): intervention group (51.7 ± 19.8); control group (not reported)• Sex (M/F): intervention group (7/6); control group (not reported)• Race: intervention group (8/13 minority race); control group (not reported)• Exclusion criteria: could not read or write; planned to move out of area or change dialysis centres
during the study period
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: PDA application
Intervention group
• PDA-based diet self-monitoring* PDA-based dietary self-monitoring using a nutrient database with individual nutrient and calorie
goals as per renal dietitian. Electronic food diary logs uploaded when meeting face-to-face* 16 weeks of dietary counselling based on Social Cognitive Theory. Primarily focused on moderating
dietary sodium intake, additional counselling if electronic record suggested inadequate protein or
caloric intake or laboratory markers showing hyperphosphataemia or hyperkalaemia. Counselling
was conducted face-to-face or via telephone and occurred twice a week during weeks 1 to 6, weekly
during weeks 7 to 12, and every other week for weeks 13 to 16
Control group
• Not reported
Outcomes • Adherence to diet self-monitoring (intervention group only)* Number of meals entered
Notes • Funding source: work was supported by the following grants: Paul Teschan Research Foundation, NIH/
NIDDK/DK-R21DK067181, NIH/NCRR/CTSA-UL1-RR024153, and NIH/NCRR/GCRC-M01- RR000056
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk The intervention and attention control activities were conducted by study staF
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Number of meals entered was an objective measure
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
BALANCEWise-PD 2011  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk Primary outcomes were not reported
Other bias Unclear risk Insufficient information to permit judgement
BALANCEWise-PD 2011  (Continued)
 
 
Methods • Study design: quasi-experimental, pretest-post-test interventional study (using each subject as his/
her own control); 155 assessed for eligibility, 97 participants randomised• Study duration: August 2013 to December 2013; conducted over 2 dialysis sessions• Study follow-up: 6 months
Participants • Country: Iran• Setting: dialysis unit• HD patients age ≥ 18 years on HD for at least 6 months• Number (randomised/completed): intervention group (48/45); control group (49/45)• Mean age ± SD (years): intervention group (33.83 ± 8.89); control group (35.87 ± 10.13)• Sex (M): intervention group (46.6%); control group (51.1%)• Exclusion criteria: not reported
Interventions • Intervention type classification: education• eHealth intervention used: video• The educational contents of both programs were similar and covered necessary information about
the ESKD and dietary management for HD, particularly fluid restrictions and identification of restrict-
ed/allowed foods, as well as skin care and stress management
Intervention group
• Video education* Educational contents were presented through showing a video film, watched during 2 consecutive
dialysis sessions in a week
Control group
• Oral education* 2 group education sessions were held after dialysis sessions. Duration of each session did not ex-
ceed 45 minutes. A teaching booklet regarding dietary control was given to each participant at the
end of the session
Outcomes Outcome measured at baseline and 6 months post intervention
• QoL: using the Iranian version of the Short Form Health Survey (SF-36)
Notes • Funding source: supported by Ahvaz Jundishapur University of Medical Sciences and financed by
them
Risk of bias
Bias Authors' judgement Support for judgement
Baraz 2014 
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Random sequence genera-
tion (selection bias)
Low risk Random allocation was performed by using the random computer-generated
numbers
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded due to the nature of the intervention
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Principle investigator delivered the intervention
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk No objective outcomes were measured
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Validated measure, however QoL is subjective and conducted in unblinded
participants
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 6% to 8% loss-to-follow-up in both groups
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Baraz 2014  (Continued)
 
 
Methods • Study design: pragmatic, two-arm, patient-level RCT; 637 assessed for eligibility, 440 randomised• Study duration: April 2012 to November 2012• Duration of follow-up: 6 months
Participants • Country: UK• Setting: multicentre (24 sites)• Stage 3 CKD with or without proteinuria• Number (randomised/self-reported data/BP data): intervention group (215/180/193); control group
(221/194/210)• Mean age ± SD (years): intervention group (72.4 ± 9.2); control group (71.8 ± 9.0)• Sex (M/F): intervention group (90/125); control group (91/130)• Exclusion criteria: unable to communicate in English; had reduced capacity to provide informed con-
sent or were in receipt of palliative care
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
BRIGHT 2013 
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• BRIGHT intervention (participants could use resources at their discretion)* A kidney information guidebook.* PLANS (patient-led assessment for networks support) booklet and access to an interactive website
with tailored access to local resources.* Telephone support from a dedicated peer support worker 2 telephone calls from lay health workers
(week 1, week 5)
Control group
• Usual care* Offer kidney guidebook at end of study* No other description
Outcomes Primary outcomes measured at baseline and 6 months
• Blood pressure: dichotomised as “controlled” versus poorly controlled in accordance with 2008 NICE
guidelines; <140/90 for those without proteinuria, <130/80 for those with proteinuria• Self-management: “The positive and Active Engagement in Life” domain of the validated HEiQ• HQoL: measured using EuroQoL EQ-5D
Secondary outcomes measured at baseline and 6 months
• Health status• Anxiety (general and CKD-specific)• Loneliness• Medication adherence• Social networks• Social involvement• Service utilisation and resource use for cost-effectiveness analysis
Intervention uptake and evaluation measured at 6 months
• Self-reported Intervention uptake and evaluation – kidney guidebook• Self-reported Intervention uptake and evaluation – PLANS website and booklet• Self-reported Intervention uptake and evaluation – telephone support call uptake
Notes • Funding source: "The study was conducted as part of the NIHR Collaboration for Leadership in Applied
Health Research and Care (CLAHRC) Greater Manchester"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Patient will be allocated to a trial arm via a minimization algorithm (incorpo-
rating a random component)
Allocation concealment
(selection bias)
Low risk Allocation adequately concealed using central allocation
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Quote: "Neither researchers or participants were blinded"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Quote: "Neither researchers or participants were blinded"
BRIGHT 2013  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures at low risk of bias
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Subjective measures self-report questionnaires filled out by unblinded partici-
pants
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intervention Self-Report: 16.2% loss to follow-up
Intervention BP: 9.4% loss to follow-up; intention-to-treat analyses
Selective reporting (re-
porting bias)
Low risk All outcomes stated in the protocol were reported
Other bias Low risk No other biases detected
BRIGHT 2013  (Continued)
 
 
Methods • Study design: parallel RCT; 7 adults and 6 paediatric families assessed for eligibility, 6 paediatric fam-
ilies randomised• Study duration: 3 months• Study follow-up: 3 months
Participants • Country: UK• Setting: single centre• Patients with ESKD receiving PD• Number: intervention group (3); control group (3)• Mean age ± SD (years): intervention group (9.2 ± 6.8); control group (7.1 ± 4.1)• Sex: intervention group (0/3); control group (1/2)• Exclusion criteria: unable to have videophone installed
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
• Telecare Intervention plus standard care* Integrates Services Data Network (ISDN) 2E line and a motion media 225 mm videophone were
installed that connected to similar videophone in nurses offices* Use of videophone at the discretion of patient or family member* All contacts by telephone/videophone and clinic/home/ward visits were recorded* Support visit for 1st dialysis session and routine monthly clinic visit
Control group
• Standard care: support visit for 1st dialysis session and routine monthly clinic visit
Outcomes Primary outcomes
• Hospital visits and ward visits (measured at 3 months)• Cost-effectiveness (measured at 3 months)• Acceptability (assessed by conducting qualitative interviews)
Notes • Originally aiming to also recruit adults which was unsuccessful
Cargill 2003 
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• Use of the videophone only occurred for 1 participant• Funding source: partially funded by a grant from Trent Research and Development
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised using sealed envelopes"
Allocation concealment
(selection bias)
Unclear risk Quote: "randomised using sealed envelopes"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk No mention of blinding but likely this would have been broken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures (hospitalisations, ward visits and cost of intervention) less
likely to be biased
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants had outcome data reported
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Very low uptake of intervention; small sample size
Cargill 2003  (Continued)
 
 
Methods • Study design: pharmacist led RCT; 44,698 assessed for eligibility, 2,199 were randomised• Study duration: 1 February 2011 to 31 January 2012• Study follow-up: 12 months
Participants • Country: USA• Setting: Community-based outpatient clinics (13 sites)• Moderate to severe CKD (eGFR < 45 mL/min and eGFR < 60mL/min in past 90 days to 2 years to confirm
chronicity of disease)* CKD (non-dialysis dependent): men (98%); age (75.7 ± 8.2 years); black ethnicity (5%)• Number: intervention group (1070); control group (1129)• Mean age ± SD (years): intervention group 75.6 ± 8.2); control group (75.7 ± 8.2)• Sex (M/F): intervention group (1054/16); control group (1106/23)• Mean eGFR ± SD (mL/min/1.73 m2): intervention group (34.2 ± 7.7); control group (34.5 ± 7.3)
Cooney 2015 
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• Exclusion criteria: end-stage renal disease (ESRD), were ever referred for hospice care, or were older
than 85 years or younger than 18 years
Interventions • Intervention type classification: clinical decision-aid• eHealth intervention used: Telehealth
Intervention group
• Pharmacists provided telephone support reviewing medications and lifestyle modifications with the
patients, ordering KDOQI recommended labs, and arranging nephrology consults for patients with
severe CKD (eGFR < 30 mL/min/1.73 m2).• Pharmacists provided self-management support by providing informational pamphlet regarding CKD
management• Electronically communicated with primary care physicians• Electronic CKD registry
Control group
• Usual care* As per primary care physicians
Outcomes • Baseline data were defined as the most recent clinic BP or laboratory value within the prior 12 months.
Final clinic BP and laboratory values were defined as the last value during the study period
Primary clinical outcome
• SBP (only for those with baseline BP >130/80 mmHg)
Primary process of care outcome
• Serum PTH (measured within the study period)
Secondary clinical outcomes
• % participants at goal BP < 130/80 mmHg• QoL: (assessed using KDQoL burden, KDQoL effects, SF-12 MCS, SF-12 PCS, and conducted in subset
of participants who had primary care appointment in first 3 months of study)• Incidence of ESKD (end of study period)• Death (end of study period)
Secondary process of care outcomes
• serum phosphorus• UACR• Number of anti-hypertensive medications prescribed to those with poorly controlled hypertension• appropriate treatment with ACEI/ARB, phosphorus binders, vitamin D and sodium bicarbonate• Medication adherence (assessed using Morisky's medication scale)• % seen by a nephrologist
Acceptability
• Satisfaction (Likert scale and open ended questions)
Notes • 552 of 1070 participants randomised to intervention group never received the intervention• Funding source: "The study was funded in part by the Cleveland VA Medical Research & Education
Foundation. Additional support was provided through a Career Development Award K23DK087919
(P.E.D.) from the National Institute of Diabetes and Digestive and Kidney Diseases"
Risk of bias
Cooney 2015  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Blinded computer-generated randomisation list and a 1:1 ratio
Allocation concealment
(selection bias)
Low risk Blinded computer-generated randomisation list
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Personnel responsible for data collection and analysis were blinded to study
group assignment, however study pharmacists conducted phone surveys and
reviews so blinding would have been broken
There were no study-related clinic visits for this pragmatic trial
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures at low risk of bias
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk "study pharmacists" phone surveys assessed QoL, med adherence HL and ac-
ceptability
"The phone surveys assessed health related quality of life (SF-12), medication
adherence using the Morisky medication scale, Kidney Disease Quality of Life
(KDQOL) Short form, health literacy, and the acceptability of the intervention"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Used intention-to-treat analyses
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk No standardised methods for measuring BP, limited ability for the pharmacist
to intervene, only 23% seen by Nephrologist, therefore medication doses etc
would not have been changed, Only 518 patients in intervention group actual-
ly received intervention so this may have diluted the benefits
Cooney 2015  (Continued)
 
 
Methods • Study design: usability RCT• Study duration: January 2013 to September 2013• Study follow-up: 1 month
Participants • Country: USA• Setting: community• Patients with CKD (< 60 mL/min)• Number: SMS group (10); PDA group (10)• Age:* ≤ 65 years: SMS groups (7); PDA group (6)* > 65 years: SMS group (3); PDA group (4)
Diamantidis 2015 
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• Sex (M/F): SMS group (5/5); PDA group (7/3)• Exclusion criteria: expected to reach ESKD or die within 1 year from enrolment
Interventions • Intervention type classification: education• eHealth intervention used: PDA and SMS• This study evaluates home-based usability of two mobile health MIS platforms• Participants asked to input each of 3 medications into respective MIS application and record device’s
responses on paper diary
SMS text
• Participants send the name of a medication by SMS text message• Receive a response text informing the patient of the medication’s safety in CKD with three potential
responses: not safe in CKD, use with caution/speak with your health care provider, and safe in CKD
PDA
• Allows users to search by the medication name or class (e.g., ibuprofen or pain medication)• PDA responses include traffic light imagery and text to emphasize safety responses: a red light for a
medication that is not safe in CKD, a yellow light for use with caution/speak with your health care
provider, and a green light for medications deemed safe in CKD
Outcomes • Usability (assessed using error rates and satisfaction)• eHealth literacy (assessed using eHealth Literacy Scale)
Notes • Funding source: " supported, in part, by the Baltimore Research and Education Foundation (C.J.D.
and L.L.), the nonprofit corporation affiliated with the Veterans Affairs Maryland Health Care System,
and National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK084017 (to J.S.G.,
M.Y., and J.C.F.)"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk No objective outcomes were measured
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Participants had to record what responses came out which may have resulted
in some inaccurate answers being recorded by accident, satisfaction survey -
no mention of whether validated or how it was administered but could be at
risk of bias
Diamantidis 2015  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No dropouts reported
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement
Other bias Unclear risk Trial patients not using their own medications or prescriptions, cash incen-
tives small population - not necessarily representative. This was a usability tri-
al
Diamantidis 2015  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 1999 to June 2000• Study follow-up: mean time 9.5 months for intervention and 7.8 months for control group
Participants • Country: France• Setting: community, dialysis unit• ESKD patients requiring PD• Number (for preliminary analysis): intervention group (15); control group (15)• Number (over 3-year study period): 94, unclear how many randomised into each study group• Mean age ±SD (years): not reported• Sex: not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: clinical decision-aid• eHealth intervention used: Blue-tooth, electronic monitoring
Intervention group
• DIATELIC telemedicine system* Allows transmission of daily medical data from patient's home to medical centre.* Patients set up with computer station and connects to database to record daily parameters:
weight, pro and decubitus BP, UF and tonicity of dialysate* All connections on secure internet* Medical data analysed using Markov model to establish probability of hydration status diagnosis.* Integrated email system to improve doctor-patient communication
Control group
• Usual care: no description
Outcomes • Frequency of planned visits to medical centre• Frequency of unexpected visits• Hospitalisation rate• Decrease in BP• Number of anti-hypertensive medications• Weight/hydration status• Cost analysis• Number of emails sent/processed
Notes • 3 abstracts with different patient numbers and results available
Durand 2000 
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• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Unlikely could have been blinded as transmitting information
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Unlikely personnel could have been blinded due to receiving information from
patients, no mention of blinding
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk All outcome measures are objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Durand 2000  (Continued)
 
 
Methods • Study design: quasi-RCT, pre-test post-test; 62 assessed for eligibility, 59 randomised• Study duration: day 5 post surgery• Study follow-up: 2 days (day 7 post surgery)
Participants • Country: USA• Setting: inpatient• Kidney transplant recipients• Number: 59• Mean age ± SD (years): 41.1 ± 13.7 years (range 20 to 69 years)• Sex (M): 57.6%• Exclusion criteria: not reported
Interventions • Intervention type classification: education• eHealth intervention used: video
Giacoma 1999 
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Intervention group
• Teaching video* Reviewed kidney transplant medications and second discussed general post discharge care activ-
ities.* Discharge information covered content pertaining to medication use, precautions, adverse effects
and transportation; monitoring vital signs; recognising signs of infection and rejection; dietary rec-
ommendations; clinic location; healthy lifestyle behaviours; steps to prevent common complica-
tions• Standard care
Control group
• Standard care (conducted prior to surgery and day 5 post-surgery)* Use of teaching checklist and review of discharge booklet which covered content pertaining to
drugs, adverse effects and signs/symptoms of rejection* Conducted prior to surgery and 5 days post surgery
Outcomes Outcomes measured at baseline and day 7 of admission
• Knowledge of Organ Transplant test (short-term knowledge retention) - not validated
Outcomes measured day of admission, day of surgery, days 1, 2, 3, 7, 10 post surgery and day of dis-
charge
• Biochemistry (serum BUN, creatinine)• Urine 24-hour protein and CrCl• medication compliance assessed by serum TAC/CSA levels• primary reason for hospital admission (unclear how long this data was collected)• Long-term knowledge retention (assessed using frequency and reason for post-discharge phone calls
(unclear how long this data was collected)
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sealed envelopes were randomly picked by participants
Allocation concealment
(selection bias)
Low risk Sealed envelope draw with non replacement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Unblinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk No mention of whether personnel were blinded. Nurse gave knowledge ques-
tionnaire and then provided video - so unlikely impossible to blind person giv-
ing intervention
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Blinding would not affect outcome as objective
Giacoma 1999  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Nurse administering, non-validated questionnaire who was aware of alloca-
tion. No mention of whether this nurse was blinded to the allocation.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement, reported outcomes (i.e. long
term knowledge retention) was not originally stated in methods.
Other bias High risk Small sample size and not powered; use of non-validated knowledge question-
naire
Giacoma 1999  (Continued)
 
 
Methods • Study design: randomised controlled trial, 142 randomised• Study duration: initiated in August 2016• Study follow-up: not stated
Participants • Country: Germany• Setting: Community• Kidney transplant recipients• Number: 148 (numbers per group not reported)• Mean age ± SD (years): 46 ± 12• Sex: not described• Medium time after transplantation 5.2 years (range 3.0 to 9.8)• Exclusion criteria: not described
Interventions • Intervention type classification: reminder• eHealth intervention used: mobile phone application
Intervention group
• Smartphone-based application supporting medication adherence
Control group
• Not reported
Outcomes • Medication adherence (MMAS-8)• Knowledge about own medication
Notes • 3 abstracts available; results only report characteristics and correlation with number of medications,
medication adherence – no data regarding the difference between intervention and control partici-
pants• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Halleck 2017 
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Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not be blinded given the nature of this intervention
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Unclear how knowledge will be assessed, MMAS is a self-reported measure of
adherence so at high risk of bias
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Halleck 2017  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: 6 months• Study follow-up: not reported
Participants • Country: Korea• Setting: community• Kidney transplant recipients, at least 12 months post transplant• Number: 124; numbers per group not reported• Mean age ± SD (years): not reported• Sex (M): 36.2%• Exclusion criteria: not reported
Interventions • Intervention type classification: reminder• eHealth intervention used: mobile phone application
Intervention group
• Mobile phone application* Internet-based application for androids provided alarm reminders at the time of dosing, provided
data logs and medication information (e.g. dosages, adverse effects, toxicities)
Control group
Han 2016 
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• Not reported
Outcomes Primary outcome is medication adherence
• Proportion of patients with adequate adherence (> 80% of prescribed doses) - measured by Medica-
tion Event Monitoring System (MEMS)• Self-reported surveys of medication adherence: Basel Assessment of Adherence to Immunosuppres-
sive Medications Scale (BAASIS)• VAS
Notes • Abstract reporting preliminary results only• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Unlikely could be blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk objective adherence measurement, MEMS
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Self-reported medication adherence
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Preliminary data only
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement, preliminary data
Other bias Unclear risk Insufficient information to permit judgement, preliminary data
Han 2016  (Continued)
 
 
Methods • Study design: parallel RCT; 100 randomised• Study duration: 12 months• Study follow-up: 12 months
Hardsta9 2002 
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Participants • Country: UK• Setting: community• Kidney transplant recipients• Number (randomised/analysed): intervention group (75/67); control group (25/24)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: clinical decision-aid• eHealth intervention used: PDA application
Intervention group
• Smart Top* Medicine bottles with a microprocessor in the cap that records the date and time on each occasion
the bottle is opened and closed* This information can then be downloaded onto a computer data base via a special modem at their
regular outpatient visits* Patients bring bottles to quarterly (regular) outpatient appointments for downloading of informa-
tion. Medications monitored were prednisone/azathioprine* Participants also grouped into receiving feedback at outpatient appointment or no feedback re-
garding adherence
Control group
• Plain top bottle* Received regular interviews by a nurse practitioner and pill counts to assess their compliance
Outcomes Primary outcome
• Medication adherence (% missed doses, consecutive missed doses, extra doses)
Notes • Unclear whether 2 papers were the same study, but this was assumed given time frame and similar
baseline numbers• High loss to follow-up at 12 months• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Intervention Feedback group received feedback at first outpatient appoint-
ment, therefore could not have been blinded
Hardsta9 2002  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Adherence downloaded from smart top lid - objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 10% loss to follow-up at 3 months, 36% loss to follow-up at 12 months
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk This study was performed on willing volunteers who most likely represented
our more compliant patients. The data available included patients who, on the
whole, remembered to bring the bottles to clinic and also returned the bottles
at the end of the study. The outstanding data are on the remaining patients
who have not returned the bottles because they kept forgetting to bring them
and so are likely to represent the less compliant patients in this cohort
Hardsta9 2002  (Continued)
 
 
Methods • Study design: parallel RCT; 90 assessed for eligibility, 80 randomised• Study duration: 12 months• Study follow-up: 12 months
Participants • Country: Sweden• Setting: community• Kidney transplant recipients, 7-14 days post transplantation• Number: intervention group (40); control group (40)• Mean age, range (years): intervention group (44.3, 9 to 68); control group (45.0, 2 to 69)• Sex (M/F): intervention group (25/15); control group (27/13)• Exclusion criteria: could not provide informed consent
Interventions • Intervention type classification: reminder• eHealth intervention used: blue-tooth, electronic monitors
Intervention group
• Electronic monitoring drug dispensary* At the prescribed time for taking the medication, the EMD gave visual and audible signals. If the
patient did not take their medication, the audible signal was repeated with increasing frequency
for 120 minutes.* After this (or after the medication was taken), the EMD sent an SMS message to the web-based
software, thus providing information about patient compliance.
Control group
• Standard care: no description
Outcomes Outcomes measured at baseline and 10 clinic visits over 12 months
Primary outcome
Henriksson 2016 
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• Medication compliance to immunosuppressive medications (defined as taking compliance, dosing
compliance, variability of dosing intervals, and number of drug holidays). Not assessed in standard
care group
Secondary outcomes (obtained from patient charts)
• Outpatient follow up visits• ED readmissions• Information about biopsies• Rejection episodes• Rejection treatment• Kidney function (SCr)• blood concentrations of immunosuppressive medications
Notes • Funding source: " The study was funded by grants from Roche AB and Tele2 Sverige AB. The project
has been awarded grants from the Lennart Jacobsson Foundation, the Stig and Gunborg Westman
Foundation, and the Paul Frankenius Foundation"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote "patients were randomized to intervention or control using prenum-
bered, sealed, and opaque envelopes in four batches (20 per batch)"
Allocation concealment
(selection bias)
Low risk Quote: "Each envelope randomly contained a note allocating the patient to ei-
ther control or intervention. The randomization envelopes were assigned to
the enrolled patients in consecutive order (1-80)"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk No mention of blinding, other than statistician was blinded
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk The data were obtained from patient charts and the web-based software ac-
cording to the study plan, over 10 visits in 1 year, by 2 of the investigators. All
outcomes were objective.
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Of all scheduled outpatient follow-up visits during the 1-year period (22 vis-
its/patient), 6 participants missed a total of 11 visits (1%). There was no signifi-
cant difference between the intervention and control groups.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Henriksson 2016  (Continued)
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Methods • Study design: parallel RCT• Study duration: December 2014 to October 2015• Study follow-up: 12 months
Participants • Country: USA• Setting: outpatient clinic (3 sites)• ESKD patients for kidney transplant evaluation; 18- 70 years of age; no previous solid or multi-organ
transplant; English-speaking; no severe cognitive or visual impairment• Number: intervention group (226); control group (217)• Mean age ± SD (years): intervention group (51.1 ± 9.9); control group (50.1 ± 10.3)• Sex (M): intervention group (63.3%); control group (61.8%)• Exclusion criteria: not reported
Interventions • Intervention type classification: clinical decision-aid• eHealth intervention used: Website, internet
Intervention group
• iChoose clinical decision aid* Provides risk estimate of patient survival on dialysis versus kidney transplantation, and living vs
deceased donor transplants to improve patients knowledge
Control group
• Usual care: Quote "center-specific transplant education was not identical, with one center requiring
patients to attend a group transplant education session led by a transplant surgeon. However, pa-
tients at all sites received printed transplant education materials with similar content, including risks
and benefits of transplant and financial and social support"
Outcomes Primary outcome
• Knowledge using a 9-item scale developed by a multidisciplinary group of transplant nephrologists,
surgeons, behavioural scientists, and patients that was included in the patient baseline and follow-
up surveys; scale not validated
Notes • Funding source: Norman S. Coplon Satellite Healthcare Foundation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "research assistants obtained informed consent and randomized pa-
tients 1:1 with a random number generator application via iPad to receive cen-
ter-specific standard of
care education about kidney transplant with (intervention) or without (con-
trol) supplemental use of iChoose Kidney"
Allocation concealment
(selection bias)
Unclear risk Quote: "via iPad"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Quote: "neither patients nor providers were blinded to the study group assign-
ment"
iChoose 2016 
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Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Quote: "neither patients nor providers were blinded to the study group assign-
ment"
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk No objective outcomes were measured
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Quote: "Transplant knowledge was measured using a nine-item scale devel-
oped by a multidisciplinary group of transplant nephrologists, surgeons, be-
havioral scientists, and patients that was included in the patient baseline and
follow- up surveys"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Nil loss to follow-up; follow-up is only 1 clinic appointment
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
iChoose 2016  (Continued)
 
 
Methods • Study design: parallel feasibility RCT); 182 screened, 60 eligible, 25 randomised• Study duration: 12 weeks• Follow-up duration: 12 weeks
Participants • Country: UK• Setting: community• ESKD patients on maintenance HD; aged ≥ 18 years, who have mild to moderately severe depressive
symptoms and/or presence of mild to moderately severe anxiety symptoms; speak English sufficiently
well to engage with screening tools; they have a basic understanding of how to use the internet and
an email address• Number: intervention group (18); control group (7)• Mean age ± SD (years): intervention group (49 ± 11.44); control group (47 ± 14.25)• Sex (M/F): intervention group (10/8); control group (5/2)• Exclusion criteria: individuals with severe depression (PHQ-9 score ≥ 20) and/or anxiety (GAD7 score ≥
15); individuals with evidence of current suicidal ideation are considered inappropriate for iDiD online
CBT
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: website, internet and Telehealth
Intervention group
• Online CBT* Participants had access to the online CBT website• Therapist support* Participants received three 30 min telephone support calls at weeks 2, 4 and 6. Telephone support
was delivered by a trained psychological well-being practitioner* The purpose of the telephone support calls was to promote engagement with the website and to
support the patient in collaboratively developing goals to work on using the resources and infor-
mation available to them on the website
iDiD 2016 
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• Usual renal care
Control group
• Online CBT• Usual renal care* Attending for HD three times per week. Whilst attending for dialysis patients may encounter multi-
disciplinary renal team members. Contact with the renal psychologist only occurs if a patient is re-
ferred or self-refers for treatment. Participants will be advised in the participant information sheet
to logon to the website once a week. iDiD targets specific cognitive, emotional, and behavioural
mechanisms associated with psychological distress in HD. Participants will also receive weekly re-
minder emails to encourage engagement with the website. iPads will be available for participants
to use during their dialysis sessions
Outcomes Primary outcome
• Feasibility and acceptability* Descriptive statistics on recruitment and retention rates were collected* Adherence to online psychotherapy sessions and therapist support calls, including number of com-
pleted calls and duration were recorded
Secondary outcomes (baseline, 12 weeks)
• Depression measured using the PHQ-9• Anxiety measured using GAD-7• QoL, measured using EuroQoL scale (EQ-5D)• ESKD illness perceptions, assessed using 8 item Brief Illness Perception Questionnaire• Health service utilisation, assessed using the Client Service Receipt Inventory combined with appro-
priate unit cost information• Treatments for depression and anxiety• Satisfaction• Serious adverse events
Notes • Protocol deviations occurred in both trial arms. It was necessary to generate an email address and
provide brief internet education for six patients (24% of consented sample; supported arm (5), unsup-
ported arm (1)), thus these patients received a higher degree of technical support and face-to-face
contact. One patient in the supported arm was unable to receive therapist calls because of their in-
tensive home-care program (e.g. carers present) and associated multi-morbidity, therefore on-dialy-
sis support was provided for this patient• A nested qualitative study will evaluate patient experience• Funding source: Guy's and St Thomas' charity (GSTT, grant number: EFT130206)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Automated random number generator with a 1:1 ratio was used
Allocation concealment
(selection bias)
Low risk The patient was informed of their group allocation via the online CBT program.
The allocation sequence remained concealed from the trial coordinator and
psychological therapists/supervisors
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants were informed of their allocation
iDiD 2016  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Blinding likely would have been broken for some participants as it was nec-
essary for the research team to complete follow-up measures with some pa-
tients.
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Measures of feasibility were objective and less likely to be biased
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Validated tools to measure self-reported depression and anxiety used. Par-
ticipants were asked to complete themselves, however some participants re-
quired assistance from research personnel which may have led to bias
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk For primary outcome analyses 92% of participants completed follow-up data,
no detail as to which group had loss to follow up.
Selective reporting (re-
porting bias)
High risk Satisfaction, serious adverse events and treatments for depression and anxi-
ety were not reported
Other bias High risk Did not meet sample size requirement (66), randomisation of 1:1 was not
achieved with no explanation why deviated from this
iDiD 2016  (Continued)
 
 
Methods • Study design: RCT, post-test-only control group design; 593 assessed for eligibility, 288 randomised• Study duration: October 2013 to December 2014 (site 1); January 2014 to July 2014 (site 2)• Study follow-up: 1 week
Participants • Country: USA• Setting: outpatient clinic• Kidney transplant candidates; aged ≥ 21 years, English speaking, never received a kidney from an IRD,
never, rarely, or sometimes need help with written information; willingness to use an iPad 2 tablet• Number: intervention group (133); control group (155)• Mean age ± SD (years): intervention group (51.2 ± 11.3); control group (50.5 ± 12.3)• Sex (M): intervention group (61.1%); control group (62.6%)• Exclusion criteria: not reported
Interventions • Intervention type classification: education• eHealth intervention used: PDA application
Intervention group
• Inform Me* iPad app to improve knowledge about increased risk donor kidneys* Using computer adaptive learning method to personalise educational materials and content ac-
cording to each participants' comprehension level in 5 interactive chapters* At the end of each chapter questions to test knowledge with additional education provided if need-
ed* Summary reports generated• Routine transplant education and clinician visits
Control group
InformMe 2017 
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• Usual care* Routine transplant education and clinician visits
Outcomes • Knowledge of IRD kidneys 31-item multiple choice test• Willingness to accept hypothetical IRD kidney (5 point Likert scale)• Acceptability (open ended questions)
Notes • Funding source: "This publication was supported by the NINR/NLM (R21NR013660 to E.J.G.)"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Using a computer-generated random number list
Allocation concealment
(selection bias)
Low risk Sealed envelopes concealed until study arm was assigned
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Trial was single blinded; research team members assessing outcomes were
blinded to assignments to the intervention
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk No objective outcomes were measured
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Outcomes were subjective and administered by research personnel who could
have been made aware of allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 18 people dropped out with no significant differences between them and
those who did not drop out but data not shown
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Provided with financial incentives, higher drop-out/refusal in intervention
group; met sample size goal
InformMe 2017  (Continued)
 
 
Methods • Study design: parallel RCT (3:1 randomisation); 4105 eligible, 601 randomised• Study duration: March 2012 to November 2013• Study follow-up: 12 months
Participants • Country: USA• Setting: community
Ishani 2016 
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• CKD (eGFR < 60 mL/min)• Number: intervention group (450); control group (150)• Mean age ± SD (years): intervention group (75.3 ± 8.1); control group (74.3 ± 8.1)• Sex (M): intervention group (98.7%); control group (98.0%)• Exclusion criteria: unable to give consent; had life expectancy less than 1 year; lived in a skilled nursing
facility; had a primary care provider unwilling to allow participation
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
• Telehealth* Video monitoring device with peripherals and broadband installed in home and participants
trained to use device and peripherals (BP cuF, scale, glucometer, pulse oximeter, stethoscope, web
camera) and how to contact team* Interprofessional team (nephrologists, nurse practitioner, clinical pharmacy specialist, psychol-
ogist, social worker, Telehealth care technician, dietitian) reviewed patient and developed pa-
tient-specific treatment plan addressing short and long term goals.* Specific issues addressed included management of BP, volume status, proteinuria, DM, lipid levels,
depression, HL, patient activation, lifestyle modification (physical activity, diet, weight reduction,
smoking cessation) Education delivered over broadband device.* Patients could interact with learning modules at their own pace.* Vital signs automatically measured by device and transmitted to study team reviewed every 30
days by health team, Reviewed by study team every 3 months
Control group
• Usual care* Invited to attend CKD education class and to follow primary care providers regarding kidney dis-
ease management* Exact care not investigated
Outcomes Primary outcome (measured at 12 months)
• Composite of death, hospitalisation, ED visits and admission to skilled nursing facility
Secondary outcomes (measured at 12 months)
• Incidence of ESKD• Death• Hospitalisation (rate and length of 1st admission)• ED visits• Admission to skilled nursing facility
Intermediate study outcomes (measured at 12 months)
• SBP• LDL cholesterol• HbA1c
Notes • Systolic BP higher in intervention at baseline, racial differences between groups at baseline
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomly assigned to receive the intervention or usual care using
a centralized computer-generated randomization scheme using permuted
Ishani 2016  (Continued)
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block sizes of 2, 4, or 6. Randomization was stratified by eGFR (<30 vs >30 mL/
min/1.73 m2), presence of diabetes, and occurrence of a hospitalization in the
past year"
Allocation concealment
(selection bias)
Low risk Quote: "Randomization occurred over the telephone by an individual blinded
to patient identity"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Likely blinding would have been broken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Outcome assessors were blinded. all outcomes were objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Only 1 participant (of 601) withdrew consent; used intention-to-treat analyses
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk baseline characteristics between groups similar, limited generalisability possi-
ble due to high proportion of men, met sample size calculation for power
Ishani 2016  (Continued)
 
 
Methods • Study design: RCT; pre- and post-intervention study; 40 randomised, 27 reported• Study duration: 7 days• Study follow-up:
Participants • Country: USA• Setting: community, dialysis unit• Maintenance HD with phosphate > 5.5 mg/dL for 2 or last 3 months• Number (randomised/received intervention): intervention group (20/13); control group (20/14)• Mean age ± SD (years): intervention group (48), control group (62)• Sex (M): 80%• Exclusion criteria: not reported
Interventions • Intervention type classification: reminders• eHealth intervention used: Mobile phone text messaging
Intervention group
• Mobile phone text message reminders* Received text message reminders to take PO4 binders at meal times
Jammalamadaka 2015 
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Control group
• Usual care: not reported
Outcomes • Serum phosphate (measured at baseline and 7 days)
Notes • Contacted author re: participant demographics, randomisation strategy and blinding• Abstract-only publication
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Abstract stated "randomised", author contacted and said "we did not ran-
domise"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Author contacted - "both participants and personnel were blinded to the strat-
egy" however participants would have known whether receiving text message
reminders
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Low risk Author contacted - "both participants and personnel were blinded to the strat-
egy", as intervention only 1 week blinding may have been upheld
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Serum phosphate
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk author quote: "no loss to follow-up"
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Small sample size, short study duration and follow-up, unlikely to change pri-
mary outcome in 7 days, intervention participants younger than control
Jammalamadaka 2015  (Continued)
 
 
Methods • Study design: parallel RCT; 60 randomised• Study duration: September to March 2014• Study follow-up: 1 month (unclear)
Participants • Country: Iran• Setting: community, dialysis unit• receiving maintenance HD
Kargar Jahromi 2016 
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• Number (randomised/completed): intervention group (30/27); control group (30/27)• Mean age ± SD: 69.13 ± 11.82 years• Sex (M): intervention group (44%); control group (60%)• Exclusion criteria: history of serious or adverse experiences in the last six months; being treated with
antidepressant medications; hospitalisation due to acute disease; unwillingness to continue to par-
ticipate in the study
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
• Telephone follow-up* 30 days after dialysis shiP (unclear how many phone calls participants received)* Content of call follow script, consultations structured and contained key subjects: communica-
tion, cognition/development, breathing / circulation, nutrition, elimination, sleep, pain/ percep-
tion, skin / tissue, sexuality/reproduction, activity and psychosocial / spirituality / culture. 30 min
conversation• Standard care
Control group
• Standard care: not reported
Outcomes • Depression, anxiety and stress measured using validated tool DASS; measured at baseline and after
intervention
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk "double blind" however participants could not have been blinded to their allo-
cation
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk "double blind" researchers conducted the intervention unlikely they could
have been blinded to a participants allocation
Quote: "All interventions are conducted by the researcher responsible for this
trial"
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk No objective outcomes were measured
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk DASS completed before intervention was carried out and then after whilst self-
report this is a validated tool.
No mention of whether research personnel present while people filling out.
Kargar Jahromi 2016  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low loss to follow-up in both groups (10%)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Small sample size limiting generalizability
Kargar Jahromi 2016  (Continued)
 
 
Methods • Study design: pilot RCT; 26 randomised, 19 completed study• Study duration: 4 months• Study follow-up: 4 months
Participants • Country: USA• Setting: community, dialysis unit• Maintenance PD patients• Number (randomised/completed): intervention group (13/10); control group (13/9)• mean age ± SD: 51.7 ± 16.4 years• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: PDA application
Intervention group
• PDA* Individualized PDA-assisted dietary adherence enhancement program based on Social Cognitive
Theory to reduce sodium intake* Monitored dietary intake with a PDA programmed with their dietary prescription and received PDA
feedback regarding % of daily targets consumed and counselling based on Social Cognitive Theory• Computer-based dietary education
Control group
• Computer-based dietary education
Outcomes Outcome measures taken at baseline and 4 months
• Dietary sodium intake• BP• PD dietary problems questionnaire• Participation in intervention (number of meals entered into system)
Notes • Abstract-only publication• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Koprucki 2010 
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Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Unlikely could have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures low risk of bias
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Insufficient information to permit judgement on who administered subjective
measures
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Small sample size
Koprucki 2010  (Continued)
 
 
Methods • Study design: RCT; 40 eligible, 32 randomised• Study duration: 4 weeks• Study follow-up: 4 weeks
Participants • Country: USA• Setting: community• Paediatric transplant recipients• Number: intervention group (16); control group (16)• Mean age ± SD (years): 13.8± 5.4 years• Sex (F): 44%• Exclusion criteria: family did not speak English or if the child’s cognitive functioning would interfere
with their ability to participate
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: blue-tooth, electronic monitor
Intervention group
Kullgren 2015 
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• Interactive water bottle* Recall fluid intake for 3 days prior to commencement of study via a log and to keep daily diaries* Calculates personal hydration needs, tracks real time fluid intake pacing throughout the day.* Participant enters weight and bottle automatically calculates fluid requirements, this can be ad-
justed manually.* HydraCoach prompts user to drink by continuously visually displaying% consumed in litres or
ounces• Standard care
Control group
• Standard care* Recall fluid intake for 3 days prior to commencement of study via a log and to keep daily diaries* Given written information regarding fluid target and choices.
Outcomes Outcome measures assessed at baseline and 1 month
• Fluid intake (Self-reported - reported intake, fluid goal achieved, fluid intake tracking - diary)• Biochemistry (BUN, sodium, creatinine - % change over the study period)
Notes • Funding source: St. Louis Children’s Hospital Nursing Research Grant and the University of Michigan
Charles Woodson Fund for Clinical Research
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Blinding not possible
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk No reporting of blinding of personnel
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Biochemical measures of creatinine, BUN and sodium are objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Self-reported measure
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No reported loss to follow up or incomplete diaries
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Kullgren 2015  (Continued)
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Other bias High risk small sample size - population not generalisable, limited follow-up time, con-
trol and intervention groups significantly different with respect to time since
transplant, low uptake rate of the intervention
Kullgren 2015  (Continued)
 
 
Methods • Study design: RCT; 186 assessed for eligibility,160 participants randomised• Study duration: 6 weeks• Study follow-up: 12 weeks
Participants • Country: China• Setting: community, dialysis unit• Maintenance PD patients• Number (randomised/completed): intervention group (80/69); control group (80/66)• Mean age ± SD (years): intervention group (57.4 ± 12.8); control group (55.2 ± 11.9)• Sex (M/F): intervention group (42/27); control group (37/29)• Exclusion criteria: TenchkoF catheters in situ for less than 3 months; receiving intermittent PD or HD
and those with planned admissions for special treatment procedures; psychosis or dementia; dying
or unable to communicate; being transferred to another unit during their hospital stay
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
• Telephone support* Comprehensive discharge planning protocol prior to discharge and standardised 6-week post-dis-
charge nurse-led telephone support intervention* Patients physical, social, cognitive and emotional needs assessed and comprehensively and indi-
vidualised education program conducted prior to discharge* After discharge nurse case managers began telephone contact with patients weekly for 6 consec-
utive weeks. First call within first 72 hours after discharge to assess status and give advice* Content of each telephone call guided by the protocol and specific problems identified in predis-
charge assessment* Case manager discussed issues patients encountered and if necessary made appropriate referrals
Control group
• Standard care* Talking to doctor about special points that need attention when returning home* Telephone hotline service* Set of free self-help printed materials on maintaining healthy lifestyle* Reminder to attend outpatient appointments
Outcomes • QoL: KDQoL-SF (baseline, 6 weeks, 12 weeks)• Complications (oedema, weight gain, peritonitis, catheter infections, biochemistry (urea, creatinine,
sodium, K, PO4, albumin), self reported and validated against hospital records (measured weeks 6-12)• Healthcare utilisation: self reported and hospital records (days between index discharge and read-
mission were extracted from the hospital information systems) (measured weeks 6-12)
Notes • Funding source: "partly supported by Outstanding young talents training project of Guangdong
Province (Grant No. LYM11035) and the Guangdong Natural Science Foundation, China (Grant No.
S2011040005590)"
Li 2014b 
eHealth interventions for people with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
65
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated numbers
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Unable to be blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk No mention but probably not blinded because of nature of intervention
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Hospital records are objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk No mention of whether blinded, some measures (QoL) used validated mea-
sures, while others (health service utilisation) was self-reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Dropout (13.7% to 17.5%), no mention of whether these drop outs significantly
different; only those with full outcome data included in study; reasons for drop
outs similar across both groups
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement
Other bias High risk Small sample size, short duration - not generalisable under powered
Li 2014b  (Continued)
 
 
Methods • Study design: proof-of-concept RCT; 41 assessed for eligibility, 21 randomised• Study duration: 3 months• Study follow-up:3 months
Participants • Country: USA• Setting: community• Kidney transplant recipients with adherence score of < 0.85• Number (randomised/analysed): intervention group (11/9); control group (10/10)• Mean age ± SD (years): intervention group (42.44 ± 12.04); control group (57.6 ± 8.28)• Sex (M): intervention group (44%); control group (70%)• Exclusion criteria: inability to self-administer medications; inability to measure own BP; inability to
use a mobile phone; history of psychiatric illness or substance abuse; pregnant, lactating or intention
of becoming pregnant during the trial; participant in another study; inabilities to speak, hear, or un-
derstand English; poor cellular coverage in their home
Interventions • Intervention type classification: reminders
McGillicuddy 2013 
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• eHealth intervention used: Blue-tooth, electronic monitoring
Intervention group
• Wireless electronic medication tray with wireless Bluetooth BP monitor and a smart phone* At prescribed dosing day and time a blinking light from specific dose compartment is activated. If
after 30 min compartment not opened, removed and returned a loud chime auto activated 30 min.
If still not opened auto reminder phone call or text message delivered to participant* Failure to open after 90 min auto generates text message or email to study co-ordinator.* Participants sent text messages every 3 days to remind to test BP. BP readings auto sent via Blue-
tooth to mobile phone and from there via cellular network to data repository* Patients contacted when indicated med non-adherence, failure to measure BP, BP outside thresh-
old ranges. If BP outside threshold study co-ordinator contacted for repeat measures, if continue
then physician contacted who made changes to medications
Control group
• Usual care* Clinic visit every 4-6/52 and post-transplant education and 24 hour phone availability
Outcomes Outcomes measured baseline, month 1, month 2, month 3
• Adherence: adherence score - 0, 0.25, 0.5, 0.75, 1 based on timing medication taken compared to pre-
scribed time• BP: seated upright with right arm resting on table at heart level; reading immediately taken and after
5 min rest 2 additional readings taken separated by 2 min interval. Average of the last 2 readings used
in analyses
Notes • Funding source: "supported by the South Carolina Clinical & Translational Research Institute, with an
academic home at the Medical University of South Carolina, CTSA NIH/NCRR, Grant no. ULIRR029882
and funding from the Duke Endowment and the Verizon Foundation"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk No mention of which personnel involved. non adherent messages etc were
sent to the study coordinator
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures (SBP) are at low risk of bias
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Participants self reported this outcome and were not blinded
McGillicuddy 2013  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Before randomisation quite high dropout but after only one person dropped
out of the intervention group because the clinic schedule was incompatible
for the patient to continue. The researchers were aiming to get 20 participants
and achieved this
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Small sample not likely generalisable randomisation of intervention and con-
trol results in sig diF in age and adherence which questions the validity of con-
clusions.
could not participant in the study if they did not have strong cellular signal at
their house. This may skew the data against rural participants, or those who
are more time poor
McGillicuddy 2013  (Continued)
 
 
Methods • Study design: parallel RCT; 1389 assessed for eligibility, 80 randomised• Study duration: 3 months• Study follow-up: 9 months
Participants • Country: Australia• Setting: community• CKD patients (< 60 mL/min) and diabetes• Number (randomised/analysed): intervention group (39/36); control group (41/39)• Mean age ± SD (years): intervention group (68 ± 8.3); control group (66 ± 10.8)• Sex (M): intervention group (56.4%); control group (56.1%)• Exclusion criteria: < 18 years; didn't comprehend English; not mentally competent; didn't have type
1 or 2 diabetes and CKD estimated by a MDRD eGFR > 15 (≤ 60 mL/min/1.73 m2) or diabetic kidney
disease (microalbumin/creatinine ratios > 2.0 mg/mmol for men, > 3.5 mg/mmol for women), and
systolic hypertension ≥ 130 mmHg treated with prescribed antihypertensive medication; live more
than 50km from the city centre; pregnant; had received a new diagnosis of cancer
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth, DVD
Intervention group
• MEMSI* self-monitoring BP, individualised med review* 20 min DVD* fortnightly follow up telephone contact for 12 weeks.* delivered by renal specialist nurse with doctoral qualifications trained in motivational interviewing
using a checklist and standing scripts for fidelity
Control group
• Usual appointment schedule
Outcomes Outcomes measured at 0, 3, 6 and 9 months post intervention
• SBP• Medication adherence: measured using pill counts, Morisky's medication adherence scale, Medication
adherence self-efficacy scale and using surrogate biochemical parameters (eGFR, urine ACR, serum
creatinine, Hb, HbA1c, CaPO4. LDL-cholesterol)
MESMI 2010 
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• QoL - SF12• Health care utilisation (unclear how this was measured)• Feasibility: attrition, participation in all aspects of care, satisfaction
Notes • Funding source: " supported by an Australian Research Council (Linkage) Grant (LP0774989), Sigma
Theta Tau International Small Grant, Nurses Memorial Centre Australian Legion of Ex- Servicemen and
Women Scholarship, and the Mona Menzies Nurses Board of Victoria Grant"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stratified block randomisation
Allocation concealment
(selection bias)
Low risk Identity kept in locked cabinet and research assistant blinded to allocation
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Low risk Research assistant blinded and participants asked not to discuss their alloca-
tion with research assistant when measures taken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Adherence (Morisky's, pill count, SF-12 - validated, serum levels, BP)
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk QoL, self-efficacy
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Less than 5% lost to follow up
Selective reporting (re-
porting bias)
High risk No reporting of QoL (SF12), medication adherence self-efficacy scale or health
care utilisation in paper as were outlined in protocol
Other bias Unclear risk Study was under powered
MESMI 2010  (Continued)
 
 
Methods • Study design: parallel RCT; 485 assessed for eligibility, 209 randomised• Study duration: July 2012 to December 2013• Study follow-up: 2 years
Participants • Country: USA• Setting: community• English-speaking adults aged 18–80 years with an eGFR 15–45 mL/min/1.73 m2• Number: intervention group (50); control group (57)
Navaneethan 2017 
eHealth interventions for people with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
69
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Median age; IQR (years): intervention group (67; 61, 72); control group (68; 64, 72)• Sex (F): intervention group (50%); control group (68%)• Exclusion criteria: kidney transplant recipients; patients on dialysis, patients with terminal illness or
cancer
Interventions • Intervention type classification: self-monitoring, behavioural counselling and self-monitoring with
education• eHealth intervention used: Internet, website
Intervention group
• Enhanced personal health records (self-monitoring and education)* The E-PHR functionality was developed with the assistance of Cleveland Clinic’s Information Tech-
nology Division MyChart team to securely review CKD education materials. These features were in
addition to the existing features available to all PHR users.* CKD alert appeared only once, and when the patient clicked on the alert, it led them to the page that
provided details for CKD. Educational resources were adapted from local and national resources,
including education materials covering topics like nutrition and physical activity, complications of
CKD, co-morbidity management and planning for dialysis.
Control group
• Usual care (self-monitoring)* Advised to use their PHR (MyChart account via EPIC [Madison,WI]) accounts to aid in the manage-
ment of their health. No specific changes to their PHR accounts were made.* All patients who use the PHR can review and schedule appointments, request prescription re-
newals, view health summaries, access a current list of medications, review test results, and send
a secure message to their physicians or health care team. Patients also receive automated impor-
tant health reminders on the basis of sex- and age-based health maintenance schedules as well as
chronic disease–related reminders.* Links within the PHR allow patients to access reliable health information about a broad range of
topics of personal interest through a third-party vendor (MedlinePlus).
Outcomes Primary outcome
Change in eGFR
Secondary outcomes
• Acquisition of appropriate laboratory measures: Hb, phosphorus, UACR, 25-hydroxy vitamin D, PTH,
LDL-cholesterol, HbA1c• Prescription of renoprotective medications (i.e. ACEi and ARB)• Referral rates to nephrologists, vascular surgeons and for kidney transplantation assessment• Achieving BP control, < 130/80 mmHg• Number of hospitalisations and ED visits• Death
Notes • 75% of study populations were white• Funding source: "This clinical trial was supported by grant R34DK094112 from the National Institutes
of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases. The creation of the
Cleveland Clinic CKD registry was funded by an unrestricted grant from Amgen, Inc. (to the Depart-
ment of Nephrology and Hypertension Research and Education Fund, Cleveland Clinic)"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation scheme that was stratified by family
health centre
Navaneethan 2017  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Quote: "Randomization allocation was concealed" however not detail on how
this was achieved
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Quote: "Participants were aware of their assignment"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Low risk Quote: "Study personnel (study coordinator and the navigators) were aware of
their assignment, but the outcome assessors were not aware of the study as-
signments".
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk All outcomes are objective and at low risk of bias
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective measures being used
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No loss to follow-up
Selective reporting (re-
porting bias)
Low risk All stated outcomes have been reported
Other bias High risk "We did not power the study specifically to estimate the interaction of the two
interventions"
Navaneethan 2017  (Continued)
 
 
Methods • Study design: parallel RCT; 182 enrolled and randomised, 157 completed 6 month assessment• Study duration: 12 months• Study follow-up: preliminary 6 month data reported only
Participants • Country: Canada• Setting: community• CKD stage 3B-5 to dialysis-dependent• Number (randomised): intervention group (89); control group (93)• Mean age ± SD (years): not reported• Sex: not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: mobile phone application
Intervention group
• eKidneyCare* Integrated mobile app allowing patients to monitor blood pressure, manage medications, assess
symptoms, review laboratory results* Real time patient feedback* Real time provider alerts
Ong 2017 
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Control group
• MyMedRecord* Commercially available app that records medical information* No feedback
Outcomes Primary outcomes (measured at baseline, 6 months, 12 months)
• SBP• DBP
Notes • Preliminary abstract-only publication; 6 month results only• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Insufficient information to permit judgement, however unlikely as providers
are given real time alerts
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk BP is objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective measures reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 25 withdrew due to incomplete data or due to medical complications; unclear
which study group withdrawals were from
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Ong 2017  (Continued)
 
 
Methods • Study design: parallel RCT; 75 assessed for eligibility, 75 randomised• Study duration: 2 months
Poorgholami 2016a 
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• Study follow-up: 2 months
Participants • Country: Iran• Setting: community, dialysis centre• Receiving maintenance HD patients• Number: intervention group 1 (25); intervention group 2 (25); control group (25)• Mean age ± SD (years): intervention group 1 (50.92 ± 6.46); intervention group 2 (47.84 ± 8.65); control
group (49.4 ± 6.04)• Sex (M): intervention group 1 (44%); intervention group 2 (60%); control group (60%)• Exclusion criteria: history of serious or adverse experiences in the last six months; treatment with an-
tidepressant medications; hospitalisation due to acute disease; and unwillingness to participate or to
continue with the study
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention groups
• Intervention group 1: self-care education* 5 consecutive one hour instructions about the disease process and symptoms as well as impor-
tance of HD, diet, fluid restriction, daily body weight control, physical activity, smoking cessation,
stress management, muscular relaxation, and monitoring the vital signs* Given a copy of an instruction booklet comprising a summary of material taught in the 5 instruc-
tional sessions• Intervention group 2: self-care education plus telephone support* 5 consecutive one hour instructions about the disease process and symptoms as well as impor-
tance of haemodialysis, diet, fluid restriction, daily body weight control, physical activity, smoking
cessation, stress management, muscular relaxation, and monitoring the vital signs* Given a copy of an instruction booklet comprising a summary of material taught in the 5 instruc-
tional sessions.* 3 telephone calls per week for the next two months following the instructions. The duration of
each call was 20 minutes, which could also vary according to the patients’ needs. The content of
telephone conversations included issues, which had been taught in the five instructional sessions
and had been mentioned in the booklet as well as answers to the patients’ questions. In addition,
the patients were told that they could call the investigator any time for their ad hoc questions.
Control group
• Routine care offered in the hospital
Outcomes • Miller’s questionnaire of hope (Conducted on day 56 after the study)
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Not possible due to nature of the intervention
Poorgholami 2016a  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Follow-up calls made by investigator or his assistant, likely blinding was not
upheld
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk No objective outcomes were measured
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Completed in the dialysis ward, no mention of who gave out to patients. Valid
questionnaire
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants included in analysis
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Poorgholami 2016a  (Continued)
 
 
Methods • Study design: RCT, 89 solid organ transplant recipients randomised (46 kidney transplant recipients)• study duration: 3 years• Study follow-up: 3 years
Participants • Country: USA• Setting: community• Kidney transplant recipients• Number: intervention group 1 (20); intervention group 2 (20); control group 1 (26); control group 2 (not
reported)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: reminders• eHealth intervention used: electronic monitoring device; SIMpill system captures medication adher-
ence system. It communicates and stores the timing of openings and doses taken to a secure server
Intervention groups
• Intervention group 1* SIMpill system plus reminders (email or text message reminders when medication doses missed)• Intervention group 2* SIMpill system plus reminders plus healthcare provider feedback (if missed dose not taken with
reminder alert)
Control groups
• Control group 1* SIMpill system• Control group 2* Not described
Potter 2016 
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Outcomes • Number of biopsies performed• Biopsy proven rejection (% of group)• Length of stay for treatment (days)• Total doses taken (%)• Days with correct dosing (%)
Notes • Preliminary data from 1 year presented• Only 4 abstracts available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Blinding of participants would not be possible with this intervention
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Study personnel notified if missed medication doses in intervention group 2
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk All outcomes described are objective and less risk of bias
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Only preliminary data is being reported
Selective reporting (re-
porting bias)
Unclear risk Only preliminary data is being reported
Other bias Unclear risk Insufficient information to permit judgement as limited detail is able to be ob-
tained from abstracts
Potter 2016  (Continued)
 
 
Methods • Study design: parallel RCT (1:1:1); 376 assessed for eligibility, 120 randomised• Study duration: 6 months• Study follow-up: 6 months
Participants • Country: USA• Setting: community
Reese 2017 
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• Kidney transplant recipients during the first 2 weeks after transplantation• Number (randomised/analysed): intervention group 1 (40/40); intervention group 2 (40/39); control
group (40/38)• Mean age ± SD (years): intervention group 1 (50 ± 12); intervention group 2 (50 ± 11); control group
(49 ± 11)• Sex (M/F): intervention group 1 (25/15); intervention group 2 (23/17); control group (24/16)• Exclusion criteria: inability to manage medications; poor English comprehension; HIV-positive
serostatus; living more than 120 miles from the centre (because these patients return to local care
soon after transplantation); and/or discharge to an acute-care facility
Interventions • Intervention type classification: reminder and reminder plus education• eHealth intervention used: blue-tooth, electronic monitor
Intervention group 1
• Wireless pill bottle: customised reminder* Each participant was provided with a wireless pill bottle (Vitality GlowCap; Vitality Inc) that record-
ed pill-cap openings; these data were transmitted in real time to the study database.* light on the bottle would illuminate and the cap would chime when the medication was due* Adherence data were transferred from the Vitality website to a web-based secure research platform
called Way to Health* Participants could select additional reminders, including texts or telephone calls with recorded
messages or e-mails with a weekly adherence summary* Each participant could change their intended times of taking medication and/or reminders
Intervention group 2
• Wireless pill bottle: customised reminder + provider feedback* Each participant was provided with a wireless pill bottle (Vitality GlowCap; Vitality Inc) that record-
ed pill-cap openings; these data were transmitted in real time to the study database.* light on the bottle would illuminate and the cap would chime when the medication was due* Adherence data were transferred from the Vitality website to a web-based secure research platform
called Way to Health.* Participants could select additional reminders, including texts or telephone calls with recorded
messages or e-mails with a weekly adherence summary.* Each participant could change their intended times of taking medication and/or reminders.* Every 2 weeks providers received notification if adherence fell below 90%
Control group
• Received a wireless pill bottle that provided no alerts and only tracked adherence.
Outcomes Primary outcome
• Adherence (measured by pill bottle electronic records): adherence only measured in the final 90 days
of the study (when clinic visits are less frequent)
Secondary outcomes
• Pill bottle–measured adherence between 14 days and the end of the study;• Coefficient of variation of TAC blood concentrations (calculated within each participant)• Coefficient of variation of any morning TAC blood concentration, measured for any indication• Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS), a validated 5-item
self-reported questionnaire specific to immunosuppression, administered at study end
Post hoc analysis
• Compared pill bottle–measured adherence with censoring of data when participants appeared to per-
manently discontinue pill bottle use
Reese 2017  (Continued)
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• Compared adherence in the final 6 weeks• Treated days when participants were hospitalised as fully adherent
Notes • Funding source: "Leonard Davis Institute (LDI) at the University of Pennsylvania and additional sup-
port was provided by the LDI’s Center for Health Incentives and Behavioral Economics"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded given the nature of the intervention
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Study coordinator contacted patients if adherence was below 90% in the feed-
back group, no mention of blinding of study coordinator for participants in
other groups
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Post hoc analyses were conducted by blinded personnel, no mention of
whether this also occurred for primary and secondary outcomes
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective outcomes were measured
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 3/120 dropped out (2.5%)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Reese 2017  (Continued)
 
 
Methods • Study design: parallel RCT; 388 assessed for eligibility, 63 randomised• Study duration: January 2010 to March 2012• Study follow-up: 6 months
Participants • Country: USA• Setting: community• kidney transplant recipients aged ≥ 18 years• Number (randomised/analysed at 2 months/analysed at 6 months): intervention group 1 (31/24/20);
intervention group 2 (232/27/22)• Mean age ± SD (years): intervention group 1 (52.6 ± 12.6); intervention group 2 (54.6 ± 11.7)
Reilly-Spong 2015 
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• Sex (M/F): intervention group 1 (8/19); intervention group 2 (16/12)• Exclusion criteria: prior transplant, prior mindfulness-based stress reduction or regular meditation
practice; serious mental health concerns (suicidality, psychotic disorder, or substance abuse identi-
fied on screening by a psychologist); hospitalised or medically unstable (e.g. recent stroke); kidney
transplant scheduled within the next 3 months
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group 1
• Telephone-adapted mindfulness-based stress reduction* Teleconferences used to deliver MBSR to make it more accessible for patients with ESKD.* Received recordings or practices in teachers voice to use at home* copy of “Full Catastrophe Living”* workbook (course guide and an educational workbook)* DVDs of “Mindful Movement and Stillness”* In-person 5 hour workshops in weeks 1 and 8, separated by 90 min teleconferences in weeks 2-7.
Overall 19 hours of class time
Intervention group 2
• Telephone-adapted support group• To provide attention from a facilitator, group support and structured study activities to balance
treatment arms with respect to known non-specific effects of MBSR.• Provide content driven and highly structured intervention with an attentive instructor to elicit pos-
itive group experience and prevent lengthy or pervasively negative discussions of problems inter-
personal communication skills and how to select health resources were selected as generic skills
that would not overlap with MBSR• Skill building with homework assignments included Homework assignments designed by leader
in weeks 1,6,7 but individual action commitments for other weeks.
Outcomes Primary outcome (measured at baseline, 2 months, 6 months)
• Anxiety (state-trait anxiety inventory STAI)
Secondary outcomes (measured at baseline, 2 months, 6 months)
• depression (centre for epidemiological studies - depression)• Insomnia (Pittsburgh Sleep Quality Index)• HRQoL (measured using SF-12: mental and physical component scores, pain interference item)• Mindfulness (mindful attention awareness scale)• Worry (Penn-state worry questionnaire)• Perceived stress (perceived stress scale PSS-14)• Fatigue PROMIS fatigue short form• 2 subscales from KDQoL (impact and burden)• Actigraphy (sleep quantity and quality - objective measure)• Salivary cortisol (objective biomarker or stress)
Other outcome (measured at 2 months)
• Feasibility and acceptability (Intervention attendance: roll call and recorded weekly rosters, confer-
ence call records provided by teleconference vendor; treatment preference and expectations of inter-
vention usefulness assessed on health and attitudes questionnaires; treatment fidelity measured by
tallies of prescribed course elements on intervention checklists with weekly calls and occasional live
monitoring by health psychologist)
Reilly-Spong 2015  (Continued)
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Notes • Funding source: National Institute of Diabetes and Digestive and Kidney Diseases Award P01
DK013083 and National Center for Advancing Translational Sciences of the National Institutes of
Health Award Number UL1TR00011
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated using permuted blocks
Allocation concealment
(selection bias)
Low risk conducted by statistician who was masked. participants completed baseline
assessments prior to randomisation
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Quote: "single blind"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Unlikely could have been blinded / blinding would have been broken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures (salivary cortisol and sleep actigraphy)
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Feasibility and acceptability measures taken with staF, QoL and anxiety mea-
sures are patient reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low loss to follow-up (12.5% to 12.9%)
Selective reporting (re-
porting bias)
High risk Salivary cortisol and sleep actigraphy and a number of emotional state out-
comes were not reported in either paper
Other bias Unclear risk Insufficient information to permit judgement
Reilly-Spong 2015  (Continued)
 
 
Methods • Study design: parallel RCT (with 2:1 randomisation); 336 assessed for eligibility, 47 randomised• Study duration: 6 months• Study follow-up: 6 months
Participants • Country: USA• Setting: community• patients with CKD stage 3 or greater with uncontrolled hypertension• Number (randomised/completed and analysed): intervention group (30/28); control group (17/15)• Mean age ± SD (years): intervention group (68.5 ± 7.5); control group (67.9 ± 8.4)• Sex (M): intervention group (93%); control group (100%)
Rifkin 2013 
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• Exclusion criteria: presence of a clear secondary cause for HTN (e.g. aldosterone producing tumour),
or estimation by clinic physicians that the individual was within 6 months of requiring dialysis or of
dying from other causes
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: Bluetooth, electronic monitors
Intervention group
• Tele-monitoring device paired with Bluetooth enabled BP cuF* Device consisted of 2 integrated subunits: automatic oscillometric BP unit and home health hub.* BP units have BP measuring range spread over 20-280 mmHg and pulse range 40-200 beats/min.* Home Health Hub is 1x4x6 inch wall unit which participant plugged into any available outlet and
leave there for study duration. It receives BP and pulse data through Bluetooth from the BP unit and
relays data through internet (using study-provided cellular modem) to secure website, accessible
to study personnel through password* Website allows viewing of BP data sorted by participant using unique study ID numbers* Participants educated about appropriate use of cuF prior to clinic appointments electronic med-
ical record updated with full recording of tele-monitored results* Study personnel met weekly to review BP logs, if participant consistently had above-goal readings
during prior week one of personnel would ring to discuss. Additional urgent or clinic physician fol-
low-up scheduled at discretion of team
Control group
• Usual care* Asked to measure and record BP at home according to physicians instructions; no specifics about
frequency
Outcomes Outcomes measured at baseline and 6 months
• change in BP (SBP and DBP)• MAP• kidney function (eGFR, SCr)• Medication adherence (Morisky's medication adherence scale)• Medication use (number of total medications, number of BP medications, number of medication
changes)• Unplanned clinic communications• Acceptability (measured at end of study)
Notes • Funding source: USCD Clinical/Translational Research Institute's Innovative Technology Pilot Grant
(Grant UL RR031980 and UL1TR000100).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Odd/even is a simple randomisation technique which is considered to main-
tain randomness
Allocation concealment
(selection bias)
Low risk Used opaque envelopes
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Rifkin 2013  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Study personnel contacted intervention participants when BP too high. study
physicians and pharmacist met weekly re: BP logs
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Not blinded but objective measures
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Questionnaires were collected by the treating physicians (not the study physi-
cians) however likely participants could have broken blinding. Self-report
questionnaires about adherence by unblinded participants
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 8.5% loss to follow-up (4 out of 47)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Small sample, short follow-up
Rifkin 2013  (Continued)
 
 
Methods • Study design: parallel RCT; 601 assessed for eligibility, 103 participants randomised• Study duration: May 2013 to July 2013• Study follow-up: 6 weeks
Participants • Country: USA• Setting: community• Kidney transplant recipients• Number (randomised/analysed): intervention group (52/50); control group (51)• Mean age, range) (years): intervention group (54, 44 to 62); control group (54, 44 to 60)• Sex (M): intervention group (63%); control group (67%)• Exclusion criteria: prior history of skin cancer, as noted in the medical record or self-reported; a history
of dermatologic disease treated with ultraviolet light, e.g., psoriasis, atopic dermatitis; under the care
of a dermatologist within the last 5 years
Interventions • Intervention type classification: Education plus reminders• eHealth intervention used: text message or email reminders
Intervention group
• Educational intervention plus text message/email reminders* Sun protection workbook to take home* series of automated electronic reminders sent via text message or email.* Over period of 5 weeks, 3 seasonal sun protection reminders were sent by telephone text message
or email (depending on patients preference)
Control group
• Standard care* Educational intervention to be delivered in nephrologist/surgeon offices
Outcomes Primary outcome measure (assessed at baseline and 6 weeks)
Robinson 2014a 
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• Sun protection behaviours (self-reported, validated tool)
Secondary outcomes (assessed at baseline and 6 weeks)
• Willingness to use sun protection (self-reported, validated tool)• Knowledge of skin cancer and sun protection (self-reported, validated tool)• Attitudes about developing skin cancer and personal risk (self-reported, validated tool)• Pigmentation – melanin index, taken using Mobile DataCollector DC3000 spectrophotometer AND
clinical dermatologist assessment
Notes • Funding source: supported by R03 CA-159083 to JKR, from the National Cancer Institute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was performed using stratified random blocks using
RCore Team (19), to assure equal allocation to groups over the accrual period,
in total, as well as within ethnic/racial groups"
Allocation concealment
(selection bias)
Low risk Quote: "Sequentially blinded sealed envelopes were provided by the statisti-
cian to the study coordinator, to be opened by the participant after the base-
line visit"
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Blinding not possible
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Low risk Biologic measures at baseline and 6 weeks assessed by research coordinator
blinded to the study group
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures of pigmentation used
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Subjective measure of pigmentation from RAs who trained by dermatologist,
used validated self-reported attitudes, knowledge and behaviour
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Loss to follow-up (1)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Did not reach power calculation, small sample population; financial incentives
provided
Robinson 2014a  (Continued)
 
 
Methods • Study design: RCT; 853 assessed for eligibility, 170 randomised• Study duration (recruitment): 30 May to 15 July 2014
Robinson 2015 
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• Study follow-up: 6 weeks
Participants • Country: USA• Setting: community• kidney transplant recipients• Number (randomised/completed): intervention group (84/78); control group (86/83)• Mean age ± SD (years): intervention group (51 ± 12.5); control group (49 ± 14.2)• Sex (M): intervention group (56%); control group (62%)• Exclusion criteria: history of skin cancer as self-reported or noted in their medical record; received
education about sun protection or participated in our previous educational sun protection study; ex-
perienced kidney rejection; visually impaired; comorbid diseases prevented participation
Interventions • Intervention type classification: Education plus reminders• eHealth intervention used: tablet application plus reminder emails or text messages
Intervention group
• Tablet app education* Research team gave brief tutorials about how to use tablet* Sun protection program delivered on personal tablet computers* During the next 5 weeks, 2 reminders provided to intervention group as telephone calls, text mes-
sages or emails (depending on participant preference)
Control group
• Usual care* 2-3 sentences in binder provided at time of transplantation surgery and during summer clinicians
gave verbal reminders to wear sunscreen
Outcomes Outcomes measured at baseline and 6 weeks
• Sun protection behaviours (self-reported, validated tool)• Willingness to use sun protection (self-reported, validated tool)• Knowledge of skin cancer and sun protection (self-reported, validated tool)• Attitudes about developing skin cancer and personal risk (self-reported, validated tool)• Skin pigmentation (clinical dermatologist + trained research coordinators + spectrophotometer)
Notes • Additional paper and abstract looking at Health Literacy sub-group analysis• Results stratified by ethnicity• Funding source: Supported by R21 CA-173196 to June K. Robinson, MD, from the National Cancer In-
stitute
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stratified random blocks using R Core Team
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Robinson 2015  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Research co-ordinators and dermatologist blinded, but may have been broken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures of pigmentation used
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Validated self-reported measures of knowledge, behaviours and attitudes. re-
search personnel assessing skin pigmentation were trained by a clinical der-
matologist for the study blinded however this blinding may have been broken
and RAs not dermatologists which may question accuracy of their assessment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 5% loss to follow-up (9/172)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Low participation rate - may not be representative; higher participation rates
among white people; monetary incentives
Robinson 2015  (Continued)
 
 
Methods • Study design: pilot RCT; 40 assessed for eligibility, 15 randomised• Study duration: 6 months• Study follow-up: 6 months
Participants • Country: USA• Setting: community• Kidney transplant recipients non-adherent prior to recruitment• Number (randomised/analysed): intervention group (8/8); control group (7/5)• Mean age ± SE (years): intervention group (55 ± 12.1); control group (44 ± 15.7)• Sex (M/F): intervention group (4/4); control group (3/4)• Exclusion criteria: participated in previous pilot study; < 18 years; received other organ (e.g. non kid-
ney) transplant in addition to kidney transplant; receiving dialysis; unable to speak, hear or under-
stand English; not able to open electronic medication cap; unable to self-administer medication; does
not have access to a telephone; has cognitive impairment as determined by the Telephone Mental Sta-
tus Screen; has a life-limiting diagnosis such as metastatic cancer; acutely unwell (e.g. hospitalised)
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: blue-tooth, electronic monitoring
Intervention group
• Electronic pill monitoring* Medication Event Monitoring System where each cap contains battery and records date and time
with each removal of the cap)* Participant and nurse collaboratively identified life routines, important people and possible solu-
tions to enhance medication taking* Participant received individualised monthly medication taking feedback delivered by a graphic
print out of daily medication taking generated from the electronic medication cap
Russell 2011 
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Control group
• Attention control* Provided with educational brochures and monthly phone calls to review education
Outcomes Primary outcome (measured daily and assessed at baseline and 6 months)
• Adherence was measured using electronic records from pill caps and with diaries to substantiate (ob-
jective and subjective). Adherence score - 0, 0.25, 0.5, 0.75, 1 based on timing medication taken com-
pared to prescribed time.
Secondary outcome (measured at 6 months)
• Perception of burden (participants asked how burdensome interventions were - subjective)
Notes • Funding source: grants from American Nephrology Nurses Association, National Kidney Foundation,
Interdisciplinary Center on Aging at the University of Missouri, University of Missouri Research Council,
and Iowa Gerontological Nursing Intervention Research Center
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation
Allocation concealment
(selection bias)
Low risk Allocation was conducted by a person independent of the research team to ei-
ther the continuous self-improvement intervention group or the attention con-
trol group. Person allocating was blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Principle Investigator conducted the home visits with the intervention group
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective: electronic monitoring records
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Subjective: adherence diaries and perception of burden - not clear who was
asking patients this but could have been influenced feasibility - could of been
influenced
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 28% (2/7) had unusable data from Medication Event Monitoring System data
Selective reporting (re-
porting bias)
High risk Number of outcomes outlined in the protocol were not reported
Other bias Unclear risk Small sample but only a feasibility study; received financial incentive
Russell 2011  (Continued)
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Methods • Study design: parallel RCT; 56 assessed for eligibility, 46 randomised• Study duration: 12 months• Study follow-up: 12 months
Participants • Country: Germany• Setting: community• Adult kidney transplant recipients• Number: intervention group (23); control group (23)• Median, range (years): intervention group (46, 18 to 59); control group (51, 19 to 66)• Sex (M): intervention group (61%); control group (48%)• Exclusion criteria: not reported
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
• Standard care + telemedically supported care* Chronic case management for 1st year post transplant, case management process applicable for
acute care situations and a telemedically equipped team* Prior to discharge nurse-trained participants in operation of interactive terminal which enabled
remote telemonitoring and prompt real-time video consultations.* Participants answered standardised multiple-choice questionnaires via the terminal daily* Data transferred through safe web-based connection* Supplementary briefings were provided by calls, voice mailbox, SMS and emails to the nurses mo-
bile telephone ensuring prompt responses* Nurse had 24-hour access to all significant medical data. After discharge nurse provided planning,
linking and monitoring for achievement of jointly agreed goals, underpinned by self-management
and self-care related actions* Participants had continuous access to expert to discuss specific challenges and to set daily prior-
ities.* Nurse regularly assessed details via telemonitoring, VC and mobile phone. If acute issues emerged
nurse contacted nephrologist for intervention* Nurse regularly assessed details via telemonitoring, VC and mobile phone. If acute issues emerged
nurse contacted nephrologist for intervention
Control group
• Standard care* Received a booklet for recording drug regimen, vital signs and fluid balance* Educational booklet* Transplant nurse provided counselling which included standardised self-management informa-
tion about disease prevention, immunosuppression adherence and self-monitoring* Regular check-ups with nephrologist combined with best clinical practice check-up program.
Physicians determined time intervals between check-ups according to risk stratification and fur-
ther consultations when needed
Outcomes Data reported at baseline, 3, 6 and 12 months. Used intention-to-treat analysis
• Medical outcomes - unplanned hospital admissions, length of unplanned admissions, acute rejection
rate, length of time before rejection therapy initiated, ambulatory care visit rate• Medication adherence - composite adherence score and CAS % grade (Basel Assessment Adherence to
Immunosuppression scale (BAASIS), collateral reports from physicians and nurses, hit target tac level)• Quality of life (fragebogen alltagskeben ALL, ESRD-SCL, BSI-18)• Cost analysis (unplanned inpatient costs, work time %)
Schmid 2016 
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Notes • Funding source: The project received funding by the European Union within the framework of the
INTERREG IV Oberrhein (grant reference number “A12—Promethee")
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation schedule provided by the Institute of
Medical Biometry and Medical Informatics
Allocation concealment
(selection bias)
Unclear risk Quote: "concealed allocation" but no further information
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Nurses delivering intervention could not have been blinded
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Hospital admissions, LOS, adherence
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Psychosocial measures were validated and assessed by psychologist - no men-
tion of whether psychologist blinded to allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Used intention-to-treat analyses, low loss to follow-up
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Small sample size
Schmid 2016  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: 3 months• Study follow-up: 3 months
Participants • Country: Germany• Setting: community, dialysis unit• Relevant health status: receiving maintenance HD and experienced average weight gain of at least 1.5
kg between 2nd and 3rd dialysis of the week• Number (randomised/analysed): intervention group (60/43); control group (60/58)• Mean age ± SD (years): intervention group (65.7 ± 14.7); control group (66.5 ± 13.8)• Sex (M/F): intervention group (30/30); control group (31/29)• Exclusion criteria: not reported
Schulz 2007 
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Interventions • Intervention type classification: self-monitoring• eHealth intervention used: Bluetooth, electronic monitors
Intervention group
• Telemetric body weight monitoring* Weight taken pre- and post-dialysis + telemetric weight monitoring* Patients instructed to weight their body weight under possibly equal terms daily before and after
dialysis and once daily on days without dialysis at a time corresponding to start of dialysis* TBWM enabled with Bluetooth interface for automatic data transmission after each weight. If > 0.75
kg alarm report sent to physician by email.* Weight gain discussed at next appointment or by telephone (If weight gain > 1.5 kg mandatory
phone intervention conducted)* Alarm generated once per day at most* Under usage report sent to physician if no weights for 3 days* Monthly and weekly reports generated of weight parameters and were given to patients during
dialysis
Control group
• Weight taken pre- and post-dialysis
Outcomes Primary outcomes (assessed baseline and 3 months)
• IDWG: average weights and weight changes• UF
Secondary outcomes
• Mean time duration on dialysis (baseline, 3 months)• SBP and DBP (baseline, 3 months)• haemoglobin variability (over 3-month intervention period)• Hospitalisations (over 3-month intervention period)• Vascular events (over 3-month intervention period)• Death (over 3-month intervention period)
Notes • Death, vascular events and haemoglobin variability data were not reported in any abstracts or papers• Funding source: supported by Roche Pharma Deutschland GmbH
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Physicians received alarms from study participants
Schulz 2007  (Continued)
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Blinding of personnel
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk All outcomes are objective
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
High risk Stated outcomes in abstracts and papers have not been reported
Other bias Unclear risk Insufficient information to permit judgement
Schulz 2007  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: 3 month intervention, 6 month maintenance phase• Study follow-up: 9 months
Participants • Country: Netherlands• Setting: outpatients• Patients with eGFR > 25mL/min with CKD or kidney transplant recipient; diagnosed with hypertension,
sodium intake > 130mmol/day• Number: 99, numbers per group not reported• Mean age ± SD: 57 ± 12 years• Sex: not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: website, internet
Intervention group
• Web-based self-management system* Dedicated to dietary sodium restriction with individual e-coaching* Two group meetings in 3-month intervention phase, followed by 6-month maintenance phase
Control group
• Not described
Outcomes Outcomes measured at baseline, 3, 6, 9 months
• BP• electrolytes• dietary sodium intake (measured using 24 urine collection)• QoL and well being• Healthcare expenditure from questionnaires• Incremental cost-effectiveness ratio
SUBLIME 2016 
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Notes • Abstract-only publication• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective data such as BP, 24-hour urine sodium, cost-analysis
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk No reporting of how well being and quality of life is measured
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 28% drop out in intervention, 3.3% drop out in control - no mention if these
participants differed; no mention of whether used ITT analyses
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
SUBLIME 2016  (Continued)
 
 
Methods • Study design: 3-phased RCT• Study duration: 20 weeks• Study follow-up: 20 weeks
Participants • Country: UK• Setting: community• Parents or carers of children with CKD stages 3-5• Number (children/parents recruited; children/parents analysed): intervention group (18/29; 14/19);
control group (21/29; 16/22)• Mean age ± SD (years): Parents ages: 5% aged 16-24 years; 60% aged 25-49 years; 35% aged 50-64 years• Sex (M parents): intervention group (40%); control group (not reported)• Exclusion criteria: not reported
Swallow 2016 
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Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: internet, website
Intervention group
• Interactive health communication application* Online parent information and support application* Website included: glossary of terms, frequently asked questions, case studies/personal accounts
of families living with CKD, including those who have experienced transplants, Renal recipes for
healthy eating, links to other CKD-specific websites with animations, family-to-family area to com-
municate with others, living with CKD videos of clinical procedures
Control group
• Usual care, support from professionals
Outcomes Outcome measures (assessed pre-test and 20 weeks)
• Usage - using Google Analytics, number and timing of site visits and page views, time spent on the site
per visit and user device type• Acceptability of OPIS was assessed using a modified version of the Suitability Assessment of Materials• Usability was assessed by a modified version of the User Interface Satisfaction questionnaire• Qualitative interviews to explore readability of materials; accessibility, perceived accuracy, tone, or-
ganization and visual interest of materials; the value and use of learning materials including any mul-
timedia content; the value and role of the family-to-family area; perceptions of personal confidence
and competence in home-based care-giving during the trial; technical issues and methods the parent
used to access OPIS
Notes • Funding source: National Institute for Health Research (NIHR) under the Research for Patient benefit
programme (PB-PG-0110-21305)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomized block sizes in an allocation ratio of 1:1 stratified by CKD stages (3
versus 4/5) and ethnicity (White/Black versus South Asian)
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Not possible due to the nature of the intervention
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Insufficient information to permit judgement but likely blinding would have
been broken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Google analytics for usage
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Unclear risk Qualitative interviews and validated questionnaires, unclear who conducted
interviews.
Swallow 2016  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk 22% to 24% loss to follow-up, reasons given; no mention of whether these par-
ticipants were different
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement
Other bias Unclear risk Only technologically savvy families could have participated. Lower recruit-
ment rate from south Asian descent participants
Swallow 2016  (Continued)
 
 
Methods • Study design: prospective, parallel, unblinded RCT• Study duration: February 2012 to May 2016• Study follow-up: 12 months, with 3 month non-intervention run-in period
Participants • Country: USA and Canada• Setting: multicentre (8 sites)• Adolescents at least 3 months post kidney transplant aged 11 to 24 years• Number: intervention group (81); control group (88)• Median age (IQR) (years): intervention group (15.5 (13.2-17.4)); control (15.8 (13.3-17.5)• Sex: 59% male; intervention group (61%); control group (57%)• Exclusion criteria: impending graP failure; severe neurocognitive disabilities lack of electronic pill-
box connectivity; use of liquid immuno-suppressive medications; having a sibling participating in the
study; participating in another adherence-promoting intervention study; inability to communicate
comfortably in English or French
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: blue-tooth, electronic monitors
Intervention group
• Usual clinical care plus electronic pill box with alerts* Adherence Support Team (AST) comprised of the participant, 1-2 parents, trained site Coach.* The coach delivered standardized education on immunosuppressive medications by slide presen-
tation, identified adherence barriers using the AMBS/PMBS27 and the last 3 months of electronic
monitoring data, and then used “Action-Focused Problem Solving” to address barriers selected as
most important by the patient. The patient chose 1 or 2 barriers to address at each session.* At subsequent sessions, the coach, patient, and parent jointly reviewed the electronic adherence
monitoring data from the prior 3 months to identify adherence patterns and guide the develop-
ment and revision of action plans. Patients could continue to work on the same barrier(s) or select
a new barrier to address.* Participant chose to receive text message, email or visual cue dose reminders throughout the study
Control group
• Usual clinical care* Control group study visits were conducted at the same intervals as intervention visits* consisted of the coach engaging in active listening and providing nonspecific support only* Adherence was not discussed with participants.* Electronic pill box to track adherence, however no alerts or feedback given to participants
Outcomes Primary outcome (12 months)
TAKE-IT 2014 
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• Medication "taking adherence" defined as proportion of prescribed doses taken. Measured through
electronic monitoring, pharmacy dispensing records, self reporting and variability in tacrolimus and
sirolimus trough levels. Each day was scored as 0%, 50%, or 100%, depending on whether the patient
took none, half, or all prescribed doses.• "Timing adherence" defined as proportion of prescribed doses taken within 1 hour before to 2 hours
after the prescribed dosing time. Timing adherence scores were given the values 0%, 50%, or 100%.
Secondary outcomes (12 months)
• Adherence: standard deviation of tacrolimus trough concentrations and self-reported (MAM-MM).• GraP outcomes: graP failures or deaths, acute rejections, percentage change in glomerular filtration
rate• adverse events: death, opportunistic viral infections, hospitalisations, other medical conditions re-
quiring treatment
Notes • Funding source: The study was funded by the American NIH, National Institutes of Diabetes, Digestive
and Kidney Diseases (R01DK092977)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation
Allocation concealment
(selection bias)
Low risk Allocation is maintained until 3 month visit
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Not blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Not blinded
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk primary and secondary outcomes predominantly measured objectively
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk Subjective assessment of adherence used in addition to objective methods
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 12% loss after randomisation in intervention group, groups were balanced
with respect to age, time since transplant, gender. Analyses conducted using
intention-to-treat and as-treated
Selective reporting (re-
porting bias)
Low risk All stated outcomes were reported
Other bias Unclear risk Insufficient information to permit judgement
TAKE-IT 2014  (Continued)
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Methods • Study design: parallel RCT; 89 assessed for eligibility, 44 randomised• Study duration: 6-week intervention• Study follow-up: 8 week follow-up
Participants • Country: USA• Setting: community, dialysis unit• Patients receiving maintenance HD• Number (randomised/analysed): intervention group (24/16); control group (20/17)• Mean age ± SD (years): intervention group (53 ± 15.1); control group (47.1 ± 11.5)• Sex (M/F): intervention group (12/12); control group (13/7)• Exclusion criteria: living in an assisted or extended care facility, receiving outpatient HD on a tempo-
rary basis following a PD complication or an episode of transplant rejection, reported having no intent
to comply with dietary or fluid restrictions and were receiving home HD.
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: PDA application
Intervention group
• Dietary Intake Monitoring Application (DIMA)* Electronic dietary self-monitoring app* Participants trained for 2-3 hours; used for 1 week to familiarise* Participants can scan food labels, feedback screen in relation to dietary prescriptions to facilitate
awareness of performance attainment, totals automatically computed* Dietary and usage data downloaded at each dialysis session* 24-hour telephone number provided
Control group
• Daily Activity Monitoring Application (DAMA)* DAMA to ensure these participants got equal time as to DIMA* Participants used DAMA for 1 week to familiarise; trained for 30 min* Instructed to self-monitor activity in 8 categories (walking, biking, weight lifting, shopping, yard
work, childcare, housework, cooking)* Selected icons representing activities and amount of time. Could view total daily activity time.* Usage data downloaded every dialysis session* 24 hour telephone number provided
Outcomes • Average IDWG (baseline and 6 weeks)• Cardiac Diet Self-Efficacy Instrument and Fluid Self-Efficacy Scale (baseline, 6 weeks, 14 weeks) - RAs
read out questionnaires to patients• Benefits of Sodium Adherence and Fluid Adherence Scale (baseline, 6 weeks, 14 weeks) - RAs read out
questionnaires to patients• 7-item mastery scale (baseline, 6 weeks, 14 weeks) - RAs read out questionnaires to patients• Dietary intake in intervention only (Week 1, week 6) - Automatically computed dietary intake data
based on patient recorded food items from DIMA. Summed weekly intake and then divided by number
of days for which entries made• Acceptability (end of study)
Notes • Dietary intake data was only recorded and reported for the intervention group• Funding source: supported by grants from NIH/National Institute of Biomedical Imaging and Bioengi-
neering (R21EB007083), a T32 Postdoctoral Training Grant (NIH T32 NR007066), and Indiana Univer-
sity School of Nursing Research Investment Funds
Risk of bias
Welch 2013 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was blocked and stratified by dialysis unit
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Blinding not possible
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk No mention of blinding but likely would be broken
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures (IDWG) used
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Participant data were collected by RAs during HD treatment. The RAs read
questionnaire items for baseline and follow-up data collections to each partici-
pant, who responded verbally to each item
Incomplete outcome data
(attrition bias) 
All outcomes
High risk overall attrition rate of 25% by the end of the 8-week follow-up. There were no
statistically significant differences in age, gender, race, dialysis unit, or group
between those who continued in the study and those who did not
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias High risk Under powered, small sample size only 2 dialysis units involved and not gener-
alisable
Welch 2013  (Continued)
 
 
Methods • Study design: pilot RCT; 40 randomised• Study duration: 6 month• Study follow-up: 6 months
Participants • Country: Canada• Setting: community, dialysis unit• Patients receiving maintenance PD patients with diabetes• Number: intervention group (20); control group (20)• Mean age ± SD (years): not reported• Sex: not reported• Exclusion criteria: not reported
Interventions • Intervention type classification: behavioural counselling• eHealth intervention used: Telehealth
Intervention group
White 2010 
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• Telemonitoring* Daily interaction with telemonitoring station, with health coaching and nursing staF responding
to patient responses* Two-way video conferencing utilised
Control group
• Usual care: no description
Outcomes • Hospitalisations• ED visits• QoL• Satisfaction• Ease of use• Self-management
Notes • 2 abstracts and 1 poster• Author contacted who gave details on randomisation• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Author replied to email stating neither participants or personnel were blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
High risk Author replied to email stating neither participants or personnel were blinded
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Objective measures (ED visits, hospitalisations) used
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
High risk Subjective measures using self-report at high risk of bias
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
White 2010  (Continued)
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Methods • Study design: RCT, 31 enrolled and randomised, 29 reported• Study duration: 5 weeks• Duration of follow-up: 5 weeks
Participants • Country: USA• Setting: community, HD unit• Adults aged 18 to 75 years receiving maintenance HD for more than 3 months; required to have the
ability to walk without assistance or assistive devices to ensure device was able to track activity• Number: intervention group (15); control group (14)• Mean age ± SD (years): intervention group (56 ± 13); control group (48 ± 15)• Sex (M): intervention group (60%); control group (21.4%)• Exclusion criteria: unstable health (e.g. acute infections, congestive heart failure NYHA class 4 and/
or unstable angina); hospitalised within 3 months before enrolment for non-access-related reasons;
cognitively impaired; nickel allergy; patients who had previously worn activity tracking devices
Interventions • Intervention type classification: self-monitoring• eHealth intervention used: blue-tooth, electronic monitor
Intervention group
• Fitbit Flex tracker with feedback* As per control group* Received a report of activity and sleep data in the week leading to the date of each HD treatment
Control group
• Fitbit Flex tracker* Activity and sleep data collected over the course of 5 weeks* Instructed to wear bracelet at all times, even when in water and worn on the non-vascular access
arm.* Fitbit Flex tracks activity parameters (steps taken, distance travelled) and sleep duration and qual-
ity (minutes asleep, total time in bed)* Data downloaded from the device to the user account during each HD treatment* Asked to keep a daily sleep log (recorded times they went to bed and the times they woke up)
Outcomes • Human activity profile (sleep and physical activity)• Physical Activity Questionnaire (regarding participant experience)• Laboratory test (obtained from electronic health records) - usual monthly blood tests plus CRP, albu-
min, pre-albumin, haemoglobin• Clinical parameters: IDWG, blood pressures (pre and post dialysis)
Notes • Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Study described as randomised, method of random sequence generation not
reported
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Williams 2017 
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Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of participants
High risk Participants could not have been blinded
Blinding of participants
and personnel (perfor-
mance bias) 
Blinding of personnel
Unclear risk Unclear who provided the feedback to participants
Blinding of outcome as-
sessment (detection bias) 
Objective outcome
Low risk Sleep and physical activity measured objectively
Blinding of outcome as-
sessment (detection bias) 
Subjective outcomes
Low risk No subjective measures, other than patient experience.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 2 participants were not included in analyses as they died during the study pe-
riod, no mention of which group they were allocated to, however low rate of
missing data overall (n = 2; 6%).
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement
Other bias Unclear risk Insufficient information to permit judgement
Williams 2017  (Continued)
ACEi - angiotensin-converting enzyme inhibitor; ACR - albumin:creatinine ratio; ARB - angiotensin receptor blocker; BP - blood pressure;
BUN - blood urea nitrogen; CBT - cognitive behaviour therapy; CKD - chronic kidney disease; CrCl - creatinine clearance; CSA - cyclosporin;
DBP - diastolic blood pressure; ED - emergency department; eGFR - estimated glomerular filtration rate; EMD - electronic medication
dispenser; ESKD - end-stage kidney disease; HbA1c - haemoglobin A1c (glycated); HD - haemodialysis; HEiQ - Health Education Impact
Questionnaire; HRQoL - health-related quality of life; IDWG - interdialytic weight gain; LDL - low density lipoprotein; MAP - mean arterial
pressure; MDRD - Modified Diet in Renal Disease; MEMSI -Medication Self-Management Intervention; PD - peritoneal dialysis; PDA - personal
digital assistant; PHR - personal health record; PTH - parathyroid hormone; QoL - quality of life; RCT - randomised controlled trial; SBP -
systolic blood pressure; SBP - systolic blood pressure; SCr - serum creatinine; SMS - short messaging service; TAC - tacrolimus; UACR - urine
albumin:creatinine ratio; UF - ultrafiltration; VAS - visual analogue scale
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abdel-Kader 2011 Wrong target population
Chen 2011e Wrong intervention
Korus 2017 Wrong target population
Morales-Barria 2016 Wrong study design
RaDIANT 2014 Wrong target population
Roberto 2009 Wrong target population
SMILE 2010 Wrong intervention
Warren 2009 Wrong study design
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Study Reason for exclusion
Wilson 2014 Wrong target population
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Assessment of telehome monitoring in patients on peritoneal dialysis: a multicentre randomized
controlled trial (CONNECT)
Methods Parallel assignment, RCT
Participants Adult patients on PD for at least 3 months, the patient or their primary care giver able to read and
speak English, the patient or primary care giver cognitively and physically capable and willing to in-
teract with a tablet computer and perform self-measurements (e.g. taking weight)
Interventions Interventions
• Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them
with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment
reminders, educational content)
Standard of care
• Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone
communication and using pen and paper log to track their treatments and supplies
Outcomes Primary outcome: composite of technique failure (switching to HD for ≥ 12 weeks), infections (peri-
tonitis, exit-site, tunnel) and hospital encounters (ER visits, hospitalisations)
Secondary outcome: HRQoL (Kidney Disease Quality of Life-36 (KDQOL-36) Instrument and EQ-5D
to assess HRQoL), time spent communicating (measured through automated telephone logs and
paper telephone logs that are documented by nurses), number of missed appointments, nurse
overtime hours, number of clinic visits, hospitalisation days, nursing costs, healthcare utilisation
costs, dialysis supply costs
Starting date June 2016
Contact information Melissa Subnath
melissa.subnath@lhsc.on.ca
Notes Clinical trials last updated on 11 December 2017, recruitment is ongoing
CONNECT 2017 
 
 
Trial name or title Medico-economic evaluation of a telemedicine system for the management of chronic renal failure
Methods Open, label, parallel group, RCT
Participants Adult patients with CKD stage 3b-4 (nephrology care < 2 years), ESKD on ambulatory dialysis, kid-
ney transplantation (> 3 months and < 12 months), patients can use IT tool or having someone in
entourage who knows how to use
Interventions Usual Care
eNEPHRO 2017 
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eNephro Application
Telemedicine system which is a collaborative and expert system, consisting of: A dynamic shared
medical record for the collection of administrative, medical, biological and clinical data for each
patient. All health professionals can access the folder and fill in the support. It is the same for pa-
tients treated at home. A secure messaging for communication between health professionals and
between patients and health professionals Expert systems analyzing data from each patient A
management tool of therapeutic education A compliance assistance: electronic pillbox and phar-
maceutical care Patients included in this study are major patients, male and female who signed a
consent form. These patients have a chronic renal failure moderate to end up being treated by am-
bulatory dialysis or kidney transplantation. The patients of each population will be randomly as-
signed in group 1 (traditional care) or in group 2 (traditional care added by telemedicine system)
Outcomes Primary outcomes: combined endpoint achievement of target BP and proteinuria (measured at 1
year), cumulative duration of hospitalisations for 1 year, cumulative duration unplanned short stay
for 1 year, survival at one year
Secondary outcomes: compliance (baseline, 6 months, 12 months), QoL (baseline, 12 months),
anxiety-depression state (baseline, 12 months), change in eGFR (baseline, 12 months), anaemia
control (12 months), consultations and hospitalisations unplanned (12 months), disease costs (12
months), intervention costs (12 months), acceptability (12 months)
Starting date November 2015
Contact information Professor Michele Kessler m.kessler@chu-nancy.fr
Notes Clinical trials last updated April 2016, recruitment for the study is ongoing, estimated completion
Dec 2016
eNEPHRO 2017  (Continued)
 
 
Trial name or title The efficacy and stability of an information and communication technology-based centralized
monitoring system of adherence to immunosuppressive medication in kidney transplant recipi-
ents: study protocol for a randomized controlled trial
Methods Multicentre, open-label, prospective, RCT (1:1 randomisation). The planned follow-up duration is 6
months.
Participants Kidney transplant recipients, n = 114
Interventions Intervention
• ICT-based centralized clinical trial monitoring group (n = 57). Participants are given a smart pill
box equipped with a personal identification system. The adherence-related information obtained
from the pill box is saved, monitored, and sent out via a home monitoring system. Of the home
monitoring system data, those necessary for the clinical trial are extracted and incorporated into
the electronic Case Report Form (eCRF) system. All data is consolidated and managed within the
comprehensive clinical trial management system (CTMS). In the ICT- based, centralized clinical
trial monitoring group, feed- back is sent to both patients and medical staF in the form of texts
and pill box alarms if there is a dosage/ dosing time error or a missed dose. To keep a drug admin-
istration diary that specifies date, whether a dose is taken or not, dosing time, and dosage
Control
• Ambulatory follow-up group (n = 57). To keep a drug administration diary that specifies date,
whether a dose is taken or not, dosing time, and dosage
Outcomes The primary outcome in this trial is adherence to medication, including dose-taking compliance,
dose-frequency compliance, dose-interval compliance, drug holidays, medication possession ratio
Jung 2017 
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Secondary outcomes: Both groups are to make six office visits after randomisation at 4, 8, 12, 16,
20, and 24 weeks. Each visit requires measurement of blood drug level, creatinine level, and esti-
mated glomerular filtration rate (eGFR). Serum BK virus is assessed at 12 weeks and Panel reactive
anti- body (PRA) at 24 weeks. At each visit, subjects go over the diary with investigators and fill out
a questionnaire using the Modified Morisky Adherence Scale. The ICT-based centralized clinical trial
monitoring group completes a patient Satisfaction Questionnaire developed by the ICT Clinical Tri-
al Support Center at 4 and 24 weeks.
Cost-effectiveness evaluation parameters include installation of the ICT-based centralized monitor-
ing system, additional hospitalisation due to non-adherence, ambulatory tests, and trips for hospi-
tal visits.
Process evaluation: The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-
AIM) framework will be used in order to evaluate translatability and feasibility of ICT- based central-
ized monitoring system
Starting date January 2017
Contact information ylkim@knu.ac.kr
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South
Korea
Notes Clinical trials registration: NCT03136588, registered on 20 April 2017
Jung 2017  (Continued)
 
 
Trial name or title The Kidney Awareness Registry and Education (KARE) study: protocol of a randomized controlled
trial to enhance provider and patient engagement with chronic kidney disease
Methods Single blind, factorial assignment, RCT
Participants CKD (eGFR < 60mL/min), speak Chinese, Spanish or Cantonese, have primary care provider
Interventions Experimental: ATSM + Health Coach and CKD Registry - primary care providers can access online
CKD registry to identify patients, get notifications of CKD status and access guidelines and educa-
tion materials + patients receive automated telephone self-management which blends automated
phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly auto-
mated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to
CKD management, preventive services, and lifestyle changes. Patients will interact with the system
using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back
within 24-48 hours by a health coach
Active comparator: CKD registry only
Active comparator: Automated telephone self-management + health coaching
Placebo comparator: usual care - primary care providers will manage their patients with CKD as per
usual
Outcomes Primary outcome: change in BP (baseline, 12 months)
Secondary outcomes: change in CKD awareness, functional status and symptoms (baseline, 12
months)
Starting date April 2013
Contact information Dr Delphine Tuot delphine.tuot@ucsf.edu
KARE 2015 
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Alexandra Velasquez velasqueza@medsfgh.ucsf.edu
Notes Clinical trials last verified October 2016, recruitment is ongoing, estimated completion December
2017
KARE 2015  (Continued)
 
 
Trial name or title Assessment of efficacy of a CKD support decision making application and home blood pressure
measurement system in patients with CKD: study protocol of a randomized, controlled trial
Methods Clinical, prospective, RCT with balanced randomisation (1:1)
Participants Inclusion criteria: patient at the kidney internal medicine outpatient clinics, age over 20 years old,
provision of informed consent, to be assure by doctor, RRT not yet selected, and eGFR < 60
Interventions Intervention: will receive conventional care from the attending physician; the patient and physician
will also be given a tablet equipped with the CKD-SDM app and an automated sphygmomanometer
for home blood pressure monitoring for 2 months. The CKD-SDM app includes 61 items in three cat-
egories: "Let’s study CKD", "What’s about RRT?", and “Learn and consent of CKD”.
Control: will receive conventional care and only the automated sphygmomanometer for 2 months
Outcomes The primary outcome measure is change in home BP data from baseline.
Secondary outcomes are renal function, spot urine test, self-efficacy for chronic illness, disease
burden, knowledge level of self-management in CKD, and decision for RRT
Starting date Recruitment began in March 2017
Contact information Shiho Kosaka
skosaka-tky@umin.ac.jp
Notes UMIN clinical trials last updated on 25/07/2017
Kosaka 2017 
 
 
Trial name or title MAGIC Study: aims, design and methods using SystemCHANGE to improve immunosuppressive
medication adherence in adult kidney transplant recipients
Methods 4 year, two-centre, RCT (single blind)
Participants Adult kidney transplant recipients, prescribed at least 1 immunosuppressive medication taken
twice daily, functioning kidney transplant, received kidney-only transplant, transplant physician
has agreed can participate, able to speak, hear and understand English, able to open electronic
medication cap, self-administering immunosuppressive medication, has telephone / access to tele-
phone, no cognitive impairment, no other life-shortening diagnoses, not currently hospitalised
Interventions Intervention: SystemCHANGE - initial home visit conducted, 2 weeks later phone review and then
monthly phone calls over 6 month intervention. Phone reviews include reviewing electronic med-
ication reports, goal setting, determining process owners, identifying lifestyle routines, identifying
cyclical nature of routines, possible solutions for change and story boards for success. Research as-
sistant encouraged patient to continue using electronic monitoring cap for an additional 6 months
during maintenance phase.
MAGIC 2016 
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Attention control: home visit and monthly phone reviews. these patients receive educational ma-
terials that address healthy living after transplantation. if participant asks questions about medica-
tion they are directed back to their transplant team. encouraged to continue using electronic med-
ication monitoring and diary for additional 6 months of maintenance phase
Outcomes Primary outcome: medication adherence - MEMS Cap, cost-effectiveness (ICER)
Secondary outcomes: Blood creatinine, BUN level, acute and chronic rejection, infection, health-re-
lated QoL, death will be collected retrospectively from medical records
Starting date June 2014
Contact information Dr Cynthia Russell RussellC@umkc.edu
Notes clinical trials last updated October 2016, recruitment in study is ongoing, estimated completion
date May 2018
MAGIC 2016  (Continued)
 
 
Trial name or title Assessing novel methods of improving patient education of nutrition: ehealth, health literacy and
chronic kidney disease
Methods RCT
Participants CKD stage 3, 4, 5, aged 18 to 90 years, ability to read English, adequate visual acuity
Interventions Intervention: web-based nutritional education intervention + usual care
Usual care
Outcomes Primary outcome: phosphorus knowledge, dietary phosphorus intake (as per serum phosphate,
calcium, PTH, calcium phosphorus product), dietary phosphorus intake as per 24 hour recall diary
Secondary outcomes: correlations between dietary phosphorus intake, serum phosphorus levels
and CECs will be made
Starting date November 2006
Contact information Dr Jonathan B Jaffery
Notes Clinicaltrials.gov not updated in 2 years, previous estimated completion date June 2009)
No published data has been found
NCT00394576 
 
 
Trial name or title Primary care eHealth intervention for improved outcomes in chronic kidney disease (CKD eHealth)
Methods Open label, parallel assignment, RCT
Participants Adult CKD stage 3a (eGFR 45-59) with poorly controlled risk factors for CKD progression and/or CVD
morbidity / death and stage 3B (eGFR 30-44) who have primary care provider, non-pregnant, ability
to use computer or smartphone, ability to understand English
NCT02097550 
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Interventions Experimental: eHealth Intervention - Patients randomized to this arm will receive eHealth materi-
als every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and
delivery channel will be informed by the formative research. Developing and testing an electronic
health intervention (that will combine secure e-mail, smartphone text message, and online video
materials) to promote patient use of effective medications.
Standard Care with physician
Outcomes Primary: CKD metabolic control (12 months) - consist of clinical and laboratory measurements that
are routinely performed in primary care settings
Secondary: new indicated medication prescriptions (12 months), adherence proxy measures (12
months) - refills for prescriptions, patient and provider satisfaction (12 months), urine albumin (6
months), SBP (6 months), HbA1c (6 months), LDL-C (6 months), CKD progression measured by eGFR
(12 months), DBP (12 months) HDL-C (12 months), total cholesterol (12 months)
Starting date May 2016
Contact information Dr Veronica Yank
Notes Clinical trials last verified September 2016, trial is ongoing but not recruiting, estimated comple-
tion may 2018
NCT02097550  (Continued)
 
 
Trial name or title Do technology apps improve compliance in adolescent renal transplant recipients?
Methods Open label, efficacy study, RCT
Participants Adolescent (12-18 years) kidney transplant recipients
Interventions Intervention: Electronic application - Use of electronic apps (iphone or iPad mini) to determine
whether it can improve compliance with transplant care and readiness to transition to adult care
Paper-based calendars, reminders, medication list and BP, fluid intake tracking methods
Outcomes Primary outcome: medication compliance (12 months) as assessed by presence or absence of anti-
body-mediated rejection based on donor-specific antibody levels
Secondary outcome: readiness to transition (baseline, 12 months) - knowledge of transplant care
and readiness to transition to adult care assessed by questionnaire of disease knowledge
Starting date April 2015
Contact information Dr Ha Tran hatran@stanford.edu
Dr Priya Chandra priyac1@stanford.edu
Notes Clinical trials last verified November 2015, recruitment ongoing
NCT02610946 
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Trial name or title A personalized follow-up of kidney transplant recipients using video conferencing based on a 1-
year scoring system predictive of long term graP failure (TELEGRAFT study): protocol for a random-
ized controlled trial
Methods Phase 4, open level, randomised, multicentric and prospective study
Randomised to novel eHealth program versus standard care
1:1 randomisation, stratified by centres and performed at 1 year post kidney transplant with pa-
tient participation planned for 2 years
Participants 1 year post kidney transplant, access to high speed internet, without ongoing CMV or BKV infection,
men and non-pregnant women, without mental disorders and provide informed consent
Interventions eHealth intervention: provided with a USB which allows collection of medication information be-
fore video conferencing. USB opens a secure internet connection via an intuitive interface specifi-
cally designed for non-internet specialist patients. Also provided with tablet computer (e.g. iPad)
devoted for video conferencing. Low risk patients will be interviewed 3 times with VC with pulse,
weight, temperature and BP collected on USB, with only 1 in-person complete checkup conducted
per year. For high risk patients they will have in person 1 complete check up and 5 standard visits +
6 additional VCs to reinforce follow-up.
Standard care: patients classified as low risk of graP failure within first 8 years post-transplantation
will be scheduled 4 visits at the hospital per year, whilst high risk patients will be scheduled 6 visits.
Standard visits include clinical examination of BP, weight, blood and urine monitoring and 1 vis-
it encompassing a complete checkup of further biochemistry, morphologic exams and question-
naires related to QoL and psychological dimensions.
Outcomes Primary outcome is composite and defined by absence of major complications until 2 years post
randomisation (e.g. patient alive with functioning kidney, without acute rejection episodes, with-
out decrease in eGFR higher than 25% and without cancer.
Secondary outcomes: to evaluate efficiency of system - incremental cost-effectiveness ratios,
transplant specific QoL, evolution of psychological dimensions related to stress and coping, anxi-
ety/depression
Starting date February 2012
Contact information aurelie.meurette@chu-nantes.fr
Notes clinical trials updated May 2016 - recruitment ongoing, estimated completion date September 2020
TELEGRAFT 2015 
 
 
Trial name or title Explore Transplant at Home: a randomized control trial of an educational intervention to increase
transplant knowledge for Black and White socioeconomically disadvantaged dialysis patients.
Methods open label, parallel assignment, RCT
Participants Dialysis patients who are aged 18-74 years, self-identify as African-American or White, household
income at or below 250% of the federal poverty line, be able to read and speak English
Interventions Standard Care - will not receive any educational materials and will only participate in surveys. dial-
ysis providers will be asked to continue their current practices throughout study period without
change.
Waterman 2015 
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Experimental: Patient-Guided - Over an 8-month period, patients in the Patient-Guided interven-
tion condition will receive four educational modules and twelve transplant education postcards
in the mail. Modules will be mailed once every other month and consist of an introductory letter, a
transplant video, and printed resources. Transplant education postcard will be mailed every two
weeks following the mailing of each module, for a total of three postcards over the course of 6-
weeks.
Experimental: Educator-Guided - Patients in the Educator-Guided intervention condition will re-
ceive the same intervention components as those in the Patient-Guided condition; however, the
key difference in this condition is that Educator-Guided patients will also receive telephonic sup-
port from an experienced clinical social worker in the role of a Transplant Educator to maximally
facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing
of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 min-
utes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an
educational text messaging service designed to supplement the ET education they are receiving in
the mail.
Outcomes Primary outcome: DDKT and LDKT knowledge (9 months)
Secondary outcomes: informed decision making (9 months), decisional balance (9months)
Starting date July 2014
Contact information Dr Amy Waterman
Notes Clinical trials last verified August 2016, study is ongoing but not recruiting patients, estimated com-
pletion august 2016
Waterman 2015  (Continued)
 
 
Trial name or title The WISHED Trial: implementation of an interactive health communication application for patients
with chronic kidney disease
Methods Multi-centre RCT comparing the use of a secured web-based Interactive Health Communication Ap-
plications (IHCA) versus usual care in the promotion of home-based dialysis therapies
Participants recruited through CKD clinics
Interventions Usual care: continue to be seen in CKD clinic
IHCA: usual care + participants will log into website during randomisation visit and provided an ori-
entation of session to familiarise with website. email reminders to log-in are sent periodically and
frequency of visits will be monitored. website provides easy navigation and provides content that
encompasses informational and social support to reduce conflict and uncertainty in ESRD therapy
decision-making. Website includes "Frequently asked questions", demonstration videos and still
photographs of equipment and pre-recorded videos with local experts and existing patients. up-
dated information will continue to be added by variety of content-expert healthcare professionals.
social support component of website will include video and text narratives of patients addressing
benefits and challenges of home dialysis and a moderated forum for patients to discuss issues sur-
rounding home dialysis with current home dialysis patients. Participants will also be able to email
"experts" including nephrologists, nurses and existing patients with questions
Outcomes Outcomes measured at baseline, 6 months, 12 months
Primary outcome: proportion of patients who receive any dialysis using home based therapy (PD or
HHD) within 3 months of dialysis initiation. Those who have not initiated or have had pre-emptive
transplant will be regarded as non-home-based dialysis outcomes.
WISHED 2016 
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Secondary outcomes: proportion of patients intending to perform home-based therapy at 1 year,
dialysis knowledge measured using locally developed tool, decision conflict, level of social support
Starting date March 2012
Contact information Dr Scott Brimble brimbles@mcmaster.ca
Cathy Moreau cmoreau@stjoes.ca
Notes Clinical trials updated April 2016, study recruitment is ongoing, estimated completion date June
2017
WISHED 2016  (Continued)
BP - blood pressure; BUN - blood urea nitrogen; CKD - chronic kidney disease; CMV - cytomegalovirus; CVD - cardiovascular disease; eGFR
- estimated glomerular filtration rate; ER - emergency room; ESKD - end-stage kidney disease; HD - haemodialysis; HRQoL - health-related
quality of life; PD - peritoneal dialysis; PTH - parathyroid hormone; QOL - quality of life; RCT - randomised controlled trial; RRT - renal
replacement therapy
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Death
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death 3 2906 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.53, 1.03]
1.1 Clinical decision-aid 1 2199 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.50, 1.01]
1.2 Behavioural counselling 1 600 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.42, 5.00]
1.3 Self-monitoring and education 1 107 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.11, 2.98]
 
 
Analysis 1.1.   Comparison 1 Death, Outcome 1 Death.
Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Clinical decision-aid  
Cooney 2015 50/1070 74/1129 89.01% 0.71[0.5,1.01]
Subtotal (95% CI) 1070 1129 89.01% 0.71[0.5,1.01]
Total events: 50 (eHealth), 74 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.9(P=0.06)  
   
1.1.2 Behavioural counselling  
Ishani 2016 13/450 3/150 7.03% 1.44[0.42,5]
Subtotal (95% CI) 450 150 7.03% 1.44[0.42,5]
Total events: 13 (eHealth), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Less with eHealth 10000.001 100.1 1 Less with usual care
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Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
1.1.3 Self-monitoring and education  
Navaneethan 2017 2/50 4/57 3.96% 0.57[0.11,2.98]
Subtotal (95% CI) 50 57 3.96% 0.57[0.11,2.98]
Total events: 2 (eHealth), 4 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.51)  
   
Total (95% CI) 1570 1336 100% 0.74[0.53,1.03]
Total events: 65 (eHealth), 81 (Control)  
Heterogeneity: Tau2=0; Chi2=1.25, df=2(P=0.53); I2=0%  
Test for overall effect: Z=1.77(P=0.08)  
Test for subgroup differences: Chi2=1.25, df=1 (P=0.53), I2=0%  
Less with eHealth 10000.001 100.1 1 Less with usual care
 
 
Comparison 2.   Interdialytic weight gains
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Interdialytic weight gain 4 335 Mean Difference (IV, Random, 95%
CI)
-0.13 [-0.27, 0.01]
1.1 Self-monitoring interventions 3 174 Mean Difference (IV, Random, 95%
CI)
-0.20 [-0.46, 0.06]
1.2 Behavioural counselling 1 161 Mean Difference (IV, Random, 95%
CI)
-0.10 [-0.27, 0.07]
 
 
Analysis 2.1.   Comparison 2 Interdialytic weight gains, Outcome 1 Interdialytic weight gain.
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.1.1 Self-monitoring interventions  
Williams 2017 15 2.7 (1.4) 14 2 (2.8) 0.76% 0.7[-0.93,2.33]
Schulz 2007 43 2.3 (0.9) 58 2.6 (1.3) 11.12% -0.27[-0.7,0.16]
Welch 2013 24 0.8 (0.5) 20 1 (0.6) 18.33% -0.19[-0.52,0.14]
Subtotal *** 82   92   30.22% -0.2[-0.46,0.06]
Heterogeneity: Tau2=0; Chi2=1.28, df=2(P=0.53); I2=0%  
Test for overall effect: Z=1.49(P=0.14)  
   
2.1.2 Behavioural counselling  
BalanceWise-HD 2013 81 1.1 (0.6) 80 1.2 (0.5) 69.78% -0.1[-0.27,0.07]
Subtotal *** 81   80   69.78% -0.1[-0.27,0.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.15(P=0.25)  
Better with eHealth 42-4 -2 0 Better with control
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Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
Total *** 163   172   100% -0.13[-0.27,0.01]
Heterogeneity: Tau2=0; Chi2=1.65, df=3(P=0.65); I2=0%  
Test for overall effect: Z=1.78(P=0.08)  
Test for subgroup differences: Chi2=0.37, df=1 (P=0.54), I2=0%  
Better with eHealth 42-4 -2 0 Better with control
 
 
Comparison 3.   Dietary sodium
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Dietary sodium intake 2 181 Mean Difference (IV, Random, 95%
CI)
-196.97 [-540.76, 146.83]
1.1 Behavioural counselling 1 162 Mean Difference (IV, Random, 95%
CI)
-191.0 [-563.72, 181.72]
1.2 Self-monitoring 1 19 Mean Difference (IV, Random, 95%
CI)
-231.0 [-1121.08, 659.08]
 
 
Analysis 3.1.   Comparison 3 Dietary sodium, Outcome 1 Dietary sodium intake.
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.1.1 Behavioural counselling  
BalanceWise-HD 2013 82 -49.8 (1212) 80 141.2
(1208.3)
85.08% -191[-563.72,181.72]
Subtotal *** 82   80   85.08% -191[-563.72,181.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
   
3.1.2 Self-monitoring  
Koprucki 2010 10 -187 (662) 9 44 (1209) 14.92% -231[-1121.08,659.08]
Subtotal *** 10   9   14.92% -231[-1121.08,659.08]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.51(P=0.61)  
   
Total *** 92   89   100% -196.97[-540.76,146.83]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=1.12(P=0.26)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.94), I2=0%  
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Comparison 4.   Quality of Life (physical)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 General health perception 3   Std. Mean Difference (IV, Random,
95% CI)
Subtotals only
1.1 Educational intervention 1 90 Std. Mean Difference (IV, Random,
95% CI)
-0.42 [-0.83, 0.00]
1.2 Behavioural counselling 2 507 Std. Mean Difference (IV, Random,
95% CI)
0.04 [-0.14, 0.21]
2 Physical functioning 2   Mean Difference (IV, Random, 95%
CI)
Totals not selected
2.1 Educational intervention 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
2.2 Behavioural counselling 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
3 Role-physical 2   Mean Difference (IV, Random, 95%
CI)
Totals not selected
3.1 Educational intervention 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
3.2 Behavioural counselling 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
4 Pain 4   Std. Mean Difference (IV, Random,
95% CI)
Subtotals only
4.1 Educational intervention 1 90 Std. Mean Difference (IV, Random,
95% CI)
0.07 [-0.34, 0.49]
4.2 Behavioural counselling 3 191 Std. Mean Difference (IV, Random,
95% CI)
0.18 [-0.42, 0.77]
5 Physical Component Score (PCS) 2   Mean Difference (IV, Random, 95%
CI)
Totals not selected
5.1 Behavioural counselling 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
5.2 Clinical decision-aid 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
6 Burden (KDQoL) 2   Mean Difference (IV, Random, 95%
CI)
Totals not selected
6.1 Behavioural counselling 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
6.2 Clinical decision-aid 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
7 Effects (KDQoL) 2   Mean Difference (IV, Random, 95%
CI)
Totals not selected
7.1 Behavioural counselling 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
7.2 Clinical decision-aid 1   Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 Quality of Life (physical), Outcome 1 General health perception.
Study or subgroup eHealth Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.1.1 Educational intervention  
Baraz 2014 45 41 (16.9) 45 48.4 (18.2) 100% -0.42[-0.83,0]
Subtotal *** 45   45   100% -0.42[-0.83,0]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.95(P=0.05)  
   
4.1.2 Behavioural counselling  
Li 2014b 69 38.2 (17.5) 66 35.7 (17.7) 26.6% 0.14[-0.2,0.48]
BRIGHT 2013 179 2.8 (1) 193 2.8 (0.9) 73.4% 0[-0.2,0.2]
Subtotal *** 248   259   100% 0.04[-0.14,0.21]
Heterogeneity: Tau2=0; Chi2=0.49, df=1(P=0.48); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
Test for subgroup differences: Chi2=3.87, df=1 (P=0.05), I2=74.14%  
Better with control 10.5-1 -0.5 0 Better with eHealth
 
 
Analysis 4.2.   Comparison 4 Quality of Life (physical), Outcome 2 Physical functioning.
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
4.2.1 Educational intervention  
Baraz 2014 45 70.2 (13.4) 45 68.6 (22.8) 1.52[-6.21,9.25]
   
4.2.2 Behavioural counselling  
Li 2014b 69 53.9 (12.9) 66 51.5 (12.5) 2.4[-1.88,6.68]
Better with control 105-10 -5 0 Better with eHealth
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Analysis 4.3.   Comparison 4 Quality of Life (physical), Outcome 3 Role-physical.
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
4.3.1 Educational intervention  
Baraz 2014 45 50.5 (18.9) 45 60.5 (22.1) -9.97[-18.48,-1.46]
   
4.3.2 Behavioural counselling  
Li 2014b 69 20.8 (16.9) 66 20.4 (15.1) 0.4[-5,5.8]
Better with control 2010-20 -10 0 Better with eHealth
 
 
Analysis 4.4.   Comparison 4 Quality of Life (physical), Outcome 4 Pain.
Study or subgroup eHealth Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
4.4.1 Educational intervention  
Baraz 2014 45 55.5 (29.1) 45 53.2 (32.3) 100% 0.07[-0.34,0.49]
Subtotal *** 45   45   100% 0.07[-0.34,0.49]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.73)  
   
4.4.2 Behavioural counselling  
iDiD 2016 13 -1.6 (0.8) 5 -2.6 (1.3) 19.3% 1[-0.09,2.1]
Reilly-Spong 2015 18 39.9 (13.9) 20 44.7 (10.4) 33.69% -0.39[-1.03,0.26]
Li 2014b 69 64.2 (18.2) 66 59.7 (18.9) 47.01% 0.24[-0.1,0.58]
Subtotal *** 100   91   100% 0.18[-0.42,0.77]
Heterogeneity: Tau2=0.17; Chi2=5.25, df=2(P=0.07); I2=61.94%  
Test for overall effect: Z=0.58(P=0.56)  
Better with control 42-4 -2 0 Better with eHealth
 
 
Analysis 4.5.   Comparison 4 Quality of Life (physical), Outcome 5 Physical Component Score (PCS).
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
4.5.1 Behavioural counselling  
Reilly-Spong 2015 17 33.2 (9.8) 19 38.5 (10.4) -5.3[-11.9,1.3]
   
4.5.2 Clinical decision-aid  
Cooney 2015 1070 39.3 (9.8) 1129 36.8 (10.3) 2.5[1.66,3.34]
Better with control 2010-20 -10 0 Better with eHealth
 
 
Analysis 4.6.   Comparison 4 Quality of Life (physical), Outcome 6 Burden (KDQoL).
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
4.6.1 Behavioural counselling  
Li 2014b 69 21.5 (11.7) 66 21.1 (12.2) 0.4[-3.64,4.44]
Better with control 105-10 -5 0 Better with eHealth
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Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
   
4.6.2 Clinical decision-aid  
Cooney 2015 1070 89.7 (20.5) 1129 89.4 (19.6) 0.3[-1.38,1.98]
Better with control 105-10 -5 0 Better with eHealth
 
 
Analysis 4.7.   Comparison 4 Quality of Life (physical), Outcome 7 E9ects (KDQoL).
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
4.7.1 Behavioural counselling  
Li 2014b 69 63.2 (14.2) 66 62.1 (14.3) 1.1[-3.71,5.91]
   
4.7.2 Clinical decision-aid  
Cooney 2015 1070 94.2 (11.9) 1129 94.4 (14) -0.2[-1.28,0.88]
Better with control 105-10 -5 0 Better with eHealth
 
 
Comparison 5.   Quality of Life (mental)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Mental Health (SF-36) 3   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Educational 1 90 Mean Difference (IV, Random, 95% CI) -5.23 [-15.07, 4.61]
1.2 Behavioural counselling 2 507 Mean Difference (IV, Random, 95% CI) 1.06 [-2.24, 4.35]
2 Social functioning (SF-36) 3   Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Educational 1 90 Mean Difference (IV, Random, 95% CI) 3.68 [-4.45, 11.81]
2.2 Behavioural counselling 2 506 Mean Difference (IV, Random, 95% CI) 1.94 [-3.35, 7.22]
3 Fatigue 4   Std. Mean Difference (IV, Random, 95%
CI)
Subtotals only
3.1 Educational 1 90 Std. Mean Difference (IV, Random, 95%
CI)
-0.40 [-0.81, 0.02]
3.2 Behavioural counselling 3 546 Std. Mean Difference (IV, Random, 95%
CI)
0.11 [-0.05, 0.28]
4 Anxiety 4   Std. Mean Difference (IV, Random, 95%
CI)
Totals not selected
4.1 Behavioural counselling 4   Std. Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5 Depression 3   Std. Mean Difference (IV, Random, 95%
CI)
Totals not selected
5.1 Behavioural counselling 3   Std. Mean Difference (IV, Random, 95%
CI)
0.0 [0.0, 0.0]
6 Sleep 2   Std. Mean Difference (IV, Random, 95%
CI)
Subtotals only
6.1 Behavioural counselling 2 186 Std. Mean Difference (IV, Random, 95%
CI)
0.07 [-0.55, 0.69]
7 Role-emotional 2   Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 Education 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Behavioural counselling 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Mental Component Score (MCS) 2   Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 Behavioural counselling 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Clinical decision-aid 1   Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 5.1.   Comparison 5 Quality of Life (mental), Outcome 1 Mental Health (SF-36).
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.1.1 Educational  
Baraz 2014 45 49.8 (18.8) 45 55.1 (27.9) 100% -5.23[-15.07,4.61]
Subtotal *** 45   45   100% -5.23[-15.07,4.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
5.1.2 Behavioural counselling  
Li 2014b 69 65.4 (17.2) 66 63.5 (18.6) 29.7% 1.9[-4.15,7.95]
BRIGHT 2013 179 74.7 (18.8) 193 74 (19.9) 70.3% 0.7[-3.23,4.63]
Subtotal *** 248   259   100% 1.06[-2.24,4.35]
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=0.63(P=0.53)  
Better with control 2010-20 -10 0 Better with eHealth
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Analysis 5.2.   Comparison 5 Quality of Life (mental), Outcome 2 Social functioning (SF-36).
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.2.1 Educational  
Baraz 2014 45 67.7 (20.1) 45 64.1 (19.2) 100% 3.68[-4.45,11.81]
Subtotal *** 45   45   100% 3.68[-4.45,11.81]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.89(P=0.37)  
   
5.2.2 Behavioural counselling  
Li 2014b 69 42.5 (19.3) 66 43.4 (18.8) 47.49% -0.9[-7.33,5.53]
BRIGHT 2013 177 73.2 (28.2) 194 68.7 (30.5) 52.51% 4.5[-1.47,10.47]
Subtotal *** 246   260   100% 1.94[-3.35,7.22]
Heterogeneity: Tau2=4.56; Chi2=1.45, df=1(P=0.23); I2=31.27%  
Test for overall effect: Z=0.72(P=0.47)  
Better with control 2010-20 -10 0 Better with eHealth
 
 
Analysis 5.3.   Comparison 5 Quality of Life (mental), Outcome 3 Fatigue.
Study or subgroup eHealth Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.3.1 Educational  
Baraz 2014 45 48.9 (15) 45 56.1 (20.6) 100% -0.4[-0.81,0.02]
Subtotal *** 45   45   100% -0.4[-0.81,0.02]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.86(P=0.06)  
   
5.3.2 Behavioural counselling  
Reilly-Spong 2015 18 -57 (6.3) 20 -56.6 (8.4) 6.97% -0.05[-0.69,0.58]
Li 2014b 69 48.4 (17.7) 66 43.3 (18.9) 24.58% 0.28[-0.06,0.62]
BRIGHT 2013 179 52.4 (22) 194 50.8 (21.8) 68.45% 0.07[-0.13,0.28]
Subtotal *** 266   280   100% 0.11[-0.05,0.28]
Heterogeneity: Tau2=0; Chi2=1.31, df=2(P=0.52); I2=0%  
Test for overall effect: Z=1.33(P=0.18)  
Better with control 10.5-1 -0.5 0 Better with eHealth
 
 
Analysis 5.4.   Comparison 5 Quality of Life (mental), Outcome 4 Anxiety.
Study or subgroup eHealth Control Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
5.4.1 Behavioural counselling  
BRIGHT 2013 179 4.6 (3.7) 194 5.2 (4.1) -0.15[-0.36,0.05]
Reilly-Spong 2015 20 41.2 (15.3) 22 38.1 (11.6) 0.23[-0.38,0.83]
Kargar Jahromi 2016 27 8.7 (0.9) 27 16.7 (2) -5.15[-6.29,-4.01]
iDiD 2016 16 4.4 (4.1) 7 3.9 (3.6) 0.12[-0.77,1.01]
Better with eHealth 105-10 -5 0 Better with usual care
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Analysis 5.5.   Comparison 5 Quality of Life (mental), Outcome 5 Depression.
Study or subgroup eHealth Control Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
5.5.1 Behavioural counselling  
Kargar Jahromi 2016 27 9 (1.2) 27 16.2 (1.6) -5.09[-6.22,-3.96]
iDiD 2016 16 7.5 (5.4) 7 7.6 (4.7) -0.02[-0.91,0.87]
Reilly-Spong 2015 24 14.7 (9.4) 27 9.1 (5.8) 0.72[0.15,1.28]
Better with eHealth 105-10 -5 0 Better with usual care
 
 
Analysis 5.6.   Comparison 5 Quality of Life (mental), Outcome 6 Sleep.
Study or subgroup eHealth Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
5.6.1 Behavioural counselling  
Reilly-Spong 2015 24 -7.3 (4.7) 27 -6.1 (3.4) 43.94% -0.29[-0.84,0.26]
Li 2014b 69 61.1 (20.6) 66 54.3 (18.1) 56.06% 0.35[0.01,0.69]
Subtotal *** 93   93   100% 0.07[-0.55,0.69]
Heterogeneity: Tau2=0.15; Chi2=3.72, df=1(P=0.05); I2=73.14%  
Test for overall effect: Z=0.21(P=0.83)  
Better with control 21-2 -1 0 Better with eHealth
 
 
Analysis 5.7.   Comparison 5 Quality of Life (mental), Outcome 7 Role-emotional.
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
5.7.1 Education  
Baraz 2014 45 50.5 (21.9) 45 44.8 (19.7) 5.77[-2.84,14.38]
   
5.7.2 Behavioural counselling  
Li 2014b 69 56.3 (14.8) 66 56.6 (16.5) -0.3[-5.6,5]
Better with control 2010-20 -10 0 Better with eHealth
 
 
Analysis 5.8.   Comparison 5 Quality of Life (mental), Outcome 8 Mental Component Score (MCS).
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
5.8.1 Behavioural counselling  
Reilly-Spong 2015 17 49.7 (10) 19 46.7 (9.8) 3[-3.48,9.48]
   
5.8.2 Clinical decision-aid  
Cooney 2015 1070 52 (10.6) 1129 52.1 (9.6) -0.1[-0.95,0.75]
Better with control 105-10 -5 0 Better with eHealth
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Comparison 6.   Medication adherence
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Medication adherence (dichoto-
mous)
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Reminders 1 360 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.21, 1.65]
1.2 Behavioral counselling 2 776 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.86, 2.24]
1.3 Clinical decision aid 1 91 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.45, 1.15]
1.4 Education plus reminders 1 360 Risk Ratio (M-H, Random, 95% CI) 1.60 [1.38, 1.84]
2 Medication adherence (continuous) 6   Std. Mean Difference (IV, Random,
95% CI)
Subtotals only
2.1 Behavioural counselling 3 248 Std. Mean Difference (IV, Random,
95% CI)
0.03 [-0.51, 0.57]
2.2 Self-monitoring intervention 1 43 Std. Mean Difference (IV, Random,
95% CI)
-0.15 [-0.78, 0.47]
2.3 Reminders 1 19 Std. Mean Difference (IV, Random,
95% CI)
3.22 [1.76, 4.68]
2.4 Clinical decision aid 1 2199 Std. Mean Difference (IV, Random,
95% CI)
-0.08 [-0.17, 0.00]
 
 
Analysis 6.1.   Comparison 6 Medication adherence, Outcome 1 Medication adherence (dichotomous).
Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 Reminders  
Reese 2017 140/180 99/180 100% 1.41[1.21,1.65]
Subtotal (95% CI) 180 180 100% 1.41[1.21,1.65]
Total events: 140 (eHealth), 99 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.42(P<0.0001)  
   
6.1.2 Behavioral counselling  
Schmid 2016 19/23 10/23 37.58% 1.9[1.15,3.14]
TAKE-IT 2014 285/365 248/365 62.42% 1.15[1.05,1.26]
Subtotal (95% CI) 388 388 100% 1.39[0.86,2.24]
Total events: 304 (eHealth), 258 (Control)  
Heterogeneity: Tau2=0.09; Chi2=3.78, df=1(P=0.05); I2=73.54%  
Test for overall effect: Z=1.34(P=0.18)  
   
6.1.3 Clinical decision aid  
Hardstaff 2002 26/67 13/24 100% 0.72[0.45,1.15]
Better with control 100.1 50.2 20.5 1 Better with eHealth
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Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 67 24 100% 0.72[0.45,1.15]
Total events: 26 (eHealth), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.38(P=0.17)  
   
6.1.4 Education plus reminders  
Reese 2017 158/180 99/180 100% 1.6[1.38,1.84]
Subtotal (95% CI) 180 180 100% 1.6[1.38,1.84]
Total events: 158 (eHealth), 99 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=6.41(P<0.0001)  
Better with control 100.1 50.2 20.5 1 Better with eHealth
 
 
Analysis 6.2.   Comparison 6 Medication adherence, Outcome 2 Medication adherence (continuous).
Study or subgroup eHealth Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.2.1 Behavioural counselling  
Russell 2011 8 0.9 (0.1) 5 0.8 (0.1) 13.72% 1.27[0.01,2.53]
MESMI 2010 36 58.4 (24.3) 39 66.6 (22.2) 39.59% -0.35[-0.81,0.11]
TAKE-IT 2014 72 1.6 (2.3) 88 1.6 (2.5) 46.69% -0.01[-0.32,0.3]
Subtotal *** 116   132   100% 0.03[-0.51,0.57]
Heterogeneity: Tau2=0.14; Chi2=5.93, df=2(P=0.05); I2=66.3%  
Test for overall effect: Z=0.12(P=0.91)  
   
6.2.2 Self-monitoring intervention  
Rifkin 2013 28 7 (1.2) 15 7.2 (1.4) 100% -0.15[-0.78,0.47]
Subtotal *** 28   15   100% -0.15[-0.78,0.47]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
   
6.2.3 Reminders  
McGillicuddy 2013 9 0.9 (0.1) 10 0.6 (0.1) 100% 3.22[1.76,4.68]
Subtotal *** 9   10   100% 3.22[1.76,4.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.32(P<0.0001)  
   
6.2.4 Clinical decision aid  
Cooney 2015 1070 6.7 (1.2) 1129 6.8 (1.2) 100% -0.08[-0.17,0]
Subtotal *** 1070   1129   100% -0.08[-0.17,0]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.95(P=0.05)  
Better with control 105-10 -5 0 Better with eHealth
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Comparison 7.   Change in serum creatinine
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Change in serum creatinine 3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
1.1 Self-monitoring interventions 2 75 Mean Difference (IV, Random, 95%
CI)
-0.14 [-0.65, 0.37]
1.2 Behavioural counselling 1 75 Mean Difference (IV, Random, 95%
CI)
-2.0 [-7.29, 3.29]
 
 
Analysis 7.1.   Comparison 7 Change in serum creatinine, Outcome 1 Change in serum creatinine.
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
7.1.1 Self-monitoring interventions  
Kullgren 2015 16 16.8 (21.2) 16 11 (15.2) 0.16% 5.8[-6.98,18.58]
Rifkin 2013 28 2.2 (0.8) 15 2.3 (0.8) 99.84% -0.15[-0.66,0.36]
Subtotal *** 44   31   100% -0.14[-0.65,0.37]
Heterogeneity: Tau2=0; Chi2=0.83, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
   
7.1.2 Behavioural counselling  
MESMI 2010 36 128 (6.4) 39 130 (15.5) 100% -2[-7.29,3.29]
Subtotal *** 36   39   100% -2[-7.29,3.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
Better with eHealth 2010-20 -10 0 Better with usual care
 
 
Comparison 8.   Knowledge
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Change in knowledge (continuous) 5   Std. Mean Difference (IV, Random, 95%
CI)
Subtotals only
1.1 Education interventions 1 288 Std. Mean Difference (IV, Random, 95%
CI)
0.59 [0.35, 0.82]
1.2 Education plus reminders 2 271 Std. Mean Difference (IV, Random, 95%
CI)
1.35 [1.08, 1.61]
1.3 Behavioural counselling 1 366 Std. Mean Difference (IV, Random, 95%
CI)
0.0 [-0.21, 0.21]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.4 Clinical decision aid 1 443 Std. Mean Difference (IV, Random, 95%
CI)
0.33 [0.15, 0.52]
 
 
Analysis 8.1.   Comparison 8 Knowledge, Outcome 1 Change in knowledge (continuous).
Study or subgroup eHealth Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
8.1.1 Education interventions  
InformMe 2017 133 17.9 (6.1) 155 14.7 (5) 100% 0.59[0.35,0.82]
Subtotal *** 133   155   100% 0.59[0.35,0.82]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.85(P<0.0001)  
   
8.1.2 Education plus reminders  
Robinson 2014a 50 9 (6.8) 51 0 (6.8) 37.45% 1.32[0.89,1.76]
Robinson 2015 84 6.7 (2.6) 86 3.7 (1.7) 62.55% 1.36[1.03,1.7]
Subtotal *** 134   137   100% 1.35[1.08,1.61]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=9.98(P<0.0001)  
   
8.1.3 Behavioural counselling  
BRIGHT 2013 175 2.6 (0.6) 191 2.6 (0.6) 100% 0[-0.21,0.21]
Subtotal *** 175   191   100% 0[-0.21,0.21]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
8.1.4 Clinical decision aid  
iChoose 2016 226 6.1 (1.9) 217 5.5 (1.9) 100% 0.33[0.15,0.52]
Subtotal *** 226   217   100% 0.33[0.15,0.52]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.48(P=0)  
Test for subgroup differences: Chi2=65.41, df=1 (P<0.0001), I2=95.41%  
Improves with control 21-2 -1 0 Improves with eHealth
 
 
Comparison 9.   Hospitalisation rate
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Hospitalisation rate (dichotomous) 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Behavioural counselling 2 735 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.65, 1.58]
1.2 Clinical decision aid 1 730 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.29]
1.3 Reminders 1 106 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.48, 1.05]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2 Hospitalisations (continuous) 3   Mean Difference (IV, Fixed, 95%
CI)
Totals not selected
2.1 Self-monitoring interventions 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
2.2 Education 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
2.3 Behavioural counselling 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
 
 
Analysis 9.1.   Comparison 9 Hospitalisation rate, Outcome 1 Hospitalisation rate (dichotomous).
Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
9.1.1 Behavioural counselling  
Li 2014b 5/69 8/66 15.35% 0.6[0.21,1.73]
Ishani 2016 134/450 40/150 84.65% 1.12[0.83,1.51]
Subtotal (95% CI) 519 216 100% 1.01[0.65,1.58]
Total events: 139 (eHealth), 48 (Control)  
Heterogeneity: Tau2=0.04; Chi2=1.23, df=1(P=0.27); I2=18.68%  
Test for overall effect: Z=0.06(P=0.95)  
   
9.1.2 Clinical decision aid  
Durand 2000 14/365 21/365 100% 0.67[0.34,1.29]
Subtotal (95% CI) 365 365 100% 0.67[0.34,1.29]
Total events: 14 (eHealth), 21 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.2(P=0.23)  
   
9.1.3 Reminders  
Henriksson 2016 22/53 31/53 100% 0.71[0.48,1.05]
Subtotal (95% CI) 53 53 100% 0.71[0.48,1.05]
Total events: 22 (eHealth), 31 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.72(P=0.09)  
Less with eHealth 100.1 50.2 20.5 1 Less with control
 
 
Analysis 9.2.   Comparison 9 Hospitalisation rate, Outcome 2 Hospitalisations (continuous).
Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
9.2.1 Self-monitoring interventions  
Schulz 2007 43 2.2 (5.5) 58 3.3 (7.3) -1.11[-3.61,1.39]
   
Lower with eHealth 105-10 -5 0 Lower with control
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Study or subgroup eHealth Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
9.2.2 Education  
Navaneethan 2017 50 4.1 (14.1) 57 2.3 (9.1) 1.77[-2.8,6.34]
   
9.2.3 Behavioural counselling  
Schmid 2016 23 0 (0.7) 23 2 (1.5) -2[-2.68,-1.32]
Lower with eHealth 105-10 -5 0 Lower with control
 
 
Comparison 10.   Behavioural outcomes
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Self-care behaviours 3   Std. Mean Difference (IV, Random,
95% CI)
Totals not selected
1.1 Behavioural counselling 1   Std. Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
1.2 Education plus reminders 2   Std. Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
2 Attitudes towards performing a behav-
iour
3   Std. Mean Difference (IV, Random,
95% CI)
Totals not selected
2.1 Education plus reminders 2   Std. Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
2.2 Self-monitoring intervention 1   Std. Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
3 Willingness to perform behaviour 3   Std. Mean Difference (IV, Random,
95% CI)
Totals not selected
3.1 Educational intervention 1   Std. Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
3.2 Education plus reminders 2   Std. Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
 
 
Analysis 10.1.   Comparison 10 Behavioural outcomes, Outcome 1 Self-care behaviours.
Study or subgroup eHealth Control Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
10.1.1 Behavioural counselling  
BRIGHT 2013 172 4.5 (1.2) 191 4.2 (1.2) 0.25[0.04,0.46]
   
10.1.2 Education plus reminders  
Improves with control 42-4 -2 0 Improves with eHealth
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Study or subgroup eHealth Control Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Robinson 2015 84 57.7 (13.1) 86 31.1 (4.9) 2.7[2.28,3.11]
Robinson 2014a 50 12.5 (19.6) 51 2.5 (17.5) 0.53[0.14,0.93]
Improves with control 42-4 -2 0 Improves with eHealth
 
 
Analysis 10.2.   Comparison 10 Behavioural outcomes, Outcome 2 Attitudes towards performing a behaviour.
Study or subgroup eHealth Control Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
10.2.1 Education plus reminders  
Robinson 2014a 50 7 (12) 51 0 (8.5) 0.67[0.27,1.07]
Robinson 2015 84 6.6 (3.9) 86 1.1 (0.7) 1.99[1.62,2.36]
   
10.2.2 Self-monitoring intervention  
Welch 2013 16 39.8 (4.5) 17 40.1 (4.9) -0.06[-0.75,0.62]
Improves with control 42-4 -2 0 Improves with eHealth
 
 
Analysis 10.3.   Comparison 10 Behavioural outcomes, Outcome 3 Willingness to perform behaviour.
Study or subgroup eHealth Control Std. Mean Difference Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
10.3.1 Educational intervention  
InformMe 2017 133 2.5 (1.5) 155 2.8 (1.2) -0.2[-0.44,0.03]
   
10.3.2 Education plus reminders  
Robinson 2014a 50 -8 (25) 51 0 (34.5) -0.26[-0.65,0.13]
Robinson 2015 84 -74.6 (21.4) 86 -22.6 (1.7) -3.43[-3.91,-2.96]
Improves with eHealth 42-4 -2 0 Improves with control
 
 
Comparison 11.   Blood pressure
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Systolic blood pressure 5   Mean Difference (IV, Random,
95% CI)
Subtotals only
1.1 Self-monitoring intervention 2 144 Mean Difference (IV, Random,
95% CI)
-2.68 [-8.34, 2.99]
1.2 Behavioural counselling 1 75 Mean Difference (IV, Random,
95% CI)
-3.90 [-12.40, 4.60]
1.3 Reminder systems 1 17 Mean Difference (IV, Random,
95% CI)
-24.20 [-36.41, -11.99]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.4 Clinical decision aids 1 947 Mean Difference (IV, Random,
95% CI)
0.70 [-1.53, 2.93]
2 Diastolic blood pressure 3   Mean Difference (IV, Random,
95% CI)
Subtotals only
2.1 Self-monitoring intervention 2 144 Mean Difference (IV, Random,
95% CI)
1.56 [-1.56, 4.69]
2.2 Behavioural counselling 1 75 Mean Difference (IV, Random,
95% CI)
0.85 [-3.07, 4.77]
3 BP within guideline recommendations 5   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Behavioural counselling 2 577 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.03, 1.37]
3.2 Clinical decision-aid 1 870 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.87, 1.19]
3.3 Reminder systems 1 17 Risk Ratio (M-H, Random, 95% CI) 4.5 [0.63, 32.38]
3.4 Education 1 107 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.86, 1.09]
 
 
Analysis 11.1.   Comparison 11 Blood pressure, Outcome 1 Systolic blood pressure.
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
11.1.1 Self-monitoring intervention  
Rifkin 2013 28 136 (15.6) 15 140 (14.4) 37.09% -4[-13.3,5.3]
Schulz 2007 43 116 (17) 58 117.9 (19.5) 62.91% -1.9[-9.04,5.24]
Subtotal *** 71   73   100% -2.68[-8.34,2.99]
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=0.93(P=0.35)  
   
11.1.2 Behavioural counselling  
MESMI 2010 36 -6.9 (20.5) 39 -3 (16.7) 100% -3.9[-12.4,4.6]
Subtotal *** 36   39   100% -3.9[-12.4,4.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.9(P=0.37)  
   
11.1.3 Reminder systems  
McGillicuddy 2013 8 131.1 (10.5) 9 155.3 (15) 100% -24.2[-36.41,-11.99]
Subtotal *** 8   9   100% -24.2[-36.41,-11.99]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=3.89(P=0)  
   
11.1.4 Clinical decision aids  
Cooney 2015 474 135.1 (17.4) 473 134.4 (17.6) 100% 0.7[-1.53,2.93]
Subtotal *** 474   473   100% 0.7[-1.53,2.93]
Lower with eHealth 5025-50 -25 0 Lower with control
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Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.62(P=0.54)  
Lower with eHealth 5025-50 -25 0 Lower with control
 
 
Analysis 11.2.   Comparison 11 Blood pressure, Outcome 2 Diastolic blood pressure.
Study or subgroup eHealth Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
11.2.1 Self-monitoring intervention  
Rifkin 2013 28 73 (10.3) 15 73 (12.6) 17.72% 0[-7.43,7.43]
Schulz 2007 43 66.9 (8.7) 58 65 (8.8) 82.28% 1.9[-1.55,5.35]
Subtotal *** 71   73   100% 1.56[-1.56,4.69]
Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.98(P=0.33)  
   
11.2.2 Behavioural counselling  
MESMI 2010 36 -2.2 (8.7) 39 -3.1 (8.6) 100% 0.85[-3.07,4.77]
Subtotal *** 36   39   100% 0.85[-3.07,4.77]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
Lower with eHealth 105-10 -5 0 Lower with control
 
 
Analysis 11.3.   Comparison 11 Blood pressure, Outcome 3 BP within guideline recommendations.
Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.3.1 Behavioural counselling  
Ishani 2016 72/135 20/39 17.12% 1.04[0.74,1.47]
BRIGHT 2013 130/193 116/210 82.88% 1.22[1.04,1.43]
Subtotal (95% CI) 328 249 100% 1.19[1.03,1.37]
Total events: 202 (eHealth), 136 (Control)  
Heterogeneity: Tau2=0; Chi2=0.69, df=1(P=0.41); I2=0%  
Test for overall effect: Z=2.36(P=0.02)  
   
11.3.2 Clinical decision-aid  
Cooney 2015 185/441 177/429 100% 1.02[0.87,1.19]
Subtotal (95% CI) 441 429 100% 1.02[0.87,1.19]
Total events: 185 (eHealth), 177 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.84)  
   
11.3.3 Reminder systems  
McGillicuddy 2013 4/8 1/9 100% 4.5[0.63,32.38]
Subtotal (95% CI) 8 9 100% 4.5[0.63,32.38]
Total events: 4 (eHealth), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.49(P=0.14)  
Better with control 500.02 100.1 1 Better with eHealth
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Study or subgroup eHealth Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
11.3.4 Education  
Navaneethan 2017 45/50 53/57 100% 0.97[0.86,1.09]
Subtotal (95% CI) 50 57 100% 0.97[0.86,1.09]
Total events: 45 (eHealth), 53 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
Better with control 500.02 100.1 1 Better with eHealth
 
 
A D D I T I O N A L   T A B L E S
 
Total studies (participants) 43 (6617)
  No. studies % studies
Country
Australia 1 2%
North America 26 60%
UK 5 12%
Europe 6 14%
Middle East 3 7%
Asia 2 5%
Number of participants
0-50 17 40%
51-100 10 23%
101-200 10 23%
201-300 3 7%
300+ 3 7%
Length of intervention
≤ 1 week 4 9%
1-3 months 16 37%
4-6 months 9 21%
> 6 months 13 30%
Table 1.   Overview of characteristics of included studies 
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unclear 1 2%
Participant age
Paediatric (including carers) 4 (9%
Adult (≥ 18 years) 39 (91%
Stage of CKD
CKD stage 1-5 11 26%
Haemodialysis 10 23%
Peritoneal dialysis 6 14%
Transplant candidates 1 2%
Transplant recipient 15 35%
eHealth modality
Telehealth 10 23%
Mobile or tablet app 11 26%
Mobile phone text message 2 5%
Electronic monitoring 11 26%
Internet website 4 9%
Video or DVD 2 5%
Mixed methods 3 7%
eHealth intervention category
Education 4 9%
Reminders 5 12%
Self-monitoring 9 21%
Behavioural counselling 16 37%
Clinical decision-aid
Mixed interventions
Unclear
4
4
1
9%
9%
2%
Publication type
Abstract or short report 10 23%
Journal article 33 77%
Table 1.   Overview of characteristics of included studies  (Continued)
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Outcome
Study ID
Outcome measure Study population (No.
of participants);
study duration
Results
Behavioural
Knowledge
InformMe 2017
31-item multiple choice test Adults, kidney trans-
plant candidates (28); 1
week
Intervention: mean 17.94 (SD 6.06)
Control: mean 14.7 (SD 5)
P = 0.001
Willingness to per-
form a behaviour
InformMe 2017
Willingness to accept an In-
creased Risk Donor Kidney
Lower scores indicate more
willingness
Adults, kidney trans-
plant candidates (188);
1 week
Intervention: mean 2.54 (SD 1.45)
Control: mean 2.81 (SD 1.2)
P = 0.09
Quality of Life
Fatigue
Baraz 2014
SF-36
Higher scores indicate better
QoL
Adults, HD (90); 6
months
Intervention: mean 48.9 (SD 15)
Control: mean 56.1 (SD 20.6)
P = 0.034
General health
perception
Baraz 2014
SF-36
Higher scores indicate better
QoL
Adults, HD (90); 6
months
Intervention: mean 41.01 (SD 16.87)
Control: mean 48.38 (SD 18.18)
P = 0.94
Mental health
Baraz 2014
SF-36
Higher scores indicate better
QoL
Adults, HD; (90); 6
months
Intervention: mean 49.84 (SD 18.84)
Control: mean 55.07 (SD 27.9)
P < 0.001
Pain
Baraz 2014
SF-36
Higher scores indicate higher
QoL
Adults, HD (90); 6
months
Intervention: mean 55.45 (SD 29.14),
Control: mean 53.22 (SD 32.34)
P = NS
Physical function-
ing
Baraz 2014
SF-36
Higher scores indicate better
QoL
Adults, HD (90); 6
months
Intervention: mean 70.15 (SD 13.4)
Control: mean 68.63 (SD 22.82)
P = 0.021
Role (emotional)
Baraz 2014
SF-36
Higher scores indicate better
QoL
Adults, HD (90); 6
months
Intervention: mean 50.53 (SD 21.92)
Control: mean 44.76 (SD 19.7)
P = 0.26
Role (physical)
Baraz 2014
SF-36 Adults, HD (90); 6
months
Intervention: mean 50.51 (SD 18.9)
Control: mean 60.48 (SD 22.14)
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Higher scores indicate better
QoL
P = 0.031
Social functioning
Baraz 2014
SF-36
Higher scores indicate better
QoL
Adults, HD (90); 6
months
Intervention: mean 67.74 (SD 20.09)
Control: mean 64.06 (SD 19.24)
P < 0.001
Table 2.   Descriptive analyses of reported outcomes for educational interventions  (Continued)
CI - confidence interval; HD - haemodialysis; QoL - quality of life; RR - risk ratio; SD - standard deviation
 
 
Outcome
Study ID
Outcome measure Study population (No. of partici-
pants);
study duration
Results
Biochemical parameters
Phosphate
Jammalamadaka 2015
Serum phosphate Adults, HD (27); 7 days Intervention: mean 6.00 (SD 1.2)
Control: mean 6.19 (SD 0.76)
P = 0.76
Blood pressure
Blood pressure within
guideline recommenda-
tions
McGillicuddy 2013
Blood pressure within
pre-specified goals
Adults, kidney transplant recipi-
ents (17); 3 months
RR 4.50 (95% CI 0.63, 32.38)
P = 0.13
Systolic blood pressure
McGillicuddy 2013
Higher readings indi-
cate poorer control
Adults, kidney transplant recipi-
ents (17); 3 months
Intervention: mean 131 (SD 10.5)
Control: 155.3 (SD 15)
P = 0.004
Clinical end-points
Hospitalisations
Henriksson 2016
Unplanned admission
rates to hospital or
emergency department
Adults, kidney transplant recipi-
ents (80); 12 months
RR 0.71 (95% CI 0.48 to 1.05)
Intervention: 22/53 events
Control: 31/53 events
Rejection episodes
Henriksson 2016
Number of rejection
episodes
Adults, kidney transplant recipi-
ents (80); 12 months
Intervention: 6 rejections in 4 partici-
pants
Control: 27 rejections in 13 participants)
Rejection episodes
Potter 2016
Number of rejection
episodes
Adults, kidney transplant recipi-
ents (46); 1 year
Intervention: 0/20
Control: 9/26
Medication adherence
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Medication adherence
McGillicuddy 2013
Measured using elec-
tronic medication tray
openings
Adults, kidney transplant recipi-
ents (19); 3 months
Intervention: mean 0.945 (SD 0.11)
Control: mean 0.574 (SD 0.11)
Table 3.   Descriptive analyses of reported outcomes for reminder interventions  (Continued)
HD - haemodialysis; RR - risk ratio; SD - standard deviation
 
 
Outcome
Study ID
Outcome measure Study population
(No. of participants); 
study duration
Results
Behavioural
Attitudes towards
performing a be-
haviour
Welch 2013
Perceived benefits of fluid ad-
herence
Higher score indicates more
perceived benefits
Adults, HD (33); 6
weeks
Intervention: mean 39.8 (SD 4.5)
Control: mean 40.1 (SD 4.9)
P = 0.28
Perceived benefits
of sodium adher-
ence
Welch 2013
Benefits of sodium adherence
Higher score indicates higher
perceived benefits
Adults, HD (35); 6
weeks
Intervention: mean 29.9 (SD 4.4)
Control: mean 30.3 (SD 4.2)
P = 0.77
Perceived control
Welch 2013
7-item mastery scale
Higher score indicates higher
perceived control
Adults, HD (35); 6
weeks
Intervention: mean 28.5 (SD 4.9)
Control: mean 23.6 (SD 14.3)
P > 0.1
Self-efficacy (diet)
Welch 2013
Cardiac diet self-efficacy instru-
ment
Higher score indicates higher
self-efficacy
Adults, HD (35); 6
weeks
Intervention: mean 32.7 (SD 10.1)
Control: mean 31.1 (SD 10.2)
P = 0.4
Self-efficacy (fluid)
Welch 2013
Fluid Self-Efficacy Scale
Higher score indicates higher
self-efficacy
Adults, HD (36); 6
weeks
Intervention: mean 41.4 (SD 5.8)
Control: mean 43.9 (SD 6.4)
P = 0.21
Biochemical parameters
Kidney function
Kullgren 2015
Serum creatinine Children, kidney trans-
plant recipients (31); 4
weeks
Intervention: mean 16.8 (SD 21.2)
Control: mean 11 (SD 15.2)
P = 0.53
Kidney function
Rifkin 2013
Serum creatinine CKD stage 3 or greater
(43); 6 months
Intervention: mean 2.17 (SD 0.76)
Control: mean 2.32 (SD 0.84)
P = 0.12
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Serum sodium
Kullgren 2015
% change in serum sodium Children, kidney trans-
plant recipients (31); 4
weeks
Intervention: median 0 (range -4.86 to 1.45)
Control: median -0.72 (range -3.52 to 2.19)
P = 0.29
Urea Nitrogen
Kullgren 2015
% change in blood urea nitro-
gen
Children, kidney trans-
plant recipients (31); 4
weeks
Intervention: median -2.38 (range -36.84 to
61.54)
Control: median 4.56 (range -31.25 to 107.33)
P = 0.78
Blood pressure
Blood pressure con-
trol
Rifkin 2013
Mean arterial pressure CKD stage 3 or greater
(43); 6 months
Intervention: mean 93.9 (SD 8.6)
Control: mean 95.2 (SD 11.7)
P = 0.67
Diastolic blood
pressure
Rifkin 2013
Higher readings indicate poorer
control
CKD stage 3 or greater
(43); 6 months
Intervention: mean 73 (SD 10.3)
Control: mean 73 (SD 12.6)
P = 0.93
Diastolic blood
pressure
Schulz 2007
Higher readings indicate poorer
control
Adults, HD (101); 3
months
Intervention: mean 66.9 (SD 8.7)
Control: mean 65 (SD 8.8)
P < 0.05
Management of hy-
pertension
Rifkin 2013
Number of anti-hypertensive
medications
CKD stage 3 or greater
(43); 6 months
Intervention: mean 4 (SD 1.2)
Control: mean 3.9 (SD 1.3)
P = 0.61
Systolic blood pres-
sure
Rifkin 2013
Higher readings indicate poorer
control
CKD stage 3 or greater
(43); 6 months
Intervention: mean 136 (SD 15.6)
Control: mean 140 (SD 14.4)
P = 0.48
Systolic blood pres-
sure
Schulz 2007
Higher readings indicate poorer
control
Adults, HD (101); 3
months
Intervention: mean 116 (SD 17)
Control: mean 17.9 (SD 19.5)
P = NS
Clinical end-points
Hospitalisations
Schulz 2007
Unplanned ad-
mission rates to
hospital or ED
Adults, HD (101); 3
months
Intervention: mean 2.2 (SD 5.5)
Control: mean 3.31 (SD 7.3)
Medication usage
Rifkin 2013
Total number
of medications
CKD stage 3 or greater
(43); 6 months
Intervention: mean 12 (SD 4.6)
Control: mean 12.8 (SD 5.1)
P = 0.62
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Sleep duration (minutes)
Williams 2017
Fitbit Flex activ-
ity tracker
Adults, HD (29); 5
weeks
Intervention: mean 389.9 (SD 69.6)
Control: mean 349.8 (SD 80.0)
P = NS
Sleep efficiency (%)
Williams 2017
Fitbit Flex activ-
ity tracker
Adults, HD (29); 5
weeks
Intervention: mean 86.1 (SD 4.6)
Control: mean 80.3 (SD 7.1)
P < 0.05
Ultrafiltration
Schulz 2007
mL/hour during
dialysis, weekly
average
Adults, HD (101); 3
months
Intervention: mean 621.6 (SD 169.7 mL/hour)
Control: mean 652.5 (SD 198.6 mL/hour)
P = 0.712
Dietary intake
Fluid intake
Kullgren 2015
3-day fluid log through electron-
ic water bottle
Children, kidney trans-
plant recipients (32); 4
weeks
Unadjusted OR 12.25 (95% CI 1.08 to 138.99)
P = 0.043
Intervention group significantly improved.
Medication adherence
Medication adher-
ence
Rifkin 2013
Morisky Medication Adherence
Scale
Higher scores indicate better
adherence
CKD stage 3 or greater
(43); 6 months
Intervention: mean 7 (SD 1.2)
Control: mean 7.2 (SD 1.4)
P = 0.58
Physical activity
Physical activity,
distance (km)
Williams 2017
FitBit Flex activity tracker Adults, HD (29); 5
weeks
Intervention: mean 2.3 (SD 1.2)
Control: mean 2.2 (SD 0.8)
P = NS
Physical activity
(steps)
Williams 2017
FitBit Flex activity tracker Adults, HD (29); 5
weeks
Intervention: mean 5365 (SD 2765)
Control: mean 5211 (SD 2010)
P = NS
Table 4.   Descriptive analyses of reported outcomes for self-monitoring interventions  (Continued)
CKD - chronic kidney disease; HD - haemodialysis; NS - not significant; OR - Odds ratio; SD - standard deviation
 
 
Outcome
Study ID
Outcome measure Study population (No. of
participants); study du-
ration
Results
Behavioural
Illness percep-
tion
Brief Illness Perception Question-
naire
Adults, HD (25); 3 months Intervention: mean 44.2 (SD 12.09)
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iDiD 2016 Higher score indicates more nega-
tive perception of ESKD
Control: mean 41.2 (SD 10.28)
Knowledge
BRIGHT 2013
Modified Morisky’s Medication Ad-
herence Scale
Higher score indicates higher med-
ication knowledge
Adults, ≥ CKD stage 3
± proteinuria (366); 6
months
Intervention: mean 2.6 (SD 0.6)
Control: mean 2.6 (SD 0.6)
P = 0.331
Self-care behav-
iours
BRIGHT 2013
Summary of Diabetes Self Care Ac-
tivities
Higher sore indicates higher self-
care
Adults, ≥ CKD stage 3
± proteinuria (374); 6
months
Intervention: mean 4.5 (SD 1.2)
Control: mean 4.2 (SD 1.2)
P = 0.019
Biochemical parameters
Kidney function
MESMI 2010
Serum creatinine Adults, CKD, eGFR < 60
mL/min + diabetes (75); 6
months
Intervention: mean 128 (SD 6.4)
Control: mean 130 (SD 15.5)
P = NS
Kidney function
TAKE-IT 2014
Annualised change in eGFR Adolescents, kidney trans-
plant recipients (169); 12
months
Intervention: median -2.3 (95% CI -10.6 to
10.3)
Control: median -3.3 (95% CI -7.7 to 3.7)
P = 0.5
Blood pressure
Blood pressure
within guideline
recommenda-
tions
BRIGHT 2013
-- Adults, ≥ CKD stage 3
± proteinuria (403); 6
months
RR 1.22 (95% CI 1.04 to 1.43)
P = 0.002
Favouring eHealth intervention
Blood pressure
within guideline
recommenda-
tion
Ishani 2016
-- Adults, CKD, eGFR < 60
mL/min (76); 12 months
RR 1.04 (95% CI 0.74 to 1.47)
P = 0.8
Diastolic blood
pressure
MESMI 2010
Higher readings indicate poorer
control
Adults, CKD, < eGFR 60
mL/min + diabetes (75); 6
months
Intervention: mean reduction 2.25 (SD 8.7)
Control: mean reduction 3.1 (SD 8.6)
P = 0.681
Systolic blood
pressure
MESMI 2010
Higher readings indicate poorer
control
Adults, CKD, < eGFR 60
mL/min + diabetes (75); 6
months
Intervention: mean reduction 6.9 (SD 20.5)
Control: mean reduction 3 (SD 16.7)
P = 0.371
Clinical end-points
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Adverse events
TAKE-IT 2014
including post-transplant lympho-
proliferative disorder, Epstein-Barr
virus infection, CMV, BK virus in-
fection, influenza, other infection,
vomiting/diarrhoea, surgery/proce-
dure, other, hospitalisations
Adolescents, kidney trans-
plant recipients (169); 12
months
Intervention: 12.9
Control: 12.7
P = 0.9
Cholesterol con-
trol
Ishani 2016
Serum LDL-C < 100 mg/dL Adults, CKD, eGFR < 60mL/
min (76); 12 months
Intervention: 31/61 (51%)
Control: 8/15 (53%)
P = 0.9
Composite end
point
Ishani 2016
Death, ED admissions, hospitalisa-
tions and admission to skilled nurs-
ing facility
Adults, CKD, eGFR < 60
mL/min (600); 12 months
HR 0.98 (95% CI 0.75 to 1.29), P = 0.9
Intervention: 208/450 (46.2%)
Control: 70/150 (46.7%)
Diabetes control
MESMI 2010
Serum HbA1c Adults, CKD, eGFR < 60
mL/min + diabetes (75); 6
months
Intervention: median 7.5 (IQR 7 to 8.5)
Control: median 7 (IQR 6 to 9)
Diabetes control
Ishani 2016
Serum HbA1c < 8% Adults, CKD, eGFR < 60mL/
min (48); 12 months
Intervention: 14/33 (42%)
Control: 3/33 (15%)
P = 0.6
GraP failure
TAKE-IT 2014
-- Adolescents, kidney trans-
plant recipients (169); 12
months
Intervention: 0
Control: 0
GraP rejection,
acute
TAKE-IT 2014
-- Adolescents, kidney trans-
plant recipients (169); 12
months
Intervention: 1.06
Control: 1.69
P = 0.3
Healthcare utili-
sation
BRIGHT 2013
Service use (Primary health care
services, community health, social
care, secondary healthcare services,
out-of-pocket expenses, costs of
loss of productivity)
Adults, ≥ CKD stage 3
± proteinuria (374); 6
months
Intervention: mean 6.1 (SD 5.5)
Control: mean 6.5 (SD 4.7)
P = 0.455
Healthcare utili-
sation
Ishani 2016
Admission to skilled nursing facility Adults, CKD, eGFR < 60mL/
min (600); 12 months
HR 3.07 (95% CI 0.71 to 13.24)
Intervention: 18/450 (4%)
Control: 2/150 (1.3%)
Healthcare utili-
sation
Li 2014b
Clinic visits, 3 or more visits Adults, PD (135); 12 weeks Intervention: 3/69 (4.4%)
Control: 5/66 (7.6%)
P = 0.039
Hospitalisations
Schmid 2016
Unplanned admission rates to hos-
pital or ED
Adults, kidney transplant
recipients (26); 12 months
Intervention: mean 0 (SD 0.74)
Control: mean 2 (SD 1.48)
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Hospitalisations
Ishani 2016
Unplanned admission rates to hos-
pital or ED
Adults, CKD, eGFR < 60
mL/min (600); 12 months
RR 1.12 (95% CI 0.83 to 1.51)
Intervention: 134/450 events
Control: 40/150 events
Hospitalisations
Li 2014b
Unplanned admission rates to hos-
pital or ED
Adults, PD (135); 12 weeks RR 0.60 (95% CI 0.21 to 1.73)
Intervention: 5/69
Control: 8/66
Hospitalisations
TAKE-IT 2014
-- Adolescents, kidney trans-
plant recipients (169); 12
months
Intervention: 4.96
Control: 5.38
P = 0.7
Kidney function
Ishani 2016
Initiation on dialysis Adults, CKD, eGFR < 60
mL/min (600); 12 months
HR 1.86 (95%CI 0.41 to 8.39), P = NS
Intervention: 11/450 (2.4%)
Control: 2/150 (1.3%)
Rejection
episodes
Schmid 2016
Number of rejection episodes Adults, kidney transplant
recipients
(46); 12 months
Intervention: 1/23
Control: 2/23
Smoking status
Ishani 2016
Number participants quit smoking Adults, CKD, eGFR < 60
mL/min (52); 12 months
Intervention: 9/40 (23%)
Control: 5/12 (42%)
P = 0.3
Medication adherence
Medication ad-
herence
Schmid 2016
% compliant according to compos-
ite adherence score
Adults, kidney transplant
recipients (26); 12 months
RR 1.90 (95% CI 1.15 to 3.14), P = 0.013
Intervention: 19/23
Control: 10/23
Medication ad-
herence
MESMI 2010
Pill counts to determine a score Adults, CKD, eGFR < 6o
mL/min + diabetes (75); 6
months
Intervention: mean 58.4 (SD 24.3)
control: mean 66.6 (SD 22.2)
P = 0.162
Medication ad-
herence
Russell 2011
Medication Event Monitoring Sys-
tem used to record opening of bot-
tles
Adults, kidney transplant
recipients
(13); 6 months
Intervention: mean 0.88 (SD 0.09)
Control: mean 0.77 (SD 0.06)
P = 0.0396
Medication ad-
herence
TAKE-IT 2014
Perfect taking adherence was de-
fined as taking all prescribed daily
doses
Adolescents, kidney trans-
plant recipients (169); 12
months
OR 1.50 (95% CI 1.06 to 2.12)
In favour of eHealth intervention
Medication ad-
herence
TAKE-IT 2014
Self-reported using the Medical Ad-
herence Measure Medication Mod-
ule (MAM-MM)
Adolescents, kidney trans-
plant recipients (169) 12
months
Taking adherence
Intervention: 98.3 (SD 4.5)
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Control: 97.1 (SD 6.0)
P = 0.2
Timing adherence
Intervention: 95 (SD 7.9)
Control: 92.9 (SD 9.3)
P = 0.2
Medication ad-
herence
TAKE-IT 2014
Standard deviation of tacrolimus
trough concentrations during inter-
vention interval
Adolescents, kidney trans-
plant recipients (169); 12
months
Intervention: 1.6 (CI 0.9 to 2.5)
Control: 1.4 (CI 0.9 to 2.1)
P = 0.5
Medication moti-
vation
BRIGHT 2013
Modified Morisky’s Medication Ad-
herence Scale
Higher score indicates higher med-
ication motivation
Adults, ≥ CKD stage 3
± proteinuria (369); 6
months
Intervention: mean 2.7 (SD 0.6)
Control: mean 2.7 (SD 0.5)
P = 0.568
Dietary intake
PD dietary prob-
lems
Koprucki 2010
Self-reported questionnaire
Unclear whether higher or lower
scores represent an improvement in
dietary problems
Adults, PD (19); 4 months Intervention: mean -10.5 points (SD 16.2)
Control: mean +0.5 points (SD 20.1)
P = 0.194
Quality of Life
Anxiety
BRIGHT 2013
Hospital Anxiety and Depression
Scale (HADS-A)
Higher score indicate more anxiety
Adults, ≥ CKD stage 3
± proteinuria (345); 6
months
Intervention: mean 4.6 (SD 3.7)
Control: mean 5.2 (SD 4.1)
P = 0.06
Anxiety
iDiD 2016
Generalised Anxiety Disorder ques-
tionnaire
Higher score indicate more anxiety
Adults, HD (25); 3 months Intervention: mean 4.4 (SD 4.1)
Control: mean 3.9 (SD 3.6)
Anxiety
Kargar Jahromi
2016
Depression Anxiety Stress Scales
(DASS)
Higher scores indicate worse anxi-
ety
Adults, HD (54); 1 month Intervention: mean 8.68 (SD 0.9)
Control: mean 16.72 (SD 1.98)
P = 0.01
Anxiety
Reilly-Spong
2015
State-Trait Anxiety Inventory
Higher scores indicate worse anxi-
ety
Adults, kidney transplant
recipients
(42); 2 months
Intervention: mean 41.2 (SD 15.3)
Control: mean 38.1 (SD 11.6)
P = 0.55
Burden
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 21.5 (SD 11.7)
Control: mean 21.1 (SD 12.2)
P = 0.86
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Cognitive func-
tion
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 74.2 (SD 15.7)
Control: mean 76.8 (SD 16.5)
P = 0.35
Depression
iDiD 2016
Patient Health Questionnaire – 9
Higher scores indicate more depres-
sive symptoms
Adults, HD (23); 3 months Intervention: mean 7.5 (SD 5.4)
Control: mean 7.6 (SD 4.7)
Depression
Kargar Jahromi
2016
Depression Anxiety Stress Scales
(DASS)
Higher scores indicate worse anxi-
ety
Adults, HD (54); 1 month Intervention: mean 8.96 (SD .17)
Control: mean 16.2 (SD 1.6)
Depression
Reilly-Spong
2015
Center for Epidemiologic Studies
Depression Scale
Higher score indicate more symp-
toms
Adults, kidney transplant
recipients
(51) 2 months
Intervention: mean 14.7 (SD 9.4)
Control: mean 9.1 (SD 5.8)
P = 0.05
Effects
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 63.2 (SD 14.2)
Control: mean 62.1 (SD 14.3)
P = 0.63
Emotional well-
being
BRIGHT 2013
heiQ
Higher score indicates higher nega-
tive affect
Adults, ≥ CKD stage 3
± proteinuria (374); 6
months
Intervention: mean 31.4 (SD 22.2)
Control: mean 34 (SD 22.2)
P = 0.329
Fatigue
BRIGHT 2013
Medical Outcomes Survey, energy
and vitality
Higher score indicates more energy
and vitality
Adults, ≥ CKD stage 3
± proteinuria (373); 6
months
Intervention: mean 52.4 (SD 22)
Control: mean 50.8 (SD 21.8)
P = 0.082
Fatigue
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 6 weeks Intervention: mean 48.4 (SD 17.7)
Control: mean 43.3 (SD 18.9)
P = 0.02
Fatigue
Reilly-Spong
2015
Patient-Reported Outcomes Mea-
surement Information System – Fa-
tigue
Higher score indicate more symp-
toms
Adults, kidney transplant
recipients (38); 2 months
Intervention: mean 57 (SD 6.3)
Control: mean 56.6 (SD 8.4)
P = 0.65
General health
perception
BRIGHT 2013
SF-36
Higher scores indicate higher QoL
Adults, ≥ CKD stage 3
± proteinuria (372); 6
months
Intervention: mean 2.8 (SD 1.0)
Control: 2.8 (SD 0.9)
P = 0.832
General health
perception
KDQoL-SF Adults, PD (135); 12 weeks Intervention: mean 38.2 (SD 17.5)
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Li 2014b Higher scores indicate higher QoL Control: mean 35.7 (SD 17.7)
P = 0.41
Health services
navigation
BRIGHT 2013
Health Education Impact Question-
naire
Adults, ≥ CKD stage 3
± proteinuria (372); 6
months
Intervention: mean 70.5 (SD 16.2)
Control: mean 69.4 (SD 15.9)
P = 0.226
Hope
Poorgholami
2016a
Miller’s questionnaire of hope
Higher score indicates greater hope-
fulness
Adults, HD (75); 2 months Intervention: mean 187.0 (SD 11.46)
Control 1: mean 170.96 (SD 7.99)
Control 2: mean 91.16 (SD 11.06)
P < 0.05
Significant improvement in the intervention
group compared to both control groups
Loneliness
BRIGHT 2013
UCLA Loneliness Scale
Higher score indicates lower loneli-
ness
Adults, ≥ CKD stage 3
± proteinuria (369); 6
months
Intervention: mean 30.3 (SD 5.3)
Control: mean 31 (SD 4.4)
P = 0.861
Mental compo-
nent score
Reilly-Spong
2015
SF-12
Higher score indicates higher quali-
ty of life
Adults, kidney transplant
recipients (63); 2 months
Intervention: mean 49.7 (SD 10)
Control: mean 46.7 (SD 9.8)
P = 0.01
Mental health
BRIGHT 2013
Medical Outcomes Survey, psycho-
logical well being
Higher score indicates higher psy-
chological well being
Adults, ≥ CKD stage 3
± proteinuria (372); 6
months
Intervention: mean 74.7 (SD 18.8)
Control: mean 74 (SD 19.9)
P = 0.286
Mental health
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 6 weeks Intervention: mean 65.4 (SD 17.2)
Control: mean 63.5 (SD 18.6)
P = 0.77
Mobility
iDiD 2016
EQ-5D
Higher score indicates reduced mo-
bility
Adults, HD (25); 3 months Intervention: mean 1.5 (SD 0.8)
Control: mean 2.4 (SD 1.5)
P = NS
Mood
iDiD 2016
EQ-5D
Higher score indicates lower mood
Adults, HD (25); 3 months Intervention: mean 1.5 (SD 0.8)
Control: mean 2.0 (SD 1.0)
Quality of life
(global score)
BRIGHT 2013
EQ-5D
Higher scored indicates reduced
quality of life
Adults, CKD ≥ stage 3
± proteinuria (372); 6
months
Intervention: mean 0.71 (SD 0.28)
Control: mean 0.67 (SD 0.29)
P = 0.027
Physical compo-
nent score
SF-12 Adults, kidney transplant
recipients (63); 2 months
Intervention: mean 33.2 (SD 9.8)
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Reilly-Spong
2015
Higher score indicates higher quali-
ty of life
Control: mean 38.5 (SD 10.4)
P =0.96
Physical func-
tioning
Li 2014b
KDQoL-SF
Higher scores indicate higher QoL
Adults, PD (135); 12 weeks Intervention: mean 53.9 (SD 12.9)
Control: mean 51.5 (SD 12.5)
P = 0.28
Pain
iDiD 2016
EurQoL EQ-5D
Higher scores indicate more pain
Adults, HD (18); 3 months Intervention: mean 1.6 (SD 0.8)
Control: mean 2.6 (SD 1.3)
P = NS
Pain
Li 2014b
KDQoL-SF
Higher scores indicate less pain
Adults, PD (135); 12 weeks Intervention: mean 64.2 (SD 18.2)
Control: mean 59.7 (SD 18.9)
P = 0.16
Pain
Reilly-Spong
2015
SF-12
Higher scores indicate less pain
Adults, kidney transplant
recipients (38); 2 months
Intervention: mean 39.9 (SD 13.9)
Control: 44.7 (SD 10.4)
P = 0.94
Patient satisfac-
tion
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 75.9, SD 13.8
Control: mean 71.3 (SD 12.3)
P = 0.04
Positive and ac-
tive engagement
in life
BRIGHT 2013
heiQ
Higher score indicates higher en-
gagement with life
Adults, ≥ CKD stage 3
± proteinuria (374); 6
months
Intervention: mean 66.4 (SD 19.7)
Control: mean 66.5 (SD 17.6)
P = 0.999
Quality social in-
teraction
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 73.2 (SD 15.1)
Control: mean 71.7 (SD 14.1)
P = 0.56
Role, emotional
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 6 weeks Intervention: mean 56.3 (SD 14.8)
Control: mean 56.6 (SD 16.5)
P = 0.77
Role, physical
Li 2014b
KDQoL-SF
Higher scores indicate higher QoL
Adults, PD (135); 12 weeks Intervention: mean 20.8 (SD 16.9)
Control: mean 20.4 (SD 15.1)
P = 0.91
Self-monitoring
and insight
BRIGHT 2013
heiQ
Higher score indicates higher self-
monitoring and insight
Adults, ≥ CKD stage 3
± proteinuria (374); 6
months
Intervention: mean 70.7 (SD 12.2)
Control: mean 70.7 (SD 11.5)
P = 0.644
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Sexual function
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 83.7 (SD 16.4)
Control: mean 78.4 (SD 15.5)
P = 0.05
Side effects from
corticosteroids,
cardiac and kid-
ney dysfunction
Schmid 2016
End-stage renal disease symptom
checklist (ESRD-SCL)
Higher score indicate improved
quality of life
Adults, kidney transplant
recipients (46); 12 months
Intervention: median 0 (IQR 0.2)
Control: median 0.4 (IQR 0.6)
P = 0.004
Skills and tech-
nique acquisition
BRIGHT 2013
heiQ
Higher score indicates higher skills
and technique acquisition
Adults, ≥ CKD stage 3
± proteinuria (369); 6
months
Intervention: mean 65.4 (SD 14.6)
Control: mean 65.0 (SD 13.1)
P = 0.218
Social network
(illness)
BRIGHT 2013
heiQ
Higher score = greater help with ill-
ness from social network
Adults, ≥ CKD stage 3
± proteinuria (342); 6
months
Intervention: mean 10.3 (SD 8.4)
Control: mean 11.5 (SD 9)
P = 0.208
Social network
(practical)
BRIGHT 2013
heiQ
Higher score = greater help with
practical work from social network
Adults, ≥ CKD stage 3
± proteinuria (342); 6
months
Intervention: mean 6.2 (SD 6.2)
Control: mean 8.1 (SD 7.1)
P = 0.017
Social support
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 74.1 (SD 14.7)
Control: mean 73.2 (SD 15.1)
P = 0.73
Self-care
iDiD 2016
EQ-5D
Higher score indicates reduced self-
care
Adults, HD (25); 3 months Intervention: mean 1.2 (SD 0.6)
Control: mean 1.4 (SD 0.9)
P = NS
Sleep
Li 2014b
KDQoL-SF
Higher score indicates better sleep
Adults, PD (160); 6 weeks Intervention: mean 61.1 (SD 20.6)
Control: mean 54.3 (SD 18.1)
P = 0.1
Sleep
Reilly-Spong
2015
Pittsburgh Sleep Quality Index
Lower score indicates better sleep
quality
Adults, kidney transplant
recipients (63); 2 months
Intervention: mean 7.3 (SD 4.7)
Control: 6.1 (SD 3.4)
P = 0.65
Social capital
BRIGHT 2013
heiQ
Higher score indicates increased
satisfaction with opportunities to
participate in the community
Adults, ≥ CKD stage 3
± proteinuria (366); 6
months
Intervention: mean 3.7 (SD 0.8)
Control: mean 3.6 (SD 0.8)
P = 0.325
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Social integra-
tion
BRIGHT 2013
heiQ
Higher score indicates higher social
integration
Adults, ≥ CKD stage 3
± proteinuria (371); 6
months
Intervention: mean 69.6 (SD 20.3)
Control: mean 69.4 (SD 15.6)
P = 0.537
Social network
(emotional)
BRIGHT 2013
heiQ
Higher score indicates greater help
with emotional work from social
network
Adults, ≥ CKD stage 3
± proteinuria (345); 6
months
Intervention: mean 13.4 (SD 10.4)
Control: mean 14.9 (SD 11.4)
P = 0.463
Social function-
ing
BRIGHT 2013
Medical Outcomes Survey, so-
cial/role activities limitations
Higher score indicates lower social
limitation
Adults, ≥ CKD stage 3
± proteinuria (371(; 6
months
Intervention: mean 73.2 (SD 28.2)
Control: mean 68.7 (SD 30.5)
P = 0.492
Social function-
ing
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 6 weeks Intervention: mean 42.5 (SD 19.3)
Control: mean 43.4 (SD 18.8)
P = 0.43
StaF encourage-
ment
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 87.3 (SD 12.8)
Control: mean 81.2 (SD 15.1)
P = 0.01
Stress
Kargar Jahromi
2016
Depression Anxiety Stress Scales
(DASS)
Higher score indicates higher stress
Adults, HD (54); 1 month Intervention: mean 8.36 (SD 1.03)
Control: mean 13.76 (SD 1.44)
P = 0.001
Symptoms/prob-
lems
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 72.8 (SD 15)
Control: mean 68.6 (SD 6.2)
P = 0.08
Usual activities
iDiD 2016
EQ-5D
Higher scores indicate reduced abil-
ity to complete usual activities
Adults, HD (25); 3 months Intervention: mean 1.5 (SD 0.8)
Control: mean 2.8 (SD 1.3)
P = NS
Work status
Li 2014b
KDQoL
Higher scores indicate improved
quality of life
Adults, PD (135); 12 weeks Intervention: mean 17.3 (SD 11.6)
Control: mean 14.8 (SD 9.9)
P = 0.19
Table 5.   Descriptive analyses of reported outcomes for behavioural counselling interventions  (Continued)
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Outcome
Study ID
Outcome measure Study population (No. of participants);
study duration
Results
Behavioural
Knowledge
iChoose 2016
9 item scale, unvali-
dated
Adults, ESKD (443); 1 clinic appointment Intervention: mean 6.11 (SD 1.91)
Control: mean 5.48 (SD 1.87)
P < 0.001
Biochemical parameters
Serum
parathyroid
hormone
Cooney 2015
-- Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: 502/1070 (46.9%)
Control: 182/1129 (16.1%)
P < 0.001
Serum phos-
phate
Cooney 2015
-- Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: 680/1070 (63.6%)
Control: 527/1129 (46.7%)
P < 0.001
Blood pressure
Blood pres-
sure within
guideline rec-
ommenda-
tions
Cooney 2015
-- Adults, eGFR < 45 mL/min or eGFR < 60
mL/min in past 90 days to 2 years (947); 12
months
RR 1.02 (95% CI 0.87 to 1.19)
P = 0.84
Management
of hyperten-
sion
Cooney 2015
Number of anti-hy-
pertensive medica-
tions
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
0 medications
Intervention: 37 (7.8%), control: 65 (13.7%)
1 medication
Intervention 52 (11%), control: 63 (13.3%)
2 medications
Intervention 128 (27%), control: 105 (22.2%)
3 medications
Intervention: 135 (28.5%), control: 121
(25.6%)
4+ medications
Intervention: 122 (25.7%), control: 119
(25.2%)
Systolic blood
pressure
Cooney 2015
Higher readings in-
dicate poorer con-
trol
Adults, eGFR < 45 mL/min or eGFR < 60
mL/min in past 90 days to 2 years (947); 12
months
Intervention: mean 135.1 (SD 17.4)
Control: mean 134.4 (SD 17.6)
P = 0.57
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Clinical end-points
Access to kid-
ney transplan-
tation
iChoose 2016
Composite score of
transplant access
(at least one of fol-
lowing outcomes:
wait-list, deceased,
deceased or living
donor transplant,
1 living donor in-
quiry)
Adults, ESKD (443); 1 clinic appointment Intervention: 168/226 (74.3%)
Control: 155/216 (71.4%)
Healthcare
utilisation
Durand 2000
Frequency of
planned medical
visits
Adults, PD (30); intervention 9.5 months,
control 7.8 months
Intervention: 1/41 days
Control: 1/33 days
Hospitalisa-
tions
Durand 2000
-- Adults, PD (30); intervention 9.5 months,
control 7.8 months
RR 0.67 (95% CI 0.34 to 1.29)
Intervention: 14/365 events
Control: 21/365 events
Kidney func-
tion
Cooney 2015
Urine albumin crea-
tinine ratio
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: 602/1070 (56.3%)
Control: 435/1129 (38.5%)
P < 0.001
Kidney func-
tion
Cooney 2015
Progression to
ESKD (dialysis or
transplantation)
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: 26/1070 (2.4%)
Control: 20/1129 (1.8%); P =0.28
Medication
usage
Cooney 2015
Prescribed appro-
priate medications
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
ACEI/ARB
Intervention: 309/481 (64.2%)
Control: 298/483 (61.7%)
P = 0.41
Phosphate binder
Intervention: 24/107 (22.4%)
Control: 19/81 (23.5%)
P = 0.87
Vitamin D
Intervention: 310/501 (61.9%)
Control: 218/416 (52.4%)
P = 0.004
Bicarbonate
Intervention: 31/132 (24%)
Control: 18/137 (13%)
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P = 0.03
Medication adherence
Medication
adherence
Cooney 2015
Morisky Medication
Adherence Scale
Higher scores indi-
cate better adher-
ence
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: mean 6.7 (SD 1.2)
Control: mean 6.8 (SD 1.2)
P = 0.7
Medication
adherence
Hardstaff 2002
Pill counts Adults, kidney transplant recipients (91) RR 0.72 (95% CI 0.42 to 1.15)
Intervention: 26/67
Control: 13/24
Quality of Life
Burden
Cooney 2015
KDQoL
Higher scores in-
dicate improved
quality of life
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: mean 89.7 (SD 20.5)
Control: mean 89.4 (SD 19.6)
P = 0.93
Effects
Cooney 2015
KDQoL
Higher scores in-
dicate improved
quality of life
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: mean 94.2 (SD 11.9)
Control: mean 94.4 (SD 14)
P = 0.92
Mental com-
ponent score
Cooney 2015
SF-12
Higher score indi-
cates higher quality
of life
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: mean 52 (SD 10.6)
Control: mean 52.1 (SD 9.6)
P = 0.9
Physical com-
ponent score
Cooney 2015
SF-12
Higher score indi-
cates higher quality
of life
Adults, eGFR < 45 mL/min or eGFR < 60 mL/
min in past 90 days to 2 years (2199); 12
months
Intervention: mean 39.3 (SD 9.8)
Control: mean 36.8 (SD 10.3)
P = 0.15
Table 6.   Descriptive analyses of reported outcomes for clinical-decision aid interventions  (Continued)
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Outcome
Study ID
Outcome measure Study population (no. of Par-
ticipants);
study duration
Results
Behavioural
Attitudes towards
performing a behav-
iour
Attitude: importance of
sun protection
Adults, kidney transplant recipi-
ents (101);
6 weeks
Intervention: mean 7 (SD 12)
Control: mean 0 (SD 8.5)
P = 0.003
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Robinson 2014a Higher score indicates
higher importance
Attitudes towards
performing a behav-
iour
Robinson 2015
Attitude: importance of
sun protection
Higher score indicates
higher importance
Adults, kidney transplant recipi-
ents (170); 6 weeks
Intervention: mean 6.59 (SD 3.87)
Control: mean 1.07 (SD 0.705)
P < 0.05
Knowledge
Robinson 2014a
Knowledge of skin cancer
and sun protection (self-
reported, validated tool
Adults, kidney transplant recipi-
ents (103); 6 weeks
Intervention: mean 9 (SD 6.75)
Control: mean 0 (SD 6.75)
P = 0.015
Knowledge
Robinson 2015
Knowledge of skin cancer
and sun protection (self-
reported, validated tool)
Adults, kidney transplant recipi-
ents (170); 6 weeks
Intervention: mean 6.66 (SD 2.57)
Control: mean 3.67 (SD 1.73)
P = 0.04
Self-care behaviours
Robinson 2014a
Sun protection performed
Higher score indicates
more sun protection be-
haviours performed
Adults, kidney transplant recipi-
ents (101); 6 weeks
Intervention: mean 12.5 (SD 19.6)
Control: mean 2.5 (SD 17.5)
P = 0.013
Self-care behaviours
Robinson 2015
Sun protection performed
Higher score indicates
more sun protection be-
haviours performed
Adults, kidney transplant recipi-
ents (170); 6 weeks
Intervention: mean 57.7 (SD 13.08)
Control: mean 31.1 (SD 4.87)
P = 0.013
Willingness to per-
form a behaviour
Robinson 2014a
Willingness to use sun pro-
tection
Higher scores indicate
more willingness
Adults, kidney transplant recipi-
ents (101); 6 weeks
Intervention: mean 8 (SD 25)
Control: mean 0 (SD 34.5)
P = 0.137
Willingness to per-
form a behaviour
Robinson 2015
Willingness to use sun pro-
tection
Higher scores indicate
more willingness
Adults, kidney transplant recipi-
ents (170); 6 weeks
Intervention: mean 74.64 (SD 21.4)
Control: mean 22.64 (SD 1.65)
P = 0.09
Biochemical parameters
Kidney function
Navaneethan 2017
Measurement of serum
creatinine
Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 42/50 (84%)
Control: 57/57 (100%)
P = 0.001
Serum parathyroid
hormone
Navaneethan 2017
-- Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 22/50 (44%)
Control: 33/57 (58%)
P = 0.34
Serum phosphate
Navaneethan 2017
-- Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 28/50 (56%)
Control: 39/57 (68%)
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P = 0.52
Measurement of 25-
hydroxy Vitamin D
Navaneethan 2017
-- Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 28/50 (56%)
Control: 37/57 (65%)
P = 0.31
Blood pressure
Blood pressure with-
in guideline recom-
mendations
Navaneethan 2017
-- Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
RR 0.97 (95% CI 0.86 to 1.09)
P = 0.98
Clinical end-points
Cholesterol control
Navaneethan 2017
Measurement of serum
LDL-C
Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 39/50 (78%)
Control: 48/57 (84%)
P = 0.36
Diabetes control
Navaneethan 2017
Measurement of serum
HbA1c
Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 19/29 (79%)
Control: 29/29 (100%)
P = 0.02
Hospitalisations
Navaneethan 2017
Unplanned admission
rates to hospital or emer-
gency department
Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: mean 4.06 (SD 14.11)
Control: mean 2.29 (SD 9.09)
P = 0.24
Kidney function
Navaneethan 2017
Urine albumin creatinine
ratio
Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 19/50 (38%)
Control: 25/57 (44%)
P = 0.13
Kidney function
Navaneethan 2017
Progression to ESKD (dial-
ysis or transplantation)
Adults, CKD, eGFR 15 to 45 mL/
min (209); 24 months
Intervention: 4/50 (844%)
Control: 1/57 (1.8%)
P = 0.36
Melanin index
Robinson 2014a
Spectrophotometry, right
upper arm with sun pro-
tection
Adults, kidney transplant recipi-
ents (101); 6 weeks
Intervention: median -0.8 (range: -110 to
186)
Control: median 5 (range: -193 to 108)
P = 0.497
Melanin index
Robinson 2014a
Spectrophotometry, right
forearm with sun exposure
Adults, kidney transplant recipi-
ents (101); 6 weeks
Intervention: median 16.3 (range -113 to
132)
Control: median 44 (range -56 to 317)
P = 0.036
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Melanin index
Robinson 2014a
Spectrophotometry, cheek
with sun exposure
Adults, kidney transplant recipi-
ents (101); 6 weeks
Intervention: median -1 (range: -59 to 240)
Control: median 15 (range: -63 to 246)
P = 0.114
Sun damage
Robinson 2014a
Personnel assessment,
right forearm
Adults, kidney transplant recipi-
ents (101); 6 weeks
Intervention: median 0 (range: -4 to 2)
Control: median 2 (range: -5 to 8)
P = 0.031
Medication adherence
Medication adher-
ence
Reese 2017
Serum tacrolimus Adults, kidney transplant recipi-
ents (117); 6 months
Intervention 1: mean 8.7 (SD 2.7)
Intervention 2: mean 8.08 (SD 1.56)
Control: mean 8.38 (SD 1.67)
P = 0.4
Medication adher-
ence
Reese 2017
Co-efficient of variation for
tacrolimus levels
Adults, kidney transplant recipi-
ents (117); 6 months
Intervention 1: mean 0.23 (SD 0.18)
Intervention 2: mean 0.21 (SD 0.15)
Control: mean 0.24 (SD 0.15)
P = 0.7
Medication adher-
ence
Reese 2017
% tacrolimus levels within
range
Adults, kidney transplant recipi-
ents (117); 6 months
Intervention 1: mean 0.35 (SD 0.32)
Intervention2: mean 0.37 (SD 0.26)
Control: mean 0.42 (SD 0.3)
P = 0.6
Medication adher-
ence
Reese 2017
% of days bottles opened
at correct times
Adults, kidney transplant recipi-
ents (117); 6 months
RR 1.41 (95% CI 1.21 to 1.65); P < 0.00
Intervention 1: 140/180
Intervention 2: 158/180
Control: 99/180
Table 7.   Descriptive analyses of reported outcomes for mixed interventions  (Continued)
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Database Search terms
CENTRAL 1. MeSH descriptor: [Kidney Diseases] explode all trees
2. MeSH descriptor: [Renal Replacement Therapy] explode all trees
 
eHealth interventions for people with chronic kidney disease (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
147
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
3. MeSH descriptor: [Renal Insufficiency] explode all trees
4. MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
5. dialysis:ti,ab,kw (Word variations have been searched)
6. hemodialysis or haemodialysis:ti,ab,kw (Word variations have been searched)
7. hemofiltration or haemofiltration:ti,ab,kw (Word variations have been searched)
8. hemodiafiltration or haemodiafiltration:ti,ab,kw (Word variations have been searched)
9. kidney disease* or renal disease* or kidney failure or renal failure:ti,ab,kw (Word variations have
been searched)
10.ESRF or ESKF or ESRD or ESKD:ti,ab,kw (Word variations have been searched)
11.CKF or CKD or CRF or CRD:ti,ab,kw (Word variations have been searched)
12.CAPD or CCPD or APD:ti,ab,kw (Word variations have been searched)
13.predialysis or pre-dialysis:ti,ab,kw (Word variations have been searched)
14.{or #1-#13}
15.(sms or mms) and messag*:ti,ab,kw (Word variations have been searched)
16.apps:ti,ab,kw (Word variations have been searched)
17.text messag*:ti,ab,kw (Word variations have been searched)
18.multimedia messag*:ti,ab,kw (Word variations have been searched)
19.facebook*:ti,ab,kw (Word variations have been searched)
20.email*:ti,ab,kw (Word variations have been searched)
21.twitter* or tweet*:ti,ab,kw (Word variations have been searched)
22.social media*:ti,ab,kw (Word variations have been searched)
23.(mobile* or cell or smart*) and phone*:ti,ab,kw (Word variations have been searched)
24.ios or android:ti,ab,kw (Word variations have been searched)
25.ipad* or iphone* or ipod*:ti,ab,kw (Word variations have been searched)
26.tablet* and computer*:ti,ab,kw (Word variations have been searched)
27.(online or web*) and (education* or train*):ti,ab,kw (Word variations have been searched)
28.personal digital assistant*:ti,ab,kw (Word variations have been searched)
29.e-health or ehealth or mhealth or m-health or telehealth or telemedicine:ti,ab,kw (Word varia-
tions have been searched)
30.{or #15-#29}
31.{and #14, #30}
MEDLINE 1. exp Telemedicine/
2. exp Internet/
3. exp communications media/
4. exp Programmed Instruction as Topic/
5. Computers, Handheld/
6. Mobile Applications/
7. exp Cell Phones/
8. ((sms or mms) and messag$).tw.
9. apps.tw.
10."text messag$".tw.
11.multimedia messag$.tw.
12.facebook.tw.
13.email$.tw.
14.(twitter or tweet$).tw.
15.social media$.tw.
16.((mobile$ or cell or smart$) and phone).tw.
17.(ios or android$).tw.
18.(ipad$ or iphone$ or ipod$).tw.
19.(tablet$ and computer$).tw.
20.((online or web$) and (education$ or train$)).tw.
  (Continued)
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21.personal digital assistant$.tw.
22.(e-health or ehealth or mhealth or m-health or telehealth$ or telemedicine$).tw.
23.or/1-22
24.Kidney Diseases/
25.exp Renal Replacement Therapy/
26.Renal Insufficiency/
27.exp Renal Insufficiency, Chronic/
28.dialysis.tw.
29.(hemodialysis or haemodialysis).tw.
30.(hemofiltration or haemofiltration).tw.
31.(hemodiafiltration or haemodiafiltration).tw.
32.(kidney disease* or renal disease* or kidney failure or renal failure).tw.
33.(ESRF or ESKF or ESRD or ESKD).tw.
34.(CKF or CKD or CRF or CRD).tw.
35.(CAPD or CCPD or APD).tw.
36.(predialysis or pre-dialysis).tw.
37.or/24-36
38.and/23,37
EMBASE 1. exp telehealth/
2. exp mass communication/
3. exp mobile application/
4. ((sms or mms) and messag$).tw.
5. apps.tw.
6. "text messag$".tw.
7. multimedia messag$.tw.
8. facebook.tw.
9. email$.tw.
10.(twitter or tweet$).tw.
11.social media$.tw.
12.((mobile$ or cell or smart$) and phone).tw.
13.(ios or android$).tw.
14.(ipad$ or iphone$ or ipod$).tw.
15.(tablet$ and computer$).tw.
16.((online or web$) and (education$ or train$)).tw.
17.personal digital assistant$.tw.
18.(e-health or ehealth or mhealth or m-health or telehealth$ or telemedicine$).tw.
19.or/1-18
20.exp renal replacement therapy/
21.kidney disease/
22.chronic kidney disease/
23.kidney failure/
24.chronic kidney failure/
25.mild renal impairment/
26.stage 1 kidney disease/
27.moderate renal impairment/
28.severe renal impairment/
29.end stage renal disease/
30.renal replacement therapy-dependent renal disease/
31.kidney transplantation/
32.(hemodialysis or haemodialysis).tw.
33.(hemofiltration or haemofiltration).tw.
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34.(hemodiafiltration or haemodiafiltration).tw.
35.dialysis.tw.
36.(CAPD or CCPD or APD).tw.
37.(kidney disease* or renal disease* or kidney failure or renal failure).tw.
38.(CKF or CKD or CRF or CRD).tw.
39.(ESRF or ESKF or ESRD or ESKD).tw.
40.(predialysis or pre-dialysis).tw.
41.((kidney or renal) adj (transplant* or graP* or allograft*)).tw.
42.or/20-41
43.and/19,42
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer ran-
dom number generator; coin tossing; shuffling cards or en-
velopes; throwing dice; drawing of lots; minimisation (min-
imisation may be implemented without a random element,
and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date
of birth; date (or day) of admission; sequence generated by
hospital or clinic record number; allocation by judgement
of the clinician; by preference of the participant; based on
the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence generation
Selection bias (biased allocation to interventions) due to inadequate
generation of a randomised sequence
Unclear: Insufficient information about the sequence gen-
eration process to permit judgement.
Low risk of bias: Randomisation method described that
would not allow investigator/participant to know or influ-
ence intervention group before eligible participant entered
in the study (e.g. central allocation, including telephone,
web-based, and pharmacy-controlled, randomisation; se-
quentially numbered drug containers of identical appear-
ance; sequentially numbered, opaque, sealed envelopes).
High risk of bias: Using an open random allocation schedule
(e.g. a list of random numbers); assignment envelopes were
used without appropriate safeguards (e.g. if envelopes
were unsealed or non-opaque or not sequentially num-
bered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Allocation concealment
Selection bias (biased allocation to interventions) due to inadequate
concealment of allocations prior to assignment
Unclear: Randomisation stated but no information on
method used is available.
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions by
participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the
review authors judge that the outcome is not likely to be in-
fluenced by lack of blinding; blinding of participants and
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key study personnel ensured, and unlikely that the blinding
could have been broken.
High risk of bias: No blinding or incomplete blinding, and
the outcome is likely to be influenced by lack of blinding;
blinding of key study participants and personnel attempt-
ed, but likely that the blinding could have been broken, and
the outcome is likely to be influenced by lack of blinding.
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but
the review authors judge that the outcome measurement
is not likely to be influenced by lack of blinding; blinding of
outcome assessment ensured, and unlikely that the blind-
ing could have been broken.
High risk of bias: No blinding of outcome assessment, and
the outcome measurement is likely to be influenced by lack
of blinding; blinding of outcome assessment, but likely that
the blinding could have been broken, and the outcome
measurement is likely to be influenced by lack of blinding.
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by out-
come assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for miss-
ing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing
bias); missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data
across groups; for dichotomous outcome data, the propor-
tion of missing outcomes compared with observed event
risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data,
plausible effect size (difference in means or standardised
difference in means) among missing outcomes not enough
to have a clinically relevant impact on observed effect size;
missing data have been imputed using appropriate meth-
ods.
High risk of bias: Reason for missing outcome data like-
ly to be related to true outcome, with either imbalance
in numbers or reasons for missing data across interven-
tion groups; for dichotomous outcome data, the propor-
tion of missing outcomes compared with observed event
risk enough to induce clinically relevant bias in interven-
tion effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized differ-
ence in means) among missing outcomes enough to induce
clinically relevant bias in observed effect size; ‘as-treated’
analysis done with substantial departure of the interven-
tion received from that assigned at randomisation; poten-
tially inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete out-
come data.
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of
the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way; the study protocol is not available
  (Continued)
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but it is clear that the published reports include all expect-
ed outcomes, including those that were pre-specified (con-
vincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified prima-
ry outcomes have been reported; one or more primary out-
comes is reported using measurements, analysis methods
or subsets of the data (e.g. sub-scales) that were not pre-
specified; one or more reported primary outcomes were
not pre-specified (unless clear justification for their report-
ing is provided, such as an unexpected adverse effect); one
or more outcomes of interest in the review are reported in-
completely so that they cannot be entered in a meta-analy-
sis; the study report fails to include results for a key out-
come that would be expected to have been reported for
such a study.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study appears to be free of other
sources of bias.
High risk of bias: Had a potential source of bias related to
the specific study design used; stopped early due to some
data-dependent process (including a formal-stopping rule);
had extreme baseline imbalance; has been claimed to have
been fraudulent; had some other problem.
Other bias
Bias due to problems not covered elsewhere in the table
Unclear: Insufficient information to assess whether an im-
portant risk of bias exists; insufficient rationale or evidence
that an identified problem will introduce bias.
  (Continued)
 
Appendix 3. World Health Organization digital health intervention classifications
 
Type of intervention Example of intervention Studies
1. Targeted client communi-
cation
• Alerts or reminders• Targeted health information Baraz 2014; Cargill 2003; Cooney 2015; Giacoma 1999; Han2016; Henriksson 2016; iChoose 2016; iDiD 2016; InformMe
2017; Jammalamadaka 2015; Kargar Jahromi 2016; Li 2014b;
McGillicuddy 2013; Poorgholami 2016a; Potter 2016; Reese
2017; Reilly-Spong 2015; Robinson 2014a; Robinson 2015;
SUBLIME 2016; TAKE-IT 2014
2. Untargeted client com-
munication
• Untargeted information to unde-
fined population
--
3. Client-to-client informa-
tion
• Peer group --
4. Personal health tracking • Client accesses own medical
record• Self-monitoring of health data• Active data capture by client
BALANCEWise-HD 2011; BALANCEWise-PD 2011; Durand
2000; Hardstaff 2002; Koprucki 2010; Kullgren 2015; Ong
2017; Rifkin 2013; Schulz 2007; Welch 2013; Williams 2017
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5. Citizen based reporting • Reporting of public health events --
6. On-demand information
services to clients
• Client look-up of health informa-
tion
Diamantidis 2015
7. Client financial transac-
tions
• Manage out-of-pocket expenses -
One study could not be classified (Halleck 2017)
Eight studies used multiple strategies (e.g. targeted client communication and personal health tracking) (BalanceWise-HD 2013;
BRIGHT 2013; Ishani 2016; MESMI 2010; Navaneethan 2017; Russell 2011; Schmid 2016; Swallow 2016; White 2010)
  (Continued)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
An additional potential harm was added to "Types of outcome measures". "Anxiety due to frequent monitoring" was added to outcomes
as this was reported by one study.
The important outcomes listed in the Summary of Findings Table have been changed. A number of the original outcomes listed were
either not reported by any study (physical activity) or were too broad to be reported in this format (quality of life). We removed change
in electrolyte management, physical activity, adherence to treatment and quality of life from the Summary of Findings table, and added
in death as this has been an important outcome to consumers in both HD and transplantation as published by the Song Initiative (SONG
2017).
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Telemedicine;  Disease Progression;  Medication Adherence;  Quality of Life;  Randomized Controlled Trials as Topic;  Reminder Systems;
  Renal InsuFiciency, Chronic  [*mortality]
MeSH check words
Humans
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